The synthesis of substituted phosphonic acids by Hanrahan, Jane
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
A Thesis Submitted for the Degree of PhD at the University of Warwick
http://go.warwick.ac.uk/wrap/55734
This thesis is made available online and is protected by original copyright.
Please scroll down to view the document itself.
Please refer to the repository record for this item for information to help you to
cite it. Our policy information is available from the repository home page.
The Synthesis of Substituted 
Phosphonic Acids 
by 
Jane Hanrahan 
Submitted for the Degree of Doctor 
of Philosophy 
Department of Chemistry 
University of Warwick 
August 1995 
Dedicated to the memory of Dr David Hutchinson 
Contents 
List of Figures Xl 
List of Tables xv 
Acknowledgements XVI 
Declaration XVll 
Abstract XVin 
Abbreviations XlX 
Chapter 1 1 
Introduction 1 
1.1. Biologically Active Phosphonic Acid Analogues of Amino 
~~ 1 
1.1.1. Enzyme Inhibition and Antimicrobial Activity of 
Aminophosphonic Acids 2 
1.1.2. Plant Growth Regulatory Aminophosphonic Acids 8 
1.1.3. Anticancer Activity of Phosphonic Amino Acids 9 
1.2. Excitatory Amino Acid Neurotransmitters 11 
1.2.1. Physiological and Pathophysiological Functions of EAA 
Receptors 11 
1.3. EAA Receptor Pharmacology 14 
1.3.1. Receptor Characterisation 15 
1.4. Excitatory Amino Acid Receptor Sub-types 15 
1.4.1. NMDA Receptor 15 
1.4.2. AMP A Receptor 20 
1.4.3. Kainate Receptor 22 
1.4.5. Metabotropic Receptor 27 
1.5. Cyclic Analogues of Phosphonic Amino Acids in EAA 30 
1.6. Aims 32 
I 
Chapter 2 33 
Synthesis of 3-Substituted-cyc1obutanephosphonates 33 
2.1. Introduction 33 
2.2. Discussion 36 
2.2.1. Malonate Synthesis of Cyc10butanes 36 
2.2.3. Arbuzov Reaction of Diethy13-Bromo 
cyclobutanecarboxylate 39 
2.3. Synthesis of Cyc10butanes using Stabilised Carbanions other than 
Malonates 44 
2.3.1. a-Phosphoryl Sulfoxides as Malonate Analogues 44 
2.3.2. Diethyl a-Phosphorylmethyl Phenyl Sulfide as a Malonate 
Analogue 
2.3.3. Diethyl a-Trimethylsilylmethylphosphonate as a Malonate 
48 
Analogue 50 
2.3.4. Synthesis of Diethy13-0xocyclobutanephosphonate 52 
2.3.5. Synthesis of Diethy13-Hydroxycyclobutanephosphonate 
from Epichlorohydrin 56 
2.4. Conclusion 58 
Chapter 3 59 
Synthesis of Aminoacid Cyclobutanephosphonic Acids 59 
3.1. Introduction 59 
3.1.2. The Bucherer-Bergs Reaction 60 
3.2. Synthesis of Diethy13-Amino-3-cyanocyclobutanephonate 61 
3.2.1. Reaction of Diethy13-0xocyclobutanephosphonate 
Under Standard Strecker Conditions 61 
3.2.2. Synthesis of Diethy13-Cyano-3-hydroxycyclobutane-
phosphonate 62 
3.2.2.1 Assignment of Configurations of Diethyl 
3-(Phenylacetoxy)-3-cyanocyclobutanephosphonate 64 
3.2.3. Reaction of Diethy13-0xocyc1obutanephosphonate under 
Bucherer-Bergs Conditions 69 
11 
3.2.4. Synthesis of DiethyI3-(Benzylamino )-3-
cyanocyclobutanephosphonate 70 
3.2.4.1 Attempted Removal of the N-Benzyl Group 73 
3.2.5. Synthesis of DiethyI3-(p-Methoxybenzylamino)-3-
cyanophosphonate 75 
3.2.5.1. Removal of the N-p-Methoxybenzyl Group 76 
3.2.5.2. Assignment of Configurations of Diethyl 
3-(p-Methoxybenzylamino)-3-cyanocyclobutanephosphonate 77 
3.3. Synthesis of Z-3-Aminocyclobutanephosphonic Acid 82 
3.4. Synthesis of DiethyI3-Hydroxy-3-methylcyclobutanephosphonate 83 
3.5. Homologation of the Ketone Functionality 84 
3.5.1. Attempted Syntheses of DiethyI3-Formylcyclobutane-
phosphonate 85 
3.5.2. Synthesis of Diethyl3-Formylcyclobutanephosphonate 87 
3.6. Synthesis of 3-(Amino-carboxymethyl)cyclobutanephosphonic 
Acid 88 
3.6.1. Synthesis of DiethyI3-((Phenylactetylamino)-
cyanomethyl)cyclobutanephosphonate 88 
3.6.2. Enzymatic Separation of Enantiomers 90 
3.6.3. Determination of Enantiomeric Excesses 92 
3.6.4. Synthesis of 3-(Amino-carboxymethyl)-
cyclobutanephosphonic Acids 92 
3.7. Conclusion 93 
Chapter 4 95 
Synthesis of Cycloalkane 1-substituted-1-phosphonate Compounds via 
Phase-transfer Catalysed Alkylations 95 
4.1. Introduction 95 
4.1.1. Development of Antiviral Agents 95 
4.2. The Viral Life Cycle 96 
4.3. Herpes Viruses 96 
4.3.1. Herpes Simplex Virus 97 
111 
4.4. Antiviral Chemotherapy 97 
4.4.1. Nucleoside Analogues 99 
4.4.2. Glucosidase Inhibitors 101 
4.4.3. Metal Ion Chelators as Antiviral Agents 102 
4.4.3.1. Thiosemicarbazones 102 
4.4.3.2. Pyrophosphate Analogues 103 
4.4. Mode of Action of Pyrophosphate Analogues 104 
4.5. Disadvantages of Pyrophosphate Analogues 104 
4.6. Structure-Activity Studies on Pyrophosphate Analogues 105 
4.6.1. Cycloalkane Pyrophosphate Analogues 108 
4.7. Synthesis of Cycloalkane Bisphosphonic and Cycloalkane 
Phosphonoacetic Acid Analogues 109 
4.7.1. Synthesis of Cyclopropane Analogues 109 
4.7.1.1. Cyclopropanebisphosphonic Acid 109 
4.7.1.2. Cyclopropane Phosphonoacetic Acid Analogue 111 
4.8. Phase-transfer Catalysed Alkylations 111 
4.8.1. Phase-transfer Catalysed Synthesis of Tetraalkyl 
Cycloalkane-bisphosphonates and Trialkyl1-
Carboxycyc1oalkanephosphonates 112 
4.9. Discussion 113 
4.9.1. SyntheSis of 1-Carboxycycloalkanephosphonic Acids 113 
4.9.2. Synthesis of Cycloalkanebisphosphonic Acids 115 
4.10. Antiviral Activity of 1-Carboxycyc1oalkane phosphonic 
Acids and Cycloalkanebisphosphonic Acids 120 
4.11. Conclusion 122 
IV 
Chapter 5 123 
a-Phosphoryl Sulfoxides and Related Compounds as Potential 
Asymmetric Catalysts 123 
5.1. Introduction 123 
5.1.1. Methods for the Preparation of Enantiomerically Pure 
Compounds 123 
5.2. Enantioselective Addition of Organometallic Reagents to 
Carbonyl Compounds 125 
5.2.1. Desirable Characteristics for Asymmetric Catalysts of 
Enantioselective Addition of Organometallic Reagents to 
Carbonyl Compounds 126 
5.3. Enantioselective Addition of Organozinc Reagents to Aldehydes 127 
5.3.1. Mechanism of Addition of Dialkylzinc to Aldehydes 129 
5.3.2. Recent Developments in the Search for Asymmetric 
Catalysts for the Addition of Dialkylzincs to Aldehydes 132 
5.4. Discussion 134 
5.4.1. Synthesis of a-Phosphoryl Sulfoxides 134 
5.4.2. Attempted Synthesis of Cyclic a-Phosphoryl Sulfoxides 137 
5.4.3. Synthesis of ~-Hydroxy Sulfoxides 139 
5.4.4. The Use of Chiral Sulfoxides as Potential Asymmetric 
Catalysts 140 
5.5. Conclusion 145 
Chapter 6 146 
Experimental 146 
6.1. General Experimental 146 
6.2. Synthesis of Amino Cyclobutane Phosphonic Acids 148 
6.2.1. 1,3-Dibromoacetone-2,2-dimethoxypropane (92) 148 
6.2.2. DiethyI3,3-Dimethoxycyclobutane-l,1-dicarboxylate (95) 148 
6.2.3. DiethyI3-Oxocyclobutane-l,1-dicarboxylate (96) 149 
v 
6.2.4. Diethyl3-Hydroxycyclobutanedicarboxylate (97) 150 
6.2.5. 1-Chloro-2-benzyloxy-3-bromopropane (91) 151 
6.2.6. Diethyl3-(Benzyloxy)cyclobutanedicarboxylate (98) 151 
6.2.7. Diethyl3-Hydroxycyclobutanedicarboxylate (97) 152 
6.2.8. Diethyl3-(Benzenesulfonyloxy)cyclobutane-1,l-
dicarboxylate (99) 153 
6.2.9. Diethyl3-Bromocyclobutane-1,l-dicarboxylate (100) 154 
6.2.10. Diethyl3-(Trifluorosulfonyloxy)cyclobutane-1,l-
dicarboxylate (106) 154 
6.2.11. Diethyl phosphorylmethyl Phenyl Sulfoxide (115) 155 
6.2.12. [1,1-2H]-Diethyl Phosphorylmethyl Phenyl Sulfoxide 
(lISa) 156 
6.2.13. Diethyl Phosphoryl(l-methylethyl) Phenyl Sulfoxide 
(118) 157 
6.2.14. Diethyl Phosphorylmethyl Methyl Sulfoxide (119) 158 
6.2.15. Diethyl Phosphoryl-[2H]-methyl [2H]-Methyl Sulfoxide 
(119a) 159 
6.2.16. Diethyl3-Hydroxy-4-bromobutanephosphonate (128) 159 
6.2.17. Diethyl3-Benzyloxy-4-chlorobutanephosphonate (130) 160 
6.2.18. Diethyl3-(Benzyloxy)cyclobutane-1-phosphonate (132) 161 
6.2.19. Diethyl3-Hydroxycyclobutane-1-phosphonate (133) 162 
6.2.20. Diethyl3-0xocyclobutane-1-phosphonate (134) 163 
6.2.21. E / Z-Diethyl 3-Cyano-3-hydroxycyclobutane-1-
phosphonate (136) 164 
6.2.22. E / Z-Diethyl3-(Acetoxy)-3-cyanocyclobutane-1-
phosphonate (137) 165 
6.2.23. Z-Diethyl3-(Phenylacetoxy)-3-cyanocyclobutane-1-
phosphonate (138a) 166 
6.2.24. E-Diethy13-(Phenylacetoxy)-3-cyanocyclobutane-
1-phosphonate (138b) 167 
VI 
6.2.25. E/ Z-DiethyI3-Spirohydantoincyclobutane-1-phosphonate 
(139) 168 
6.2.26. E/ Z-DiethyI3-(N,N-Diacetylspirohydantoin)cyclobutane-
1-phosphonate (140) 169 
6.2.27. E/ Z-3-Amino-3-carboxycyclobutane-1-phosphonic acid 
~~ 1m 
6.2.28. Z-Diethyl 3-(Benzylamino )-3-cyanocyclobu tane-
1-phosphonate (141a) 171 
6.2.29. E-DiethyI3-(Benzylamino )-3-cyanocyclobutane 
1-phosphonate (141b) 172 
6.2.30. E-DiethyI3-(Benzylamino )-3-(aminomethyl)-cyclobutane-
phosphonate (143) 172 
6.2.31. Z-3-(Benzylamino )-3-carboxycydobutanephosphonic 
Acid (l44a) 173 
6.2.32. E-3-(Benzylamino )-3-carboxycydobutanephosphonic Acid 
(l44b) 174 
6.2.33. Z-DiethyI3-(p-Methoxybenzylamino )-3-cyano-
cyclobutanephosphonate (145a) 175 
6.2.34. E-DiethyI3-(p-Methoxybenzylamino )-3-cyano-
cyclobutanephosphonate (145b) 176 
6.2.35. Oxidative Removal of the N-p-Methoxybenzyl Group 177 
6.2.36. Removal of the N-p-Methoxybenzyl Group by 
Hydrogenation 177 
6.2.37. Z-DiethyI3-Amino-3-cyanocyclobutanephosphonate 
(135a) 178 
6.2.38. E-DiethyI3-Amino-3-cyanocyclobutanephosphonate 
(135b) 178 
6.2.39. Z-3-Amino-3-carboxycyclobutanephosphonic Acid (78a) 179 
6.2.40. E-3-Amino-3-carboxycyclobutanephosphonic Acid (78b) 180 
6.2.41. Diethyl3-0ximinocyclobutanephosphonate (146) 180 
6.2.42. Z-3-Aminocyclobutanephosphonic Acid (148) 181 
6.2.43. Z-DiethyI3-Hydroxy-3-methylcyclobutanephosphonate 
(149) 182 
Vll 
6.2.44. Z-Diethyl3-Methoxymethyl-3-hydroxycyclobutane-
phosphonate (155) 183 
6.2.45. E / Z-Diethyl3-Formylcyclobutanephosphonate (158) 184 
6.2.46. (+)-E/Z-Diethyl3-(Amino-cyanomethyl)-
cyclobutanephosphonate (159) 185 
6.2.47. (+)-E-Diethyl 3-( (Phenylacetylamino )-cyanomethyl)-
cyclobutanephosphonate (160a) 186 
6.2.48. (+)-Z-Diethyl3-(Phenylacetylamino)-cyanomethyl)-
cyclobutanephosphonate (160b) 187 
6.2.49. Enantioselective Enzyme Hydrolysis of (+)-E-Diethyl 
3-«Phenylacetylamino)-cyanomethyl)cyclobutanephosphonate 
(+)-(160a) 188 
6.2.50. (+ )-E -3-(Amino-carboxymethyl)cyclobutanephosphonic 
Acid (+ )-(79a) 189 
6.2.51. (-)-E-3-(Amino-carboxymethyl)cyclobutanephosphonic 
Acid (-)-(79a) 190 
6.2.52. Enantioselective Enzyme Hydrolysis of (+)-Z-Diethyl 
3-«Phenylacetylamino )-cyanomethyl)cyclobutanephosphonate 
(+)-160b) 190 
6.2.53. (+ )-Z-3-(Amino-carboxymethyl)cyclobutanephosphonic 
Acid (+)-(79b) 191 
6.2.54. (-)-Z-3-(Amino-carboxymethyl )cyclobutanephosphonic 
Acid (-)-(79b) 192 
6.2.55. Preparation of a-Methoxy-a-trifluoromethyl-
phenylacetylamino Derivatives 193 
6.3. Synthesis of Cycloalkane 1,1-Bisphosphonic and l-Carboxy-
I-Phosphonic Acids 194 
6.3.1. t-Butyl Diethyl phosphonoacetate (192) 194 
6.3.2. General Procedure for Preparation of Diethyl t-Butyll-
carboxycycloalkanephosphonates (201-203) 194 
6.3.3. Diethyl t-Butyll-Carboxycyclobutanephosphonate (201) 195 
6.3.4. Diethyl t-Butyll-Carboxycyclopentanephosphonate (202) 195 
6.3.5. Diethyl t-Butyll-Carboxycyclohexanephosphonate (203) 196 
V111 
6.3.6. General Procedure for the Preparation of 
1-Carboxycycloalkane-1-phosphonic Acids (207-209) 196 
6.3.7. 1-Carboxycyclobutanephosphonic Acid (207) 197 
6.3.8. Dicyclohexylammmonium 1-Carboxycyclobutane-
phosphonic Acid (210) 197 
6.3.9. 1-Carboxycyclopentanephosphonic Acid (208) 198 
6.3.10. Dicyclohexylammonium 1-Carboxycyclopentane-
phosphonic Acid (211) 198 
6.3.11. 1-Carboxycyclohexanephosphonic Acid (209) 198 
6.3.12. Dicyclohexylammonium 1-Carboxycyclohexane-
phosphonic Acid (212) 199 
6.3.14. Tetraethyl1,1-Cyclobutanebisphosphonate (214) 200 
6.3.15. Tetraethyl Diprop-2-enemethanebisphosphonate (219) 200 
6.3.16. Tetra-iso-propyl1,1-Cyclopentanebisphosphonate (215) 201 
6.3.17. Tetra-iso-propyl1,1-Cyclohexanebisphosphonate (216) 201 
6.3.18. General Procedure for the Preparation of Cycloalkane-1,1-
bisphosphonic acids (220-222) 202 
6.3.19. Cyclobutane-1,1-bisphosphonic Acid (220) 202 
6.3.20. Bisdicyclohexylammonium Cyclobutane-1,1-
bisphosphonic Acid (223) 202 
6.3.21. Cyclopentane-1,1-bisphosphonic Acid (221) 203 
6.3.22. Bisdicyclohexylammonium Cyclopentane-1,1-
bisphosphonic Acid (224) 203 
6.3.23. Cyclohexane-1,1-bisphosphonic Acid (222) 204 
6.3.24. Biscyclohexylammonium Cyclohexane-1,1-bisphosphonic 
Acid (225) 204 
6.4 Synthesis of a-Phosphoryl Sulfoxides and Related Compounds 205 
6.4.1. (-)-(R)-Diethyl Phosphorylmethyl p-Tolyl Sulfoxide (256) 205 
6.4.2. (-)-(R)-Di-isopropyl Phosphorylmethyl p-Tolyl Sulfoxide 
(257) 206 
6.4.3. (lR)-Diethyl1-Phosphorylethyl p-Tolyl (R)-Sulfoxide (265) 207 
IX 
6.4.4. (-)-(S)-1,1-DiphenyI1,2-Dihydroxypropane (259) 208 
6.4.5. (-)-(2R,5S)-trans-4,4-Diphenyl-5-methyl-1,3,2-dioxathiolane 
2-0xide (260) 209 
6.4.6. (-)-(1R,SS)-2,2-Diphenyl-1,2-dihydroxy-propyI2-O-t-
Butylsulfinate (262) 210 
6.4.7. (+)-(S)-Diethyl Phosphorylmethyl t-Butyl Sulfoxide (263) 211 
6.4.8. (+ )-(S)-Di-iso-propyl Phoshorylmethyl t-Butyl Sulfoxide 
(264) 212 
6.4.9. General Procedure for the Synthesis of Diethyl 
1-Phosphorylcycloalkane Phenyl Sulfides 213 
6.4.10. Diethyl1-Phosphorylcyclobutane Phenyl Sulfide (121) 214 
6.4.11. Diethyl1-Phosphorylcyclopentane Phenyl Sulfide (266) 214 
6.4.12. DiethyI1-Phosphory1cyclohexane Phenyl Sulfide (267) 215 
6.4.13. (+)-(S)-Methyl Tolyl Sulfoxide (268) 215 
6.4.14. (+)-(R)-2,2-dimethyl-2-hydroxymethyl p-Tolyl Sulfoxide 
(269) 216 
6.4.15. (+ )-(R)-2,2-Diphenyl-2-hydroxymethyl p-Tolyl Sulfoxide 
(270) 217 
6.4.16. General Procedure for Diethylzinc Reactions 218 
6.4.17. General Procedure for Diethylzinc Reaction with 
Titanium Tetra-iso-propoxide 218 
References 220 
Appendix 1 Crystal Data and Structure Refinement for Z-Diethyl 
3-(Phenylacetoxy)-3-cyanocyclobutanephosphonate 230 
Appendix 2 Crystal Data and Structure Refinement for E-Diethyl 
3-(p-Methoxybenzylamino )-3-cyanocyclobutanephosphonate 236 
x 
List of Figures 
Figure 1.1 Aminomethanephosphonic acid (1), AEP (2) and (HO)-AEP 1 
Figure 1.2 Angiotensin Converting Enzyme Inhibitor 2 
Figure 1.3 (R)-( -)-1-Amino-l-( 4-hydroxyphenyl)ethylphosphonic Acid 3 
Figure 1.41-Amino-(2-(3,4)-dihydroxyphenyl)ethylphosphonic Acid 
and Amino-((3,4)-dihydroxyphenyl)methylphosphonic Acid 4 
Figure 1.5 Inhibitors of Alanine Racemase 
Figure 1.6 Naturally Occurring Aminophosphonic acids and 
Phosphonopeptides with Antibacterial Properties 
Figure 1.7 Naturally Occurring Aminophosphonous Acids 
4 
5 
8 
Figure 1.8 Commercial Herbicidal Phosphonic Amino Acid Derivatives 9 
Figure 1.9 Anticancer Phosphonic Amino Acid Derivatives and 
Phosphonopeptides 10 
Figure 1.10 Endogenous Neuroactive Amino Acids 11 
Figure 1.11 Exogenous Neurotoxins 13 
Figure 1.12 Possible Candidates for an Endogenous EAA 
Neurotransmitter 15 
Figure 1.13 Potent and Selective Agonists at the NMDA Receptor 16 
Figure 1.14 Conformationally Restrained NMDA Agonists 16 
Figure 1.15 Competitive NMDA Receptor Antagonists 18 
Figure 1.16 Conformationally Restrained NMDA Antagonists 19 
Figure 1.17 Agonists at the AMP A Receptor 20 
Figure 1.18 Structurally Restrained and Sterically Hindered AMP A 
Agonists 21 
Figure 1.19 Competitive Antagonists at the AMP A Receptor 22 
Figure 1.20 Agonists at the Kainic Acid Receptor Sub-type 23 
Figure 1.21 Competitive Antagonists at the Kainic Acid Receptor 24 
Figure 1.22 Compounds that Act at the AP4 Receptor 26 
Figure 1.23 Compounds that Act at Metabotropic Receptor 29 
Figure 1.24 3-Amino-3-carboxycyclobutanephosphonic acid 30 
Figure 1.25 3-(Amino-carboxymethly)cyclobutanephosphonic Acid 31 
Figure 2.1 DialkyI3-substituted-cyclobutanephosphonate 33 
Figure 2.2 Synthesis of Cyclopentane and Cyclohexane Analogues of 
AP4 34 
Figure 2.3 Synthesis of (E/ Z)-2-Amino-4,5-methano-5-
phosphonopentanoic Acid 
Figure 2.4 Malonate Synthesis of Cyclobutanes 
Scheme 2.1. 
Xl 
35 
36 
38 
Scheme 3.8. 75 
Scheme 3.9. 76 
Scheme 3.10. 77 
Figure 3.8 13C Nmr spectrum of Z-DiethyI3-(p-Methoxybenzyl-
amino )-3-cyanocyclobutanephosphonate 78 
Figure 3.9 13C Nmr spectrum of E-DiethyI3-(p-Methoxybenzyl-
amino )-3-cyanocyclobutanephosphonate 79 
Figure 3.10 Ortep Plot of E-DiethyI3-(p-Methoxybenzylamino )-3-
cyanocyclobutanephosphonate 81 
Scheme 3.11. 82 
Figure 3.11 Lower energy conformation of DiethyI3-0ximino-
cyanocyclobutanephosphonate 83 
Scheme 3.12. 83 
Figure 3.12 Nucleophilic Addition to the Low and High Energy 
Conformations of DiethyI3-0xocyanocyclobutane-
phosphonate 84 
Scheme 3.13. 85 
Scheme 3.14. 86 
Scheme 3.15. 88 
Scheme 3.16. 89 
Scheme 3.17. 91 
Scheme 3.18. 91 
Scheme 3.19. 93 
Figure 4.1 The Structure of Amantadine and Rimantadine 99 
Figure 4.2 The Structure of Ribavirin and Acyclovir 100 
Figure 4.3 The Structure of Some Nucleosides with Antiviral Activity 101 
Figure 4.4 The Structure of Some Alkaloid Antiviral Compounds 102 
Figure 4.5 Thiosemicarbazones with Antiviral Activity 103 
Figure 4.6 Pyrophosphate and Antiviral Pyrophosphate Analogues 104 
Figure 4.7 Clinically Used Bone Chelating Bisphosphonic Acids 105 
Figure 4.8 Tetazole and Triazole Analogues of Phosphonoacetic Acid 106 
Figure 4.9 Metal Chelates of Phosphonoformic, Phosphonacetic, and 107 
Figure 4.10 Methylenebisphosphonic acid and Methylenebis-
thiophosphonic Acid 108 
Figure 4.11 Synthesis of Cyclopropanebisphosphonic Acid 110 
Figure 4.12 Synthesis of Diethyl1-Carboxycyclopropanephosphonic 
Acid 111 
Figure 4.13 Suggested Mechanism for Extractive Alkylation 112 
Scheme 4.1. 113 
XUI 
Scheme 4.2. 115 
Scheme 4.3. 115 
Scheme 4.4. 117 
Scheme 4.5. 118 
Figure 4.14 Synthesis of l-Substitutedcycloalkanephosphonates 119 
Figure 4.15 Aromatic l-Substituedcycloalkanephosphonates 119 
Figure 4.16 Synthesis of Diethyl1-Isocyanocycloalkanephosphonates 120 
Figure 5.1 Synthesis of (+)-Vincamine from L-Aspartic Acid 124 
Figure 5.2 Evans Chiral Oxazolidone Auxiliary 125 
Figure 5.3 Asymmetric Catalysis by (-)-DAIB 128 
Figure 5.4 Highly Enantioselective Asymmetric Catalysts for the 
Addition of Dialkylzincs to Aldehydes 128 
Figure 5.5 Proposed Transition State Complex for the Reaction Between 
Diethylzinc and Benzaldehyde 129 
Figure 5.6 Stereocontrol of the Reaction Between Diethylzinc and 
Benzaldehyde 130 
Figure 5.7 Alternative Transition State Complexes for the Reaction 
Between Diethylzinc and Benzaldehyde in the Presence of 
(-)-DAIB 131 
Figure 5.8 p-Hydroxy Sulfoximides 132 
Figure 5.9 Dialkyl thiophosphoramidates 133 
Figure 5.10 a-Phosphoryl Sulfoxides and p-Hydroxy Sulfoxides 133 
Scheme 5.1. 134 
Scheme 5.2. 135 
Scheme 5.3. 136 
Scheme 5.4. 137 
Scheme 5.5. 138 
Scheme 5.6. 139 
Scheme 5.7. 140 
Scheme 5.8. 140 
Figure 5.11 Proposed Transition State Complex for the Action of 
p-Hydroxy Sulfoximides 143 
Figure 5.12 Stereocontrol of the Reaction Catalysed by (S)- p-Hydroxy 
Sulfoximides 144 
Figure 5.13 Proposed Transition State Complexes for Catalysis by 
Chiral Sulfoxides 144 
XIV 
List of Tables; 
Table 4.1 Licensed Antiviral Drugs 
Table 4.2 Antiviral Activity of Cycloalkane Compounds 
Table 5.1 Catalytic Activity of Chiral Sulfoxides 
xv 
98 
121 
141 
Acknowledgements 
I would like to express my deepest gratitude to the late Dr D. W. Hutchinson 
who encouraged me to start this work and whose memory encouraged me to 
complete it. I would also like to thank Dr P. C. Taylor and Professor D. H. G. 
Crout for taking on the supervision of this project and for their advice and 
encouragement during the course of my studies. 
Thanks is also due to Mr P. Moore for doing the microanalyses, Dr J. Hastings 
for running some of the nmr spectra, Mr I. Katyal for the mass spectra, Dr W. 
E. Errington for doing the X-ray crystallography and Dr A. Easton in the 
Department of Biological Sciences Warwick University, for carrying out the 
antiviral assays. 
I would also like to thank all my colleagues in the department of chemistry, 
both past and present, for providing amusement and encouragement and 
generally making it a fun place to work. Last but not least, a special thankyou 
to Derek Pert for his help and encouragement during the course of this work 
and for finding other things to do while I completed this thesis . 
. 
XVI 
Declaration 
The work described in this thesis is the original of the author, except 
where acknowledgement has been made to results and ideas previously 
published. The work was carried out at the Department of Chemistry, 
University of Warwick, between January 1st, 1991 and December 30th, 1994 
and has not been previously submitted for a degree at any institution. 
XVll 
Abstract 
Cyclic phosphonic acid analogues of the endogenous amino acids 
L-aspartic acid and L -glutamic acid have played a major role in the 
characterisation of excitatory amino acid receptors in the central nervous 
system. The aim of the first section of this work is to describe the development 
of a synthetic route that gives access to a novel series of compounds, 
3-substituted-cyclobutanephosphonic acids. The synthesis of a valuable 
intermediate diethyl3-oxocyclobutanephosphonate is described. Elaboration 
of the ketone functionality of this compound provides allows the synthesis of a 
number of previously inaccessible 3-substituted-cyclobutanephosphonates, 
including E- and Z-3-amino-3-carboxy-cyclobutanephosphonic acid, 3-amino-
cyclobutanephosphonic acid and the four stereoisomers of 3-(amino-carboxy-
methyl)-cyclobutanephosphonic acid. Enzymatic hydrolysis of the 
phenyl acetyl derivative of diethyl 3-(amino-cyanomethyl)-
cyclobutanephosphonate by penicillinacylase allowed the preparation of 
3-(amino-carboxy-methyl)-cyc1obutane-phosphonic acid with high 
enantiomeric purity. 
The antiviral activity of phosphonoacetic acid (P AA) has long been 
recognised. However, a number of problems are associated with the 
administration of this compound as an antiviral, these include high toxicity to 
the hosts cells, poor uptake in to cells and absorbtion by teeth and bones. One 
approach to solving some of these problems may be to make the compounds 
more lipophilic by increasing the number of carbon atoms in the molecule. The 
synthesis of a number of cyclic analogues of P AA and the related 
bisphosphonic acids is described. These compounds are prepared by phase 
transfer catalysed alkylation of trialkyl phosphonoacetate and tetra alkyl 
methylenebisphosphonate. The antiviral activity of these compounds against 
Herpes simplex virus 1 (HSVl) was investigated. 
A series of chiral at sulfur, a-phosphoryl sulfoxides and ~-hydroxy sulfoxides 
were prepared. These compounds were investigated for their ability to 
enantioselectively catalyse the reaction between diethylzinc and 
benzaldehyde. Although this reaction was catalysed by all of these 
compounds, this action was not accompanied by enantioselectivity. 
Comparison of our results with those obtained for ~-hydroxy sulfoximides 
enabled this lack of enantioselectivity to be explained by the analysis of the 
proposed transition state complexes . 
... 
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Chapter 1 
Introduction 
1.1. Biologically Active Phosphonic Acid Analogues of Amino 
Acids 
Aminoalkanephosphonic acids (Figure 1.1) are broadly defined as 
analogues of amino acids in which a carboxylic group is replaced by a 
phosphonic (or related) group. Although they were first mentioned in the 
literature in 1943 in a patent describing the synthesis of 
aminomethanephosphonic acid (1),1 interest in these compounds increased 
during the 1960s with the discovery of 2-aminoethanephosphonic acid (AEP) 
(2) in cultures of Tetrahymena thermophila. Since that time AEP has been found 
in a variety of living organisms from micro-organisms to marine creatures and 
mammals, including humans2 and its biosynthesis has been studied in detai1.3 
More recently, the related compound, 2-amino-1-hydroxyethylphosphonic 
acid «HO)-AEP) (3) has been isolated from cultures of Acanthamoeba 
castellanii. 4, 5 However, it was during the 1970s that the wide range of 
biological activities of both synthetic and natural aminophosphonic acids 
became apparent. 
(1) (2) (3) 
Figure 1.1: Aminomethanephosphonic acid (1) , AEP (2) and (HO)-AEP (3) 
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Because they are structural analogues of amIno acids, 
aminophosphonic acids usually act as their antagonists and compete with 
their carboxylic counterparts for the active sites of enzymes or other cell 
receptors. As inhibitors of metabolic processes, they exert their physiological 
activity as antibacterial agents, neuroactive compounds, anticancer drugs or 
pesticides. 
1.1.1. Enzyme Inhibition and Antimicrobial Activity of Aminophosphonic 
Acids 
The concept that phosphonic and phosphinic acids mimic the putative 
tetrahedral transition states of enzyme reactions taking place at carbonyl 
groups of carboxylic acids has proven an effective basis for designing potent 
enzyme inhibitors. The compound (Figure 1.2) that represents the most 
successful commercial implementation of the concept of a transition state 
analogue is Fosinopril (4), an inhibitor of angiotensin converting enzyme 
(ACE).6 This compound is a derivative of 2-phosphonopyrrolidine, the 
phosphonic acid analogue of proline. Fosinopril (4) is an acyloxy prodrug of 
the active compound, which is metabolised to the active phosphonic acid (4a) 
by intestinal and hepatic esterases. It has been proposed that the phosphinyl 
function coordinates to the zinc ion at the active site of the enzyme and 
approximates the tetrahedral geometry of the hydrated amide transition state 
resulting from the addition of water to the scissile amide bond of the substrate, 
resulting in inhibition of the enzyme. 7 
CH3 
(4) Fosinopril R= {- CH
3 
O~CH3 
o 
(4a) Active ACE inhibitor R=H 
Figure 1.2: Angiotensin Converting Enzyme Inhibitor 
2 
I-Aminocyclopropanephosphonate (ACPP) has been prepared 
synthetically. It is the phosphonic acid analogue of I-amino 
cyclopropanecarboxylate, a compound that is found in trace amounts in the 
tissues of many plants. The effect of ACPP on pyridoxal 51-phosphate linked 
enzymes has been investigated. ACPP was found to be a potent inhibitor of 
I-aminocyclopropanecarboxylate deaminase from Psuedomonas sp. and alanine 
racemase from Bacillus steaothermophilus.8 More recently the synthesis of a 
large number of 2-substituted- and 2,3-disubstituted-l-
aminocyclopropylphosphonic acids has been described. However, no 
biological data has yet been reported.9 
The only known naturally occurrIng a-aminophosphonic acid 
(Figure-1.3) is (R)-( -)-I-amino-I-(4-hydroxyphenyl)ethylphosphonic acid (5), 
the phosphonic acid analogue of tyrosine. This compound was identified as a 
novel amino acid in two tripeptides with antihypertensive activity isolated 
from cultures of Actinomycetes K-26 and Actinommadura spiculaspora.lO 
(5) 
Figure 1.3: (R)-(-)-1-Amino-1-(4-hydroxyphenyl)ethylphosphonic Acid (5) 
Although many phosphonic acid analogues of naturally occurring 
amino acids act as inhibitors of enzymes, it has also been reported that 
structural differences between phosphonic and carboxylic groups do not 
prevent aminophosphonic acids serving as substrates for enzymes that 
normally utilise amino acids. The relatively few reported examples include 
only reactions that proceed without direct participation of the carboxylic (or 
phosphonic) function. I-Amino-(2-(3,4)-dihydroxyphenyl)ethylphosphonic 
3 
acid (Figure 1.4) (6), the phosphonic acid analogue of 
L-3,4-dihydroxyphenylalanine (L-DOPA), has been found to be converted into 
a melanin like-compound by the enzyme tyrosinase from mushrooms. 
Shortening of the alkyl chain by one methylene unit gave amino-((3,4)-
dihydroxyphenyl)methylphosphonic acid (7), one of the most powerful 
inhibitors of this enzyme .11 
HO 
(6) 
NH2 
II"~ I""ILJ 
'. "un 
P- OH H II 
o 
HOX) I NH2 
HO ~ 11,..1 - " a-i 
r- P - I""ILJ H II un 
o 
(7) 
Figure 1.4: l-Amino-(2-(3,4)-dihydroxyphenyl)ethylphosphonic Acid (6) and 
Amino-«3,4)-dihydroxyphenyl)methylphosphonic Acid (7) 
The inhibition of enzymes is also the underlying mechanism for a 
variety of aminophosphonic acids (Figure 1.5) that act as antibiotics. The 
group of enzymes known as alanine racemases are an attractive target for 
antibacterial drug development. These enzymes operate in the early stages of 
cell growth. By catalysing the racemisation of alanine they provide D-alanine 
for inclusion in to the bacterial cell wall. The phosphonic acid analogue of 
alanine, L-1-aminoethylphosphonic acid (Ala -P) (8), along with alafosfolin (9), 
a synthetic peptide incorporating Ala-P, have been found to be potent 
inhibitors of a racemase from Gram-positive bacteria. 12 
HO 
\~ 
",P NH2 HO II 
o 
(8) (9) 
Figure 1.5: Inhibitors of Alanine Racemase 
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A number of natural antibiotic aminophosphonic acids produced by a 
variety of micro-organisms have been identified (Figure 1.6). Many of these 
natural aminophosphonic acids are incorporated in to small peptides. These 
include; bialaphos (10) (Streptomyces viridochromogenes ),13 phosalacine (11) 
(Kitasporia phosalacinea) ,14 phosphinothricin (12) ( S. hygroscopicus),15 
plumbeomycins (13) (5. plumbeus),16 the related rhizotocins (14) (Bacillus 
subtilis),17 fosmidomycin (15) and other related compounds (16-18) 
(5. lavendulae and S. rubellomurins).18 
(10) 
OH 0 OH 0 
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(17) (18) 
(11) 
0 
II OH 
H2NY"'P( 
CH3 
002H 
(12) 
(13) 
X=OH,NH2 
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(14) 
R=H, i-Pr, i-Bu,s-Bu 
Figure 1.6: Naturally Occurring Aminophosphonic acids and Phosphonopeptides with 
Antibacterial Properties 
The plumbeomycins (13) and rhizocticines (14) are groups of di- and 
tripetide antibiotics that are thought to interfere with threonine or threonine-
related metabolism. The unusual aminophosphonic acid, E-2-amino-5-
phosphono-3-pentenoic acid, a constituent of both rhizocticines and 
plumbeomycins, has been shown to irreversibly inhibit threonine synthase 
5 
from Escherichia coli. These data indicate that the toxicity of rhizocticines and 
plumbeomycins is due to inhibition of threonine synthase by E-2-amino-S-
phosphono-3-pentenoic acid, which is liberated by peptidases after uptake 
into the cell. 19 
Fosmidomycin, 3-( N- formyl-N -hydroxyamino )propylphosphonic acid 
(15), is a promising antibiotic. It is thought to inhibit the biosynthesis of an 
isoprenoid precursor (possibly farnesyl phosphate). This compound has 
already passed phase I tolerance trials and has been recommended for further 
clinical evaluation.12 A number of related compounds have also been isolated 
from 5 trep tomycete s p e c Ie s. Of 
hydroxyamino)propylphosphonic acid (16) 
these 3-(N-acetyl-N-
and (2R)-3-(N-acetyl-N-
hydroxyamino)-2-hydroxypropylphosphonic acid (17) have weaker 
antibacterial action than fosmidomycin. 3-(N-Formyl-N-hydroxyamino )-1-
trans-propenylphosphonic acid (18) has greater antibacterial activity than the 
previous two compounds, but is still less active than fosmidomycin (15).2 
Several phosphonopeptides are known to have potent antibacterial 
activity. Alafosfalin (9), a synthetic phosphonopeptide containing the 
phosphonic acid analogue of alanine (8), is probably the most intensively 
studied member of the phosphorus containing antibiotics. Extensive studies 
have established its usefulness in the treatment of urinary tract infections.2o 
The mechanism of action of these phosphonopeptides involves active 
transport through the bacterial cell wall by means of peptide permeases and 
enzymatic cleavage of the peptide bond within the cell to liberate the active 
aminophosphonic acid. In the case of alafosfalin (9), this is 
L-1-aminoethylphosphonic acid (8) which then inhibits alanine racemase. The 
naturally occurring peptide Bialaphos (10) releases phosphinothricin (12), a 
phosphinic amino acid which is also produced by various Streptomycete 
species. It is a potent inhibitor of the enzyme glutamine synthase which 
converts glutamic acid to glutamine,21 a reaction of primary importance in the 
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metabolism of nitrogen. Interaction of phosphinothricin with glutamine 
synthase occurs only under conditions in which phosphorylation can occur. 
This strongly suggests that further enzymatic modification occurs to produce 
phosphorylated phosphinothricin, which is thought to mimic a putative 
tetrahedral transition state of the enzymatic reaction.12 
Since the wide range of biological activities of phosphinothricin (12) 
and related compounds were first reported, many further studies of both their 
biological activities and total synthesis have been carried out. 21 It has been 
discovered that the L-phosphinothricin is twice as active as the racemic 
mixture, indicating that the active enantiomer is the L-isomer. Many 
asymmetric syntheses of both antipodes of phosphinothricin have been 
reported using a variety of different methods to ensure optical purity.21 These 
range from starting with the chiral pool compounds L-methionine, L-glutamic 
acid22 or L-aspartic acid23 or other chiral building blocks such as a chiral bis-
lactim ether,24 to asymmetric hydrogenation of phosphino a-acylmido 
acrylates25 and enzymatic hydrolysis of amide, carboxylic and phosphinic 
ester intermediates. 15,26,27 
A number of a - and y-substituted phosphinothricins have been 
prepared and their activity as inhibitors of glutamine synthetase investigated. 
Substitution in the a-position did little to change the inhibitory action of these 
compounds. However, activity was significantly reduced by substitution in 
the y-position. Interestingly, trans-3-amino-3-carboxycyclohexylphosphinic 
acid, in which the a- and y-positions are joined in a six-membered ring, 
showed similar activity to phosphinothricin. 28 
The phosphonous acid analogues (Figure 1.7) of both aspartic acid and 
glutamic acid, l-amino-l-carboxyethanephosphonous acid (19) and l-amino-l-
carboxypropanephosphonous acid (20) respectively, have been isolated from 
S. hygroscpicus. The glutamic acid analogue has been shown to be an 
intermediate in the synthesis of phosphinothricin.29 A number of 
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phosphonous acid analogues of naturally occurring amino acids have been 
synthesised.3o Several of these compounds showed moderate to good 
antibiotic activity in vitro. The most active compounds were the analogues of 
L-alanine, L-valine and L-methionine. 3o 
o 
" ~ HO c.. ~ .P'"vn 
2 - "-"" "-"" , 
~ H 
NH2 
(19) (20) 
Figure 1.7: Naturally Occurring Aminophosphonous Acids 
1.1.2. Plant Growth Regulatory Aminophosphonic Acids 
Glyphosate, (N-phosphonomethyl)glycine (Figure 1.8) (21) is best 
known under Monsanto's trade name Roundup, which is now marketed in 
more than 100 countries. Glyphosate has been shown to elicit its herbicidal 
properties via inhibition of 5-enolpyruvylshikimate-3-phosphate synthase, 
thus blocking the shikimate pathway.31 The lead provided by the structure of 
(N-phosphonomethyl)glycine (21) has been explored exhaustively. However, 
information on the structures and activities of these analogues is presented 
almost exclusively in the patent literature and little is recorded about the 
structure-activity relationships. 12 One other amino phosphonic acid derivative 
with herbicidal properties is the compound di-n-butyl l-(N-n-
butylamino)cyclohexylphosphonate (22) which is licensed for use in Germany 
under the tradename Trakephon. The mechanism of action of this compound is 
not clear, although it appears to disrupt the integrity of the plant cell 
membrane.12 
8 
HO[(' ~ /OH N P 
II'OH 
o H 0 
(21) (22) 
Figure 1.8: Commercial Herbicidal Phosphonic Amino Acid Derivatives 
The antibacterial compound phosphinothricin (12) also has important 
herbicidal activity.21 The mono ammonium salt of phosphinothricin 
(glufosinate-ammonium) is an active ingredient of Basta, Hoechst's herbicide 
which is marketed in Europe and Japan. It appears that its mechanism of 
herbicidal activity is the same as that of its antibacterial action, that is it 
inhibits glutamine synthase so that plants treated with it rapidly accumulate 
toxic levels of ammonia.12 The phosphonous acid analogue (20) of 
phosphinothricin also shows interesting plant growth inhibiting properties. 30 
The unusual, naturally occurring amino acid 3,4-didehydro-5-
phosphono-D-norvaline is found in the antibacterial phosphonopeptides 
plumbeomycins (13). This aminophosphonic acid has been shown to have 
pronounced herbicidal activity, with high selectivity towards 
monocotyledons.32 
1.1.3. Anticancer Activity of Phosphonic Amino Acids 
Some analogues of phosphinothricin have been shown to have 
anti-tumour properties (Figure 1.9). The phospha c-peptides (23 & 24) have 
both been shown to inhibit the growth of the experimental tumour L1210 in 
mice.27 The cyclic analogue of phosphinothricin (25) and an analogue (26) of 
the tripeptide Bialaphos, incorporating this cyclic amino acid have also been 
shown to have anti-cancer properties. Interestingly, all these compounds 
exhibit very low herbicidal activity, unlike other phosphinothricin derived 
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compounds. Little information is available about the anticancer activities, but 
both compounds were active against the tumour cell lines L-1210 and 5180-
ascides in mice. IS It is also reported that all these compounds have low 
toxicity, especially the phospho lane amino acid. The azaphosphorinane (27), a 
cyclic analogue of norvaline, has also been shown to have pronounced 
antitumour activity. However, unlike the phosphinic acid derivatives it also 
shows a high toxicity.32 
(23) (24) 
(25) (26) (27) 
Figure 1.9: Anticancer Phosphonic Amino Acid Derivatives and Phosphonopeptides 
Aminoalkanephosphonic acids and the related aminophosphinic and 
aminophosphonous acids are found throughout nature and they have been 
shown to have a wide range of biological activities. Since the discovery of their 
biological activities, phosphonic acid analogues of almost all the proteinergic 
amino acids have been synthesised.3o Because of the well recognised 
involvement of various amino acids in neurotransmission processes, it is not 
surprising that aminophosphonates are also among the various amino acid 
analogues examined for neurophysiological activities. Aminophosphonic acids 
are now recognised as extremely important neuroactive compounds that have 
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played a significant role in the development of understanding of excitatory 
amino acid neurotransmission. 
1.2. Excitatory Amino Acid Neurotransmitters 
Amino acids (Figure 1.10) play an intimate role in neurotransmission 
processes in the mammalian central nervous system (CNS). y-Aminobutyric 
acid (GABA) (28) and its analogues have inhibitory actions mediated via two 
distinct receptor types termed GABA-A and GABA-B. The excitatory amino 
acids L-aspartic acid (29) and L-glutamic acid (30) have been shown to mediate 
their actions via several distinct classes of excitatory amino acid (EAA) 
receptors, known as NMDA, AMP A, kainate, AP4 and metabotropic sub-
types. 
H02~NH2 
(28) (29) (30) 
Figure 1.10: Endogenous Neuroactive Amino Acids 
1.2.1. Physiological and Pathophysiological Functions of EAA Receptors 
EAA receptors are now accepted to be the main transmitter receptors 
mediating synaptic excitation in the mammalian CNS. They are involved with 
many physiological phenomena, ranging from the processing of sensory 
information through coordinated movement patterns to cognitive processes, 
learning and memory. 33, 34 Dysfunction of these systems leads to various 
neurological disorders including memory disorders, epilepsy and spasticity. 
There is also considerable evidence to indicate that EAA receptors playa role 
in neurodegenerative conditions such as those associated with Huntington's 
disease, stroke, schizophrenia and Alzheimer's disease.35 
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A number of neurological disorders are characterised by excitatory 
amino acid neuronal degeneration and excitotoxicity due to hyperactivation of 
EAA receptors may be involved in the aetiology of these diseases. Strong 
evidence for the involvement of excitatory amino acids in these disorders 
arises from the fact that administration of excitatory amino acids to animals 
induce similar patterns of neurodegeneration to those observed in human 
neurodegenerative disorders. The fact that administration of excitatory amino 
acid antagonists can block these effects also indicates that these receptors play 
an important role in these diseases. 
Neuronal loss after ischaemia, arISIng from stroke, hypoxia and 
hypoglycemia also appears to be due to an excitotoxic mechanism mediated 
by hyperstimulation of excitatory amino acid receptors. These energy deficient 
states cause an extracellular increase in concentrations of L-aspartic (29) and 
L-glutamic (30) acids, resulting in the neurons literally being excited to death. 
The brain damage that results from these conditions occurs mainly in regions 
with prominent excitatory systems and, in animal models, can be prevented to 
a large degree by the administration of certain excitatory amino acid receptor 
antagonists. 35 
One syndrome characterised by acute neurodegeneration arises due to 
poisoning by domoic acid (Figure 1.11) (31). It is probably induced by selective 
activation of kainate receptors. Domoic acid is produced by the marine algae 
Psuedo-nitzchia australis and can be consumed in toxic quantities by people 
eating mussels that have fed on the algae. An outbreak of domoic acid 
poisoning occurred in western Canada in 1987. Symptoms arose a few hours 
after ingestion of the mussels and included acute sensorimotor disturbances 
and in some cases a chronic syndrome with amnesia resulted. Four of the cases 
were fatal and the pathology was found to be largely confined to areas of the 
brain with high densities of kainate receptors. 36 
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Two chronic neurological syndromes have been tentatively linked to 
dietary consumption of amino acid toxins of plant origin. Neurolathyrism, a 
spastic disorder, occurring in East Africa and southern Asia is associated with 
the consumption of chick peas, a staple food in times of drought. The toxin has 
been identified as ~N-oxalylamino-L-alanine (BOAA) (32), which behaves as a 
glutamate-like excitant principally at AMP A receptors. The Chamorros living 
on the Pacific island of Guam show a high incidence of amyotropic lateral 
sclerosis (ALS), often associated with clinical signs of senile dementia. Guam 
disease is thought to be linked to a plant whose seeds are used to make flour. 
The flour contains the amino acid ~-N-methyl-amino-L-alanine (BMAA) (33), 
that is thought to be the exogenous excitotoxin in Guam disease. BMAA is a 
neutral amino acid that is not directly excitotoxic in vitro. However, in the 
presence of bicarbonate (often used in baking) it becomes excitotoxic, perhaps 
due to the formation of an a-methyl carbamate. The excitotoxicity of BMA (33) 
in vitro can be blocked by NMDA antagonists indicating an action at NMDA 
receptors.35 
31 
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Figure 1.11: Exogenous Neurotoxins 
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There is a need for effective prophylaxis and therapy In acute 
disorders that involve excitotoxic mechanisms and in chronic 
neurodegenerative disorders. Thus, excitatory amino acid receptor agonists 
and antagonists are of major interest as both experimental tools and as 
potential drugs for the treatment for CNS disorders. 
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1.3. EAA Receptor Pharmacology 
It is now 40 years since the convulsant effects of L-aspartic acid (29) 
and L-glutamic acid (30) were first reported. 37 Since that time a wide array of 
electrophysiological, biochemical, pharmacological and anatomical studies 
have been carried out using excitatory amino acids. Although the 
development of selective agonists and antagonists has led to an increased 
understanding of EAA receptors, the identification of an endogenous 
neurotransmitter has proved more difficult. 
Both L-aspartic acid (29) and L-glutamic acid (30) are present in the 
CNS and both have the ability to cause excitatory responses at EAA receptors. 
However, the ubiquity of L-glutamic acid in the brain and its involvement in 
both protein synthesis, nitrogen metabolism and finally its role as a precursor 
of the inhibitory neurotransmitter GABA (28) makes studies of its function as a 
neurotransmitter very complicated.38 Considerable evidence has led to the 
proposal that L-aspartic acid (29) and probably also L-glutamic acid (30) are 
both endogenous neurotransmitters in the mammalian eNS.39 The most likely 
scenario is that each of these compounds acts as the endogenous 
neurotransmitter on different populations of receptors. 33 However, three 
agents (Figure 1.12) other than L-aspartic acid (29) and L-glutamic acid (30) 
have also been postulated as transmitter candidates for synapses mediated by 
excitatory amIno acid receptors; homocysteaic acid (34), 
N-acetylaspartylglutamic acid (NAAG) (35) and quinolinic acid (36). All these 
compounds fulfil many of the criteria for an endogenous neurotransmitter and 
it is possible that some or all of these compounds may act at different receptor 
populations. 40 
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(34) (35) (36) 
Figure 1.12: Possible Candidates for an Endogenous EAA Neurotransmitter 
1.3.1. Receptor Characterisation 
As both L-aspartic acid (29) and L-glutamic acid (30) are both flexible 
molecules capable of existing in a multitude of conformations. This is probably 
a major factor in their ability to activate a range of different EAA receptors. 
However, this makes them rather poor tools for the understanding of these 
receptors. The classification of EAA receptor sub-types has, therefore, relied 
on the development of potent and selective exogenous compounds. Initial 
studies utilising a variety of agonists and antagonists of excitatory 
neurotransmission indicated that at least three ionotropic receptor systems 
mediate the actions of excitatory amino acids, NMDA, AMP A and kainate 
receptor types, all of which are linked to ion channels. More recently, two 
other receptor classes have been identified. The AP4 receptor type and the 
'metabotropic receptor' have both been recognised as having actions linked to 
adenylate cyclase activity and the metabolism of phosphonoinositol 
respectively. 41,42 
1.4. Excitatory Amino Acid Receptor Sub-types 
1.4.1. NMDA Receptor 
The NMDA receptor is named after the first potent and selective 
agonist, N-methyl-D-aspartic acid (37), known for this receptor type. Several 
very potent and selective agonists for this receptor type have now been 
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discovered (Figure 1.13). Two of the most potent known agonists are 
D,L-(tetrazol-5-yl)glycine43 (38) and (E-1-aminocyclobutane-1,3-dicarboxylic 
acid (E-ACBD) (39), which is 20 times more potent than NMDA.44 The Z-
isomer of this compound, a natural product found in the seeds of Ateleia 
herbert smithii Pittier,45 shows only one third the potency of NMDA. 
(37) (38) (39) 
Figure 1.13: Potent and Selective Agonists at the NMDA Receptor 
The conformationally restrained trans-ACBD (39) and other less 
potent, but selective, conformationally restrained NMDA agonists (Figure 
1.14) such as (2R,3R)-trans-2,3-piperidinedicarboxylic acid (trans-PDA) (40), 
(lR,3R)-1-amino-cyclopentane-l,3-dicarboxylic acid (lR,3R-ACPD) (41), 
(25 ,3R,45)-a-( carboxy-cyclopropyl)glycine ((25 ,3R,45 )-CCG) (42) and ibotenic 
acid (43) are held in a 'folded' conformation. This suggests that the active 
conformation of glutamic acid at the NMDA receptor may be a folded one. 46, 47 
(X CO 2H I-O~C02H H02C H HO ~NH2 
" H : C02H NH2 
N "'/ C02H 
:., C02H ~,\. 
H NH2 
(40) (41) (42) (43) 
Figure 1.14: Conformationally Restrained NMDA Agonists 
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The finding that a racemic mixture of a-amino adipate (a-AA), the 
next higher homologue of glutamic acid, possessed an inhibitory action 
against the amino acid induced excitations, marked the starting point in the 
search for NMDA receptor antagonists (Figure 1.15). D-a-Aminoadipate (44) 
was identified as the first competitive antagonist at NMDA receptors. 48 
Isosteric replacement of the ro-carboxylate group of the amino acid by 
other functionalities resulted in the finding that some compounds in which the 
ro-carboxylate group was replaced by a phosphonic acid moiety showed a very 
potent inhibitory action. 48 Further investigation identified D-2-amino-S-
phosphonopentanoic acid (D-APS) (45) and D-2-amino-7-phosphonoheptanoic 
acid (D-AP7) (46) as metabolically stable, potent and highly selective 
antagonists at the NMDA receptor. 49, 50 Interestingly, neither, 2-amino-4-
phosphonobutanoic acid (AP4) or 2-amino-6-phosphonohexanoic acid (AP6) 
were found to show any inhibitory action at this receptor type.39 More 
recently, the first succesful attempt to replace the a-amino acid moiety of a 
glutamate antagonist has been reported. A 3,4-diamino-3-cyclobutene-l,2-
dione (47) functionality was successfully utilised as the a-amino acid isostere, 
resulting in a highly selective, systemically active NMDA receptor 
antagonist. 51 Incorporation of a ketone functionality into the carbon backbone 
of APS afforded (R)-4-oxo-S-phosphononorvaline (48), an orally active NMDA 
antagonist with increased potency relative to APS.52 
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Figure 1.15: Competitive NMDA Receptor Antagonists 
Once again, all these compounds are flexible molecules and give only 
a limited indication of the structure of the receptor site. Further exploration of 
these leads provided a series of structurally restricted analogues (Figure 1.16). 
These rigid analogues of AP7 i.e., 3-(2-carboxypiperazin-4-yl)propyl-1-
phosphonic acid (CPP) (49), and 3-(2-carboxypiperazin-4-yl)propenyl-1-
phosphonic acid (CPPene) (50) and AP5, that is cis4-phosphonomethyl-2-
piperidine carboxylic acid (CGS 19755) (51) and (E )-2-amino-4-methyl-5-
phosphono-3-pentenoic acid (CGP 37849) (52) respectively, are more active in 
vitro than their parent compounds. Indeed CPPene is the most potent known 
NMDA antagonist. 53,54 
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Figure 1.16: Conformationally Restrained NMDA Antagonists 
Many other similar compounds have been prepared and their activity 
at this receptor type investigated, allowing detailed stucture activity studies to 
be undertaken in conjunction with molecular modelling. 55-58 However, the 
exact details of antagonist binding at NMDA receptors are still not fully 
understood. In general there are three structural features seen in antagonists of 
the NMDA receptor: with the exception of the achiral cyclobutenedione 
compound (47), they all are a-amino acids that possess the D configuration; 
secondly the chain length that separates the a-acidic function and the co-acidic 
side chain moiety is either four or six atoms and thirdly making the co-acidic 
side chain functionality a phosphonic acid group greatly increases the 
potency.47 The increased chain length of antagonists, relative to glutamic acid, 
and the fact that the most potent conformationally restrained antagonists are 
fixed in an extended chain form, indicate that the co-acidic side-chain 
functionality of antagonists may bind to a different site on the receptor than 
the co-acidic side-chain functionality of agonists, whilst the amino and a-acidic 
functionalities bind to the same site in both cases. 33 Another possibility is that 
agonists and antagonists bind to the same sites on the receptor but the binding 
of antagonists results in the receptor undertaking a different conformation to 
that which agonists bind to.33 Initially it was suggested that different 
antagonists may bind to different sites on the receptor. For example, the 
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phosphonic acid group of AP5 may bind to a different site than the 
phosphonic acid group of AP7. 55 However, further study has indicated that 
this is unlikely and that there appears to be only one binding site for 
antagonists. 59 
1.4.2. AMP A Receptor 
Willardine (Figure 1.17) (53) and quisqualic acid (54) were the first two 
agonists shown to be selective at the AMPA-type receptor. In fact, AMPA-type 
receptors were initially classified as quisqualate-type receptors until recent 
studies showed that quisqualic acid also acts at kainate-type receptors and its 
structural analogue L-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMP A) (55) is a far more selective agonist. 60 
o 
HO 
(53) (54) (55) 
Figure 1.17: Agonists at the AMP A Receptor 
The isoxazole group of compounds allows comparisons to be made, in 
particular between the requirements for activation of the NMDA receptor and 
those for activation of the AMP A receptor. The highly conformationally 
restricted analogues of AMPA (Figure 1.18), (RS)-3-hydroxy-4,5,6,7-
tetrahydroisoxazolo [5,4-c ]pyridine-5-carboxylic acid (5-HPCA) (56) and the 
related compound (RS)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo [5,4-c]pyridine-
7-carboxylic acid (7-HPCA) (57), a similarly immobilised analogue of AMPA, 
are both potent and selective agonists at this receptor sub-type.33 In 
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comparison the relatively flexible (cf 5-HPCA and 7-HPCA) 3-isoxazole 
bioisostere of glutamate, ibotenic acid (43) is a potent NMDA agonist. 33 
The conformational similarity between 7-HPCA and 5-HPCA has been 
confirmed by x-ray crystallography and IH-nmr spectroscopy. Both 
compounds are planar, with the carboxyl group in the axial and equatorial 
positions respectively. This fact, as well as their virtually identical 
pharmacological profiles, has resulted in the suggestion that these compounds 
represent the active conformations of AMP A and glutamic acid (30) at AMP A-
type receptors. 33 It is also recognised that AMP A-type receptors are capable of 
accommodating bulky substituents of agonist molecules.39 This has been 
confirmed by the recent report that (RS)-2-amino-3-(5-cyc1opropyl-3-
hydroxyisoxazol-4-yl)propionic acid (58), a cyc1opropyl substitited analogue 
of AMPA, is equipotent with AMPA itself as an agonist.61 
HO 
(56) (57) (58) 
Figure 1.18: Structurally Restrained and Sterically Hindered AMP A Agonists 
Until recently, potent and selective antagonists for the AMP A-type 
receptor were unavailable. However, two quinoxalinediones (Figure 1.19), 
6,7-dinitroquinoxaline-2,3-dione (DNQX) (59) and 6-cyano-7-nitroquinoxaline-
2,3-dione (CNQX) (60), have been shown to be potent competitive antagonists 
at non-NMDA-type receptors. These two compounds act predominantly at 
AMPA receptors but also show weak activity at kainate-type receptors.62 
Centrally administered CNQX (60) reduced knee joint inflamation and 
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behaviour manifestations of arthritis in rats suggesting a role for central 
AMP A receptors in the development of peripheral joint inflammation.63 The 
AMP A analogue, (R S)-2-amino-3-[3-carboxymethyl-S-methylisoxazol-4-
yl]propionic acid (AMOA) (61) has also been found to competitively inhibit 
AMPA (55) induced excitations whilst showing only a slight effect on 
excitations mediated by NMDA (37) and kainate. 62 A series of 
2-phosphonoethylphenylalanines have been prepared and their activity 
investigated, 2-phosphonoethyl-(S-methyl)phenylalanine (62) was found to be 
the most potent of this series. 63 
(59)DNQX 
(60) CNQX 
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Figure 1.19: Competitive Antagonists at the AMP A Receptor 
1.4.3. Kainate Receptor 
The prototypic agonist at this kainate type receptors is the compound 
a-kainic acid (Figure 1.20) (63), a neurotoxin from the seaweed Digena simplex. 
Two other pyrrolidine amino acids, domoic acid (31) and acromelic acid (64), 
are even more potent than kainic acid as neuroexcitants. This receptor-type 
exhibits a high degree of stereoselectivity, the ~-isomer, with the 2-carboxyl 
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group in the opposite configuration, being inactive. It also appears that an 
unsaturated side chain at the 4-position, although not essential, is preferable. 
A common structural feature of kainate receptor agonists is the presence of a 
1t-electron system in the molecule. This unsaturated moiety appears to be 
advantageous for interactions with kainate receptors, with the extended 
conjugation in domoic acid and acromelic acid resulting in even more potent 
excitatory effects than observed with kainic acid. However, the unsaturated 
moiety is not an absolute requirement, with 3 out of the 4 stereoisomers of 
1-aminocyclopentane-1,3-dicarboxylic acid (ACPD) showing weak action at 
this receptor type. 39 
(63) (64) 
Figure 1.20: Agonists at the Kainic Acid Receptor Sub-type 
As in the case of AMP A-type receptors, the lack of potent and 
selective antagonists for the kainate type receptor has hindered further 
classification of this class of receptors. Two compounds known to act 
preferentially as NMDA antagonists also block responses to kainic acid: the 
two compounds are the dipeptide y-D-glutamylglycine (y-DGG) (Figure 1.21) 
(65) and cis-2,3-piperidine dicarboxylic acid (cis-2,3-PDA) (66).48, 64 More 
recently, the AMP A dimer (RS)-2-amino-3-[2-[3-methyl-3-oxoisoxazolin-4-yl)-
methyl]-S-methyl-3-oxoisoxazolin-4-yl]-propionic acid (AMNH) (67) has been 
reported to be a selective kainate-type antagonist.65 
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In all cases where both enantiomers of compounds that show 
antagonist activity at the kainate recptor are available, the D-isomer shows 
greater activity. Although the number of compounds that show potent and 
selective antagonist activity at this receptor is limited, and the most potent 
antagonist, AMNH (67) has not yet been prepared in an enantiomerically pure 
form. This may indicate that, like the NMDA receptor, the D-configuration at 
the a-carbon is necessary for antagonist activity at the kainate receptor. 65 
o 
(65) 
(67) 
(66) 
Figure 1.21: Competitive Antagonists at the Kainic Acid Receptor 
1.4.4. AP4 Receptor 
In contrast to the NMDA, AMP A and kainate receptor sub-types, 
which were defined through the actions of exogenous excitatory amino acids, 
the L-AP4 receptor was discovered because L-2-amino-4-phosphonobutanoic 
acid (L-AP4) (Figure 1.22) (68) appeared to be a potent antagonist at 
subpopulations of synaptically evoked excitatory responses.66 Recent 
experiments indicate that L-AP4 (68) most probably acts as an agonist, 
presynaptically, causing a reduction of endogenous EAA release and thus 
causing an apparent inhibitory action. 39 It now appears that the AP4 receptor 
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is not in fact ionotropic as first thought, but is fact a sub-class the of 
metabotropic receptor which is linked to adenylate cyclase activation.42 
The ro-phosphonic acid analogue of glutamic acid L-AP4 (68) has now 
been reported independently by several groups to inhibit synaptic responses 
in several different neuronal systems. The inhibition was selective for L-AP4 
(68) as the D-isomer and a variety of related compounds were found to be 
inactive in these systems. These findings led to the classification of a the AP4-
type receptor.47 L-Serine-O-phosphonic acid (69) was found to mimic the 
inhibitory effects of L-AP4, indicating that is was also active at this site. 39 
It now appears that there are at least three distinct AP4 binding sites in 
the CNS. Two quisqualic acid-sensitive sites are found in the medial perforant 
path and a third site in the lateral perforant path that is insensitive to 
quisqualic acid. The quis-sensitive sites were discovered when it was shown 
that brief exposure of rat hippocampal slices to quisqualic acid (54) sensitised 
these neurons to depolarisation by a number of compounds. The potency of 
some compounds, including L-AP4, L-AP5, phosphinothricin (12) which is the 
phosphinic acid analogue of AP4 and Z-3-amino-3-carboxy-
cyclopentylphosphonic acid (Z-ACPP) (70) increased more than four-fold after 
exposure to quisqualic acid. This sensitisation can be reversed by exposure to 
L-a-aminoadipate (L-a-AA). The two separate quis-sensitive sites are now 
distinguished by the action of L-2-amino-6-phosphonohexanoic acid (L-AP6) 
(71), which is a potent and selective agonist at one of the quis-sensitive sites. 
The second quis-sensitive site appears to be activated by L-AP4 (68) but not by 
L-AP6 (71). The third site is activated by L-AP4 but is insensitive to quisqualic 
acid.67 
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Figure 1.22: Compounds that Act at the AP4 Receptor 
As the spectrum of activity of Z-ACPP (70) closely resembles that of 
L-AP4 in the medial perforant path, it has been suggested that the quis-
sensitive site, at which L-AP4 is active and L-AP6, is inactive requires a spatial 
arrangement of functional groups similar to that of Z-ACPP (70).68 Since the 
amino and the phosphonic acid moieties are cis to one another in this isomer, 
the possibility of ionic interaction between these two moieties exists. This 
would give rise to a highly folded conformation. 47 It is also thought that the 
presence of a primary amino group and a mono- or dicationic phosphorus 
group are necessary for activity at this receptor, however a carboxylic group 
does not appear to be a requirement as 3-aminopropanephosphonic acid 
shows significant activity at this site.68 
Recently, the highly rigid and conformationally extended l-amino-3-
(phosphonomethylene )cyclobutane-l-carboxylic acid (72) was shown to inhibit 
evoked responses in the rat lateral perforant pathway, suggesting that the 
L-AP4 (68) assumes an extended conformation at quis-insensitive AP4 
receptors.69 
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L-AP4 (68) assumes an extended conformation at quis-insensitive AP4 
receptors.69 
There are clearly three distinct sub-classes of AP4 receptors, two 
quis-sensitive sites; one at which L-AP4 (68) is more active and one at which 
L-AP6 (71) is specific. This suggesting that L-AP4 (68) binds in a folded 
conformation at one and an extended conformation at the other site. The third 
receptor is activated by L-AP4 (68) but is not sensitised to quisqualic acid. 
However, there is still little detailed information about the binding sites of 
these different sub-populations of AP4 receptors in the central nervous 
system. Clearly, further investigation of stucture-activity relationships is 
required. 
1.4.5. Metabotropic Receptor 
The ionotropic (NMDA, AMPA and Kainate) EAA receptors are 
directly linked to the influx of sodium and calcium ions into the target cell. In 
contrast, metabotropic receptors are G protein linked to activation of inositol 
specific phospholipase C and the hydrolysis of phosphoinositides to form 
intracellular second messengers (IP3 and diacylglycerol). This different 
receptor mechanism, when compared to that of ionotropic receptors, suggests 
that the functional role and potential utility of pharmacological agents acting 
at metabotropic EAA receptors may be unique. The pharmacological 
properties of this receptor indicate that it is distinct from previously described 
receptors, in that quisqualic acid, ibotenic acid and glutamic acid are potent 
agonists and NMDA, AMP A and kainic acid are not. 66 
Molecular cloning techniques have revealed the existence of at least 
seven sub-classes of metabotropic receptor (mGlul-mGlu7) that can be divided 
into three general classes on the basis of sequence similarity: mGlul and 
mGlu51 which are linked to through phosphoinositide specific phospholipase 
to phosphoinositide hydrolysis and intracellular Ca + mobilisation; mGlu2 and 
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formation; and mGIU4, mGlu6 and mGlu7 also negatively linked to adenylate 
cyclase activity, this third class is the AP4-type receptor described above. 
Initially, this receptor type was only distinguished from ionotropic 
receptors by the nature of its second messenger system - phosphoinositol 
hydrolysis. The compound (IS,3R)-I-amino-l,3-cyclopentanedicarboxylic acid 
((IS,3S)-ACPD) (Figure 1.23) (73) was found to be a selective agonist and 
allowed this receptor to be distinguished pharmacologically?O This was 
followed by the discovery that the conformationally restricted analogue of 
glutamic acid, (2S, 3S, 4S }-a-(carboxycyclopropyl)glycine ((2S,3S,4S)-CPG) 
(74), is even more potent than (IS ,3S)-ACPD (73) in stimulating 
phosphoinositol hydrolysis in the rat hippocampus.71 trans-Azetidine-2,4-
dicarboxylic acid (75) is a selective agonist which stimulates phosphoinositol 
hydrolysis in rat cerebral granular cells. 63 
Quisqualic acid (54) and ibotenic acid (43) were the first agonists 
described for this receptor type, but neither of these is selective and both 
compounds appear to act as partial agonists rather than full agonists.72 
However, quisqualic acid is one of the most potent agonists known for these 
receptors. 
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Figure 1.23: Compounds that Act at Metabotropic Receptors 
Both L-2-amino-3-phosphonopropanoic acid (AP3f3 (76) and L-AP4 
(68) are known to have antagonist activity at metabotropic EAA receptors. 
L-AP3 (76) has greater selectivity and potency for metabotropic receptors than 
ionotropic receptors and L-AP4 is inactive in many preparations from 
immature sources, indicating that these receptors may be involved in 
developmental processes. L-Aspartate-~-hydroxamate (L-asp-~-HA) (77) has 
been found to act as an antagonist of ibotentate stimulated phosphonoinositol 
hydrolysis. However, it does not appear to be competitive or reversible. L-AP3 
(76) blocks responses to quisqalic acid (54), ibotenic acid (43) and (15,35)-
ACPD) (73) to the same degree, whereas L-AP4 appears to antagonise 
ibotenate induced responses to a greater extent than those induced by 
quisqualate. 72 D-Aspartate induced responses are not antagonised by L-AP3 
(76) or L-asp-~-HA (77).14 Both L-SOP (69) and NAAG (35) have been shown to 
selectively activate metabotropic receptors which are negatively coupled to 
andenyl cyclase.63 Both ((15,35)-ACPD) (73) and ((25,35 ,45)-CPG) (74) show 
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some selectivity for mGlu2 and mGlu3 receptors.42 Thus judicious use of 
agonists can be used to explore the subgroups of metabotropic receptors. 
1.5. Cyclic Analogues of Phosphonic Amino Acids in EAA 
Pharmacology 
Since the endogenous excitatory amino acids are extremely flexible 
molecules, use has been made of structurally restricted analogues in an 
attempt to characterise the EAA receptors. An effective method of restricting 
the flexibility of a compound is to incorporate part of the compound into a 
ring structure. This has already resulted in the development of some potent 
and specific compounds. 
One such compound, E-l-amino-l,3-cyclobutanedicarboxylic acid 
(E-ACBD) (39), has been found to be an extremely potent NMDA agonist.44 
Many other potent and selective compounds have been developed using this 
strategy, For example, ACPP (70), ACPD (41), CPG (42) etc. and have been 
invaluable in the characterisation of excitatory amino acid receptors. 
All possible isomers of the cyclopentyl and cyclohexyl analogues of 
AP4 have been prepared and their activity investigated. Despite the fact that 
L-AP4 (68) plays such an important role in the pharmacology of two receptor 
types (AP4 and metabotropic) and the fact that L-AP3 (76) is also active at the 
metabotropic receptor, indicating that the active conformation is likely to be 
intermediate between these two compounds, the simplest structurally 
restricted analogue of AP4, namely 3-amino-3-carboxycyclobutanephosphonic 
acid (78) (Figure 1.24) has yet to be prepared. 
(78) 
Figure 1.24: 3-Amino-3-carboxycyclobutanephosphonic acid 
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As there is still little information regarding the active binding 
conformation of L-AP4 (68) at the AP4 receptor and given that L-AP4 is not 
specific for the AP4 receptor but also interacts at the metabotropic receptor, a 
need for further structurally constrained compounds is apparent. More 
importantly, antagonists, in particular those with subtype selectivity, are 
required to elucidate the roles of metabotropic glutamate receptors in synaptic 
activity. 
It has already been shown that subtle changes in the way a compound 
is structurally restrained can result in large changes in activity. For example, 
the cyclobutane analogue of glutamic acid is around 100 fold more active than 
the cyclopentane analogue at the NMDA receptor. Similarly, 1-amino-3-
(phosphonomethylene)cyclobutanecarboxylic acid (72) has been prepared and 
has been found to act at the AP4 receptor.68 However, the corresponding 
analogue (Figure 1.25) 3-(amino-carboxymethyl)cyc1obutanephosphonic acid 
(79) , with the phosphonic acid group directly attached to the cyc10butane ring 
and the amino acid functionality removed from the ring by one carbon has not 
been made. Again, it would be interesting to see what effect the subtle 
difference in the way that this compound is constrained would have in terms 
of activity. 
o 
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Figure 1.25: 3-(Amino-carboxymethyDcyclobutanephosphonic Acid 
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1.6. Aims 
We concluded that completion of the systematic investigation of 
cyclobutanephosphonic acid analogues of excitatory amino acids as 
neurotransmitters required investigation of cyclobutanes in which the 
phosphonic acid group is directly attached to the cyclobutane ring. However, 
judging by the absence of such compounds in the literature it would appear 
that the methodology for their preparation is lacking. Thus, the aim of the first 
part of this work was to develop a method for the synthesis of a 3-substituted-
cyclobutanephosphonate building block, which could be used to prepare a 
variety of other 3-substituted-cyclobutanephosphonates, in particular the 
aminocyclobutane phosphonic acids described above. The use of chemical 
and/ or enzymatic techniques to separate the stereoisomers of the 
aminocyclobutanephosphonic acids was also to be investigated. 
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Chapter 2 
Synthesis of 3-Substituted-cyclobutanephosphonates 
2.1. Introduction 
Cyclobutanes are versatile synthetic intermediates, whilst being 
undoubtedly the most difficult of the small to medium sized rings to prepare. 
Although procedures are available for the preparation of cyclobutane, 
methylenecyclobutane and 1,1-disubstituted cyclobutanes, routes to 
1,3-disubstituted derivatives with functionality amenable to further 
elaboration are not as plentiful. 75 Those that do exist generally have a 
carboxylate group as one of the substituents. In particular, the synthesis of 
intermediates that would allow access to 3-substituted-
cyclobutanephosphonates (80) (Figure 2.1) has not been described. These 
3-substituted-cyclobutane-1-phosphonates (80) are of interest, not only 
because they can be converted into cyclobutanephosphonic acid analogues of 
amino acids, but also for other uses such as potential achiral spacers in 
synthetic nucleotides. 76 
o 
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Figure 2.1: DialkyI3-substituted-cyclobutanephosphonate 
Many related cyclopropane, cyclopentane and cyclohexane 
aminophosphonic acid analogues have been prepared and have subsequently 
provided much interesting structure-activity information.77 The synthesis of 
the five (84a) and six membered (84b) ring analogues of AP4 (Figure 2.2) is 
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facilitated by the availability of cyclopent-2-enone (8Ia) and cyclohex-2-enone 
(8Ib) respectively. Treatment of these cyclic conjugated ketones (8Ia-b) with a 
trialkylphosphite in the presence of phenol yields the racemic 
3-ketophosphonate (82a-b). These intermediates are easily converted to the 
dialkyl 3-amino-3-cyanocyclopentane- (83a) or dialkyl 3-amino-3-
cyanocyclohexanephosphonate (83b) by a Strecker reaction. Hydrolysis of the 
aminonitrile yields the desired aminophosphonic acids (84).77 
(8Ia) n=1 
(8Ib) n=2 
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Figure 2.2 Synthesis of Cyclopentane and Cyclohexane Analogues of AP4 
The corresponding cyclobut-2-enone is not available. Cyc1opent-2-
enone (82a) and cyc1ohex-2-enone (82b) are both stable compounds. However, 
cyc1obut-2-enone is extremely unstable. It rapidly rearranges to the give the 
considerably more stable vinylketene. 78 
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Related cyclopropane compounds (87a-d) (Figure 2.3) have been 
prepared by the reaction of (R)-N-(benzyloxycarbonyl)-allylglycine (85) with 
dimethyl diazomethylphosphonate and rhodium diacetate dimer to give an 
inseparable mixture of all four possible diastereoisomers of methyl 
2-[N-[(benzybxy)aubonyijamIDo }4,5-methano-5-(dimethylphosphono ~tanoate (86a-d). 
Hydrolysis of the mixture of diastereoisomers afforded a mixture of the 
desired amino acids (87a-d),79 
(85) (86a-d) 
(87a-d) 
Figure 2.3: Synthesis of (ElZ)-2-Amino-4,5-methano-5-phosphonopentanoic Acid 
However, as this method is applicable only to the synthesis of 
cyclopropane rings it was unsuitable for our requirements. Two options for 
the synthesis of 3-substituted-cyclobutanephosphonates (80) were identified: 
either preparation of a suitably 1,3-functionalised cyclobutane by a known 
route, such that further transformation could introduce a phosphonate 
functionality, or development of the direct synthesis of a dialkyI3-substituted-
cyclobutanephosphonate (80). 
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2.2. Discussion 
Initially we decided to investigate the synthesis of cyclobutanes such 
as dialkyl3-hydroxycyclobutanedicarboxylates by known synthetic methods, 
with subsequent conversion of this intermediate into dialkyl 
3-bromocyclobutanedicarboxylates which have the potential to undergo an 
Arbuzov reaction to give 3-substituted-cyclobutanephosphonates (80). This 
would provide useful intermediates, in which the carboxylic ester groups 
could then undergo a variety of functional group transformations furnishing a 
range of compounds. 
2.2.1. Malonate Synthesis of Cyc10butanes 
Alkylation of a malonate ester (88) with a 1,3-dibromopropane (89) 
produces an alkylmalonate, intramolecular alkylation of which leads to a 
l,l-disubstituted-cyclobutane (90) in moderate yields (Figure 2.4). This is one 
of the most common methods of preparing cyclobutanes. Using a suitable 
2-substituted-l,3-dihalopropane allows the synthesis of 1,3-disubstituted 
cyclobutanes (93). A vram et al first reported the synthesis of a 1,3-disubstituted 
cyclobutane (93a) in yields of 36 % using l-chloro-2-benzyloxy-3-
bromopropane (91) with sodium ethoxide as the base. 80 
(88) 
Base 
1 2 1 (89) R =R =H, X=X =Br 
(91) R1=H, R2=OCH2Ph, X=Br, X1=Cl 
(92) Rl=R 2=OMe, X=X1=Br 
(90) Rl=R2=H 
(93a) R1=H, R2=OCH2Ph 
1 2 (93b) R =R =OMe, 
Figure 2.4: Malonate Synthesis of Cyclobutanes 
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More recently, the use of 1,3-dibromo-2,2-dimethoxypropane (92), 
which is easily prepared from acetone, methanol and bromine,81 has been 
used in the synthesis of 1,3-disubstituted cyc10butanes (93b) (Figure 2.4). 
Reaction of a dialkylmalonate with 1,3-dibromo-2,2-dimethoxypropane (92) in 
the presence of sodium hydride produces the desired 1,3-disubstituted 
cyclobutane (93b). Yields were in the range 30-56 % depending on the 
alkylmalonate used. 75 
As 1,3-dibromo-2,2-dimethoxypropane (92) is economical and easy to 
prepare, we decided to use this method to prepare diethyl 
3-oxocyc1obutanedicarboxylate (96) (Scheme 2.1), the reduction of which with 
sodium borohydride would yield diethyl 3-hydroxycyc1obutanedicarboxylate 
(97) allowing subsequent conversion to a phosphonate, possibly through a 
3-halocyclobutane intermediate. The synthesis of diethyl 3,3-dimethoxy-
cyc1obutanedicarboxylate (95) from 1,3-dibromo-2,2-dimethoxypropane (92) 
and diethyl malonate (94) in the presence of sodium hydride proceeded 
smoothly in 45 % yield. Deprotection of the methyl ketal (95) was 
accomplished by treatment with trimethylsilyl iodide (TMSI) in 
dichloromethane. The dealkylation of methyl ethers is known to proceed with 
selectively in the presence of esters with TMSI. 82 The reaction of TMSI was 
complete in 60 minutes and no evidence of any deesterified product was seen. 
The corresponding reaction with trimethylsilyl bromide (TMSBr) took in 
excess of 24 hours. The diethyl 3-oxocyc1obutanedicarboxylate (96) was used 
without any further purification. Unfortunately, the sodium borohydride 
reduction of diethyl 3-oxocyc1obutanedicarboxylate (96) proved problematical. 
At room temperature the ketone was not reduced even after extended reaction 
times, and at reflux in ethanol, only poor yields « 25 0/0) of diethyl 
3-hydroxycyc1obutanedicarboxylate (97) were obtained. 
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Br OMe (95) 
(94) (93) 30% 
Scheme 2.1. 
TMSI 
CH20 2 
o ==0< 002Et ... 
002Et 
(96) 
98% 
NaBH4/EtOH 
Reflux 
I-O--0<OO2
Et 
002Et 
(97) 
25% 
Due to the problems with reduction of the ketone functionality and as 
the cyclisation itself was not particularly high yielding, we decided to 
investigate the route described by A vram for the synthesis of diethyl 
3-hydroxycyclobutanedicarboxylate (97) (Scheme 2.2). This route proceeds 
directly to the alcohol, avoiding the reduction step. l-Chloro-2-benzyloxy-3-
bromopropane (91) was prepared from epichlorohydrin and benzyl bromide 
in the presence of a catalytic amount of mercurous chloride. 80 Formation of the 
diethyI3-(benzyloxy)cyclobutanedicarboxylate (98) proceeded smoothly using 
a modification of the route described by Avram, in which the alkylation was 
carried out with NaH in dioxane rather than using sodium ethoxide as the 
base.83 The crude mixture was purified by distillation to give the cyclobutane 
(98) in 53 % yield. Hydrogenation using palladium on carbon (10 0/0) as a 
catalyst rapidly removed the benzyl protecting group, giving the alcohol (97) 
as a pale orange oil in quantitative yield. 
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(94) (91) (98) 
53% 
Scheme 2.2. 
(97) 
97% 
Conversion to the benzenesulfonate (99) was achieved quantitatively, 
by reaction of the alcohol (97) with benzenesulfonyl chloride in pyridine 
(Scheme 2.3). Reaction of the benzenesulfonate (99) with fused lithium 
bromide in anhydrous acetone at reflux provided the diethyl 
3-bromocyc1obutanedicarboxylate (100), again in quantitative yield. 84 The 
bromocyclobutane (100) was purified by column chromatography. This route 
provided the desired diethyl 3-bromocyclobutanecarboxylate (96) in high 
overall yield. 
__ PhSO_ .... 2a~-l .. ~ PhSO~ use 1 r ... HO 
--<XC02Et --<xC02Et F d L"B Br ---<)<C02Et C02Et pyridine C02Et acetone/reflux C02Et 
(97) (99) 
91 % 
Scheme 2.3. 
2.2.3. Arbuzov Reaction of Diethyl 3-Bromo cyclobutanecarboxylate 
(100) 
95% 
The Arbuzov reaction (Figure 2.5) is one of the most versatile methods 
of forming carbon-phosphorus bonds and involves the reaction of an ester of 
trivalent phosphorus (101) with alkylhalides (102). It is a two step reaction 
which results in the conversion of trivalent phosphorus in to pentavalent 
phosphorus. The lone pair of the electrons of the phosphite (101) attacks the 
alkyl group of the alkylhalide (102) to form the addition compound (103), in 
which the alkyl group of the alkyl halide becomes attached to the phosphorus" 
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In the second step of the reaction, an alkyl group of the phosphite dissociates 
from the addition compound (103), resulting in the formation of the p=o bond 
of the phosphonate (104); the alkyl group is eliminated as a new alkyl halide 
(102a). It is reported that the conversion of the trivalent ester linkage to the 
pentavalent P( =O)-C involves a net energy gain of between 32 and 65 
kcal/ mol in the total bond stability and acts as the driving force for the 
rearrangement. 85 
FO, ~ 
FO-P: R' / I) 
FO X 
(101) (102) 
R=alkyl, aryl 
R'=alkyl, acyl 
X=CI, Br, I, OTos, OTf 
R ..... O ~+ 
FO-P-R' 
/ -
FOX 
(103) 
o 
II 
----i .. ~ R'-P- OR 
'OR 
(104) 
+ 
R-X 
(l02a) 
Figure 2.5: Mechanism of the Arbuzov Reaction 
As would be expected from this mechanism, the reactivity of the alkyl 
halides in the Arbuzov reaction follows the usual sequence for SN2 
displacement, i.e. R(C=O)-halide > RCH2-halide > R2CH-halide » 
RR'R"C-halide and RI > RBr > RCI. This indicates that an alkyl halide capable 
of reacting with nucleophilic reagents by an SN2 mechanism is suitable as a 
substrate for the Arbuzov reaction. However, the majority of Arbuzov 
reactions have been carried out on primary alkyl halides and reaction with 
only a few secondary alkyl halides have been reported, for example, isopropyl 
iodide and ethyl a-bromopropionate. 85 One problem with the use of 
secondary alkyl halides as substrates is the fact that a primary alkyl halide is 
formed as a by-product of the reaction and this then competes with the 
substrate in the reaction. As a primary alkyl halide reacts faster than a 
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secondary alkyl halide this must be removed from the reaction mixture to 
allow the desired reaction to occur. Following the successful SN2 displacement 
of the benzenesulfonate group by the bromide ion, we were hopeful that the 
Arbuzov reaction could be carried out smoothly to effect the synthesis of 
diethyl 3,3-dicarboethoxycyclobutanephosphonate (105). 
When carried out on a small scale « 10 mg), treatment of diethyl 
3-bromocyclobutanecarboxylate with excess triethyl phosphite (100 fold) 
(Scheme 2.4) appeared promising as a method of preparing diethyl 
3,3-dicarboethoxycyclobutanephosphonate (105). The reaction mixture was 
heated at 100°C for 24 hours with an air condenser. Remaining 
triethylphosphite and any diethyl ethanephosphonate formed in the reaction 
were removed by distillation. lH Nmr analysis of the residue indicated that 
the distinctive quintet signal at 4.5 ppm, assigned to the proton attached to the 
same carbon as the bromine, had almost disappeared. The two individual 
multiplets, at 2.9 and 3.1 ppm, attributed to the methylene protons of the 
cyclobutane ring had broadened to one large multiplet (2.1-2.7 ppm) which 
now integrated to greater than four ( ..... 4.4). This indicated that the bromine had 
been displaced by something less electronegative, suggesting that the Arbuzov 
reaction had taken place. Mass spectrometry of the crude sample indicated 
that some of the desired product had formed (peak at 336 mass units 
corresponding to the molecular weight of diethyl 
3,3-dicarboethoxycyclobutanephosphonate (105»), although some of 
bromocyclobutane (100) starting material was still present. 
However, when the reaction was carried out on a multigram scale 
with a 5-10 fold excess of diethyl phosphite, under conditions in which the 
ethylbromide formed was removed from the reaction mixture by distillation, 
little of the desired product was formed. Removal of the unreacted triethyl 
phosphite yielded the starting alkylhalide and less than 5 % of the diethyl 
3,3-dicarboethoxycyclobutanephosphonate (105). Prolonged reaction times 
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and higher temperatures (> 125 h, 140 °C) did little to increase the yield. The 
low yield of product, despite the fact that the cyclobutane is able to undergo 
SN2 reactions, is possibly due to the fact that the phosphite is a weaker 
nucleophile than the bromide ion used in the SN2 substitution and the 
bromide ion is a poorer leaving group than the benzenesulfonate. 
(100) 
o 
P(OEt)3 II-0<OO2Et 
----~---l.~ (EtO)2P Reflux 
002Et 
Scheme 2.4. 
(105) 
<5% 
Reports in the literature indicate that a better procedure for the 
formation of the carbon-phosphorus bonds is a modified Arbuzov reaction, 
using the sodium salt of dibutyl phosphonate to displace 
trifluoromethanesulfonate as the leaving group.86 The sodium salt is used so 
that the by-product is the salt, sodium trifluoromethanesulfonate, which will 
not compete as a substrate in the reaction. The butyl phosphite ester is used in 
preference to methyl or ethyl esters because the sodium dibutylphosphite is 
soluble, unlike the sodium salts of the lower esters, thus avoiding solubility 
problems. As trifluoromethanesulfonate is a better leaving group than a 
bromide ion, it was expected that this would facilitate the displacement 
reaction at the secondary carbon. 
The alcohol was converted into diethyl 
3-( trifluoromethanesulfonyloxy )cyclobutanedicarboxylate (106) in quantitative 
yield by treatment with trifluoromethanesulfonyl anhydride and triethylamine 
in dichloromethane at 0 °C (Scheme 2.5). After extractive work up using ice 
cold water, the triflate was used without further purification. Sodium 
dibutylphosphite was formed by the addition of sodium metal to 
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tributylphosphite in anhydrous THF. The triflate (106), in a solution of THF, 
was added to the reaction mixture which was refluxed for two days. After 
work up and distillation, 1 H nmr analysis indicated that none of the desired 
dibutyl 3,3-dicarboethoxycyclobutanephosphonate (107) had formed. The 
quintet at 5.3 ppm due to the proton geminal to the triflate group was still 
clearly visible. Interestingly no evidence was seen of any elimination of the 
trifluoromethanesulfonic acid to form the cyclobutene. Elimination of 
secondary triflates under the reaction conditions described above is quite 
common. One possible explanation for the total absence of any elimination 
product is the inability of the cyclobutane ring to adopt a conformation such 
that the proton ~ to the triflate group is antiperiplanar to the triflate, 
preventing elimination from occurring via an E2 mechanism. 
(97) 
Scheme 2.5. 
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(106) 
NaOP(OBuh 
THF/reflux 
(107) 
2.3. Synthesis of Cyclobutanes using Stabilised Carbanions 
other than Malonates 
As the Arbuzov reaction was not a suitable method of producing the 
desired diethyl 3,3-dicarboethoxycyclobutanephosphonate on a preparative 
scale, it was necessary to investigate other routes to the target compounds. 
One method that appeared promising was to exploit the phosphonate 
functionality as an integral part of the ring synthesis, using compounds (10B-
111) (Figure 2.6) which are analogues of dialkyl malonates, where one of the 
carboxylic ester groups is replaced by a phosphonate ester and the other by a 
second electron withdrawing group which could be removed after 
cyclobutane had formation. As sulfur is easily removed from most compounds 
by reaction with Raney nickel, we decided, initially, to investigate reactions in 
which the second carboxylic ester group was replaced by a sulfur-containing 
functional group, the trimethylsilyl group also appeared as a promising 
alternative. 
o 
1 I ..... OEt 
R ............... P, 
OEt 
(108) R= S02R' 
(109) R= SOR' 
(110) R=SR' 
(111) R= SiMe3 
Figure 2.6: Phosphonate Analogues of Dialkyl malonate 
2.3.1. a-Phosphoryl Sulfoxides as Malonate Analogues 
It has been reported that [(phenylsulfonyl)methylene]dilithium, 
generated from methyl phenyl sulfone (112) and two equivalents of 
n-butyllithium in THF, reacts readily with a series of bifunctional organic 
substrates, such as dihalides and haloepoxides, amongst others, to give 
carbocyclic compounds in good yields (Figure 2.7).87 The geminal dianion of 
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methyl phenyl sulfone reacts with epichlorohydrin (113), attacking first at the 
epoxide followed by cyclisation to give the 1-(phenylsulfonyl)-3-
hydroxycyclobutane (114). If the initial attack were to occur at the carbon-
halide centre, then the resulting intermediate would cyclise to give the smaller 
cycloalkane.88 
PhSO2CH 3 
(112) 
(i) 2 n-BuLi/THF /0 °C 
(ii) /0, 
~CI 
(113) 
• 
PhO:!S--O- Cl-I 
(114) 
Figure 2.7: Reaction of [(Phenylsulfonyl)methylene1dilithium with Epichlorohydrin 
As it can be difficult to cleanly remove the sulfone functionality from 
organic compounds using Raney nickel, we decided to study the ability of 
a-phosphoryl sulfoxides to form geminal dilithio salts, and the reaction of 
these salts with difunctional electrophilic compounds. Diethyl 
phosphorylmethyl phenyl sulfoxide (115) was prepared by oxidation of the 
commercially available diethyl phosphorylmethyl phenyl sulfide using 
sodium metaperiodate.89 Although the mono lithium salt of diethyl 
phosphorylmethyl phenyl sulfoxide is known to decompose at temperatures 
above -50 °C,90 the dilithio salt did not form at temperatures below 0 °C. 
Generation of the geminal dilithio salt of diethyl phosphorylmethyl phenyl 
sulfoxide (Scheme 2.6) was achieved by treating a THF solution of the 
sulfoxide (115) with two equivalents of n -butyllithium at room temperature, 
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followed by cooling to -78°C. Quenching this reaction mixture with 
deuterium oxide and analysis by 1 H nmr spectroscopy and mass spectrometry 
indicated that the geminal dianion had indeed formed. The 1 H nmr spectrum 
of the dideuterated (llSa) compound showed almost no trace of the signals at 
3.34 and 3.22 ppm due to the diastereotopic methylene protons. The mass 
spectrum showed a molecular ion of 278, two mass units greater than that of 
the undeuterated compound (115). 
o 0 
II II 
PhS X.. P(OEt) 2 
H'" H 
(115) 
(i) 2 eq. n-BuLi/THF /RT 
(ii) D 20 
Scheme 2.6. 
.. 
(115a) 
>95% 
Despite the formation of the geminal dianion, reaction with l-chloro-
2-benzyloxy-3-bromopropane (91) did not lead to cyclobutane formation, nor 
did reaction with 1,3-dibromo-2,2-dimethoxy-propane (92) or even the less 
hindered 1,3-dibromopropane (89) (Scheme 2.7). Various reaction conditions 
were investigated including different reaction temperatures (-78 to -40°C) and 
different reaction times (one hour to 24 hours). However, in no case were any 
of the desired cyclobutane products (117) formed. 
Ph 
\ 
S=O 
< P(OEt)2 
II 
o 
(115) 
(i) 2 eq. n-BuLi/1HF /RT X 
(ii) R X 
R>C"X1 
1 1 (89) R=R =H, X=X =Br 
1 1 (92) R=R =OMe, X=X =Br 
1 1 (93) R=OCH2Ph, R =H, X=Cl, X =Br 
1 1 (116) R=R =H, X=X =OTf 
Scheme 2.7. 
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Two factors may have been preventing the alkylation reaction 
occurring: firstly the bromine was not a sufficently good leaving group and 
secondly the size of the bromine may be hindering the electrophilic carbon to 
such an extent that the bulky carbanion was unable to get close enough to 
attack. To improve the ability of the leaving group and to some degree 
alleviate the bulk of the bromine functionality we decided to use 
1,3-bis(trifluoromethanesulfonyloxy)propane (116) as a model compound 
(Scheme 2.7). Reaction of the geminal dilithio salt of diethyl phosphorylmethyl 
phenyl sulfoxide (115) with the bistriflate (116) returned only starting 
materials. 
Unsuccessful reactions were also carried out in the presence of 
potassium t-butoxide, crown ether, TMEDA and HMP A. Reaction of the 
mono lithium salt with methyliodide is known to give diethyl 
phosphoryl(l-methylmethyl) phenyl sulfoxide.91 Likewise, we found that the 
reaction of the dilithio salt of diethyl phosphorylmethyl phenyl sulfoxide (115) 
(Scheme 2.8) with two equivalents of methyliodide gives diethyl 
phosphoryl(l,l-dimethylmethyl) phenyl sulfoxide (118). 
o 0 
II II 
PhS Y P(OEt) 2 
Hl"'H 
(115) 
(i) 2 eq. n-BuLi/THF /RT 
(ii) Mel 
Scheme 2.8. 
.. 
(118) 
>95% 
Attempts to form the geminal dianion of diethyl phosphorylmethyl 
methyl sulfoxide (119) (Scheme 2.9), as a less hindered and slightly less 
stabilised alternative to the phenyl sulfoxide, were unsuccessful. Addition of 
two equivalents of n -butyllithium followed by a deuterium oxide quench 
indicated that only one of protons a to both the sulfoxide and the phosphonate 
47 
functionalities had been removed and that the second proton was removed 
from the methyl group to give the l,3-dideuterated compound (119a). 
o 0 
II II 
C,............ SXP(OEt)2 H3 . 
.: 
H'" H 
(119) 
(i) 2 eq. n-BuLi/THF /RT 
Scheme 2.9. 
o 0 
II II 
H C,............ SXP(OEt)2 
21 
D H D 
(119a) 
>90% 
Since the lithium salt of diethyl phosphorylmethyl phenyl sulfoxide is 
known to react with carbonyl compounds in Wittig-Horner reactions89 and we 
have shown that the dilithio salt can be methylated by reaction with 
methyliodide, the apparent inability of the dilithium salt to react with carbon-
halide and carbon-triflate centres suggests that these centres may not 
electrophilic enough to undergo attack by this anion. 
2.3.2. Diethyl a-Phosphorylmethyl Phenyl Sulfide as a Malonate Analogue 
As the geminal dianions of a-phosphoryl sulfoxides were found to be 
unsuitable as nucleophiles for formation of carbon-carbon bonds by displacing 
a bromide or triflate, we decided to investigate a-phosphorylsulfides. The 
geminal dianion of diethyl phosphorylmethyl phenyl sulfide (120) is not 
formed by treatment of this compound with n-butyllithium, s-butyllithium or 
t-butyllithium at room temperature, 0 °C or -78°C. However, we found that 
reaction of the monoanion of diethyl phosphorylmethyl phenyl sulfide 
(Scheme 2.10) with the model compound, l,3-dibromopropane (89) in THF at 
-78°C, for one hour, followed by reaction at room temperature for one hour 
and subsequent cooling to -78 °C before the addition of a second equivalent of 
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n-butyllithium resulted In high yields of diethyl 1-
(phenylthio )cyclobutanephosphonate (121). 
Ph 
\ ( 
P(OEt)2 
II 
o 
(120) 
(i) 1 eq. n-BuLi/THF/-78 °C to RT 
(ii) Br~Br 
(89) 
Scheme 2.10. 
Ph 
\ 
S 
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Ph 
\ 
S 
O<P(OEt)2 
II 
(121) 
-80% 
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Unfortunately, when the reaction was carried out using 1-chloro-2-
benzyloxy-3-bromopropane (91) or l,3-dibromo-2,2-dimethoxy-propane (92), 
none of the desired cyclobutanes (123) are formed, only a small amount of the 
monoalkylated compound (122) and starting materials were isolated after work 
up (Scheme 2.11). Reaction with epichlorohydrin was similarly unsuccessful. 
The fact that a reaction occurs with l,3-dibromopropane (89) but not with 2-
substituted-1,3-dibromopropanes (92 & 93) indicates that the added bulk of 
the functional group at the 2-position may preventing the reactions from 
occurring. 
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Scheme 2.11. 
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2.3.3. Diethyl a-Trimethylsilylmethylphosphonate as a Malonate 
Analogue 
Trimethylsilylmethyl phenyl sulfide (124) reacts with n-butyllithium 
and epibromohydrin (125) to form useful amounts of 1-(phenylthio)-3-
(trimethylsilyloxy)cydobutane (126a) and l-(phenylthio)-3-hydroxy-
cydobutane (126b) (Figure 2.8). It is suggested that the cydobutane products 
arise due to attack of the epoxide by the carbanion, opening of the epoxide, 
followed by a l,4-migration of the trimethylsilyl group from the carbon to the 
oxygen generating a carbanion. This carbanion then undergoes intramolecular 
alkylation displacing the bromine, to form the cydobutane product. The 
desilylated compound results from hydrolysis during work up of the 
reaction. 92 A similar reaction has been reported for 
a,a-bis(trimethylsilyl)methyllithium phenyl sulfide with epichlorohydrin.93 
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Me3Si 
(0 
J~8r PhS)):(, ~(i~)_Bu_L_i/_TH _ F~.~PhS~- ______ ~.~ & 
(ii) ,0\ Br I Me3Si ° -~ Me3Si U 
(124) (125) 
PhSVoSiMe3 
(126a) 
+ 
PhSVCJ-I 
(126b) 
... 
PhS '<Y OSiMe3 
-~h 
Br) 
Figure 2.8: Synthesis of 1-Phenylthio-3-hydroxycyclobutane 
As trimethylsilylmethyl phenyl sulfide (124) and 
bis(trimethylsilyl)methyl phenyl sulfide are both rather sterically hindered 
molecules, we hoped that even with the presence of a bulky phosphonate 
group our anion would be sufficiently reactive. Treatment of diethyl 
trimethylsilylmethylphosphonate (127) wi th n-butyllithium and 
epibromohydrin (125) at room temperature resulted only in the isolation of 
starting material (Scheme 2.12). Heating the reaction mixture to reflux resulted 
in the formation of diethyl 3-hydroxy-4-bromobutanephosphonate (128). This 
suggested that carbanion attack of the epoxide and migration of the 
trimethylsilyl group occurred to give diethyl 3-(trimethylsilyloxy)-4-
bromobutanephosphonate which did not cyclise, but was hydrolysed to the 
alcohol (128) on work up. 
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Scheme 2.12. 
2.3.4. Synthesis of Diethyl 3-0xocyclobutanephosphonate 
Since all the a-substituted phosphonate analogues of diethyl malonate 
that we investigated appeared to be too unreactive and/or too hindered to 
react with a 2-substituted-1,3-dihaloalkane, we decide to investigate reactions 
using diethyl methanephosphonate (129). As was expected, the dianion of this 
compound could not be formed. Treatment of diethyl methanephosphonate 
(129) (Scheme 2.13) with n-butyllithium (or LDA), 1-chloro-2-benzyloxy-3-
bromopropane (91) and a second equivalent of n-butyllithium (or LDA), 
sequentially, as with diethyl phosphorylmethyl phenyl sulfide, resulted only 
in the formation of diethyl 3-(benzyloxy)butanephosphonate (130). Although 
the anion had formed and reacted with the alkylbromide, the addition of the 
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second equivalent of n-butyllithium appears to result in lithium-chloride 
exchange at a rate faster than abstraction of a proton a to the phosphonate 
group. 
o 
II (i) n-BuLi/THF / -78°C to RT 
CH3 P(OEt}2 --:..(u.:.....)-Br--.:.--..:.....-------:...-I.-
(129) '--OCH2Ph CI~ 
(92) 
Scheme 2.13. 
° II (EtO)2P~ 
I CI 
o 
II 
OCH2Ph 
(i) n-BuLi/THF 
-78°C toRT 
(ii) H20 
(EtO}2P~CH3 
OCH2Ph 
(130) 
Reaction of two equivalents of diethyl methanephosphonate (129) with 
two equivalents of n-butyllithium and one equivalent 1-chloro-2-benzyloxy-3-
bromopropane (91) results In the formation of diethyl 
3-(benzyloxy)cyclobutanephosphonate (132) in good yields for this type of 
cyclisation reaction (Scheme 2.14). We have suggested that the mechanism of 
the reaction is as follows: the addition of n -butyllithium results in the 
formation of the lithiophosphonate, which displaces the bromide to form a 
carbon-carbon bond. The second equivalent of the lithiophosphonate then acts 
as a base to abstract a proton a to the phosphonate group of the intermediate 
diethyl 3-(benzyloxy)-4-chlorobutanephosphonate (131), which then cyclises, 
displacing the chloride to gIve the desired diethyl 
3-(benzyloxy)cyclobutanephosphonate (132). 
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(i) 2 eq. n-BuLi/THF /-78 °C to RT 
(ii) Br ~ OCH2Ph 
CI--.r-
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Scheme 2.14. 
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The cyclobutanephosphonate (132) is formed as a 2:1 mixture of the 
two diastereoisomers. As the lithium cation can only be chelated by the 
carbanion and the phosphonate, chelation will not playa significant 
stereochemical directing role in this reaction. The stereochemistry is directed 
mainly by the steric interaction of the bulky substituents, thus the major 
isomer is most likely to be the E -isomer with the phosphonate and the 
benzyloxy substituents on opposite sides of the ring. 
This reaction is also successful if the di-iso-propyl phosphonate ester 
IS used, although the yield is slightly lower. However, if dimethyl 
methanephosphonate is used, only the monoalkalated intermediate, dimethyl 
3-(benzyloxy)-4-chlorobutanephosphonate, is obtained. This suggests that the 
second equivalent of dimethyllithiomethylphosphonate does not act as a base 
to abstract the second proton. One possible explanation for this may be that 
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the smaller ester groups of dimethyl methanephosphonate allow greater 
aggregation of the dimethyllithiomethylphosphonate, making it more stable 
than the diethyl lithiomethylphosphonate and thus not able to abstract the 
second proton from dimethyI3-(benzyloxy)-4-chlorobutanephosphonate. 
Diethyl 3-(benzyloxy)cyclobutanephosphonate (132) was isolated as a 
crude residue after unreacted starting material and any remaining diethyl 
3-(benzyloxy)-4-chlorobutanephosphonate (131) were removed by distillation 
under reduced pressure. The crude residue was then purified by Kugelrohr 
distillation to give pure diethyl 3-(benzyloxy)cyclobutanephosphonate (132). 
The benzyl protecting group was removed in quantitative yield by 
hydrogenation over palladium on carbon (Scheme 2.15). The alcohol (133) was 
oxidised without further purification to gIve diethyl 
3-oxocyclobutanephosphonate in high yields (134). 
o 
~AAAII PhCH20~ •• P(OEt)2 
(132) 
MeOH 
Scheme 2.15. 
55 
o 
~AAAIi HO~ •• P(OEt)2 
(133) 
99% 
RuC13/CH20 2 
NaI°4/H20 
o 
~II 
0----v-- P(OEt) 2 
(134) 
90% 
2.3.5. Synthesis of Diethyl 3-Hydroxycyclobutanephosphonate from 
Epichlorohydrin 
Due to the success of the reaction between the anion of diethyl 
methanephosphonate (129) and 1-chloro-2-benzyloxy-3-bromopropane (91) we 
decided to investigate the reaction between the anion of diethyl 
methanephosphonate and epichlorohydrin (113) as a simpler procedure for 
the preparation of diethyl 3-hydroxycydobutanephosphonate (133) (Scheme 
2.16). Again, two equivalents of diethyl methanephosphonate (129) and 
n-butyllithium were required to react with one equivalent of epichlorohydrin 
(113). Diethyl 3-hydroxycydobutanephosphonate (133) was produced in 
approximately 25-30 % yield. 
o 
II 
2 eq. CH3 P(OEt)2 
(129) 
(i) 2 eq. n-BuLi/THF / -78°C to RT .-
(ii) 0 
~CI 
(113) 
o 
-0-11 HO P(OEt)2 ... 
(133) 
25-30 % 
z- isomer only 
Scheme 2.16. 
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(135) 
(136) 
Unfortunately, separation of the diethyl 3-hydroxy-
cyc1obutanephosphonate (133) from monosubstituted diethyl 3-hydroxy-4-
chlorobutanephosphonate (135) by distillation proved to be problematic. 
These two compounds could not be separated by Kugelrohr distillation. 
Distillation through a vigreux column gave some separation. However, to 
obtain pure diethyl 3-hydroxycyc1obutanephosphonate (133) several 
distillations were required. Thus, we used the l-chloro-2-benzyloxy-3-
bromopropane method for the synthesis of diethyl 
3-hydroxycyc1obutanephosphonate (133) in this project. 
In contrast to the l-chloro-2-benzyloxy-3-bromopropane method, the 
reaction with epichlorhydrin produced only one diastereoisomer. The signals 
in the 13e nmr spectrum of this compound corresponded to the signals that we 
had assigned to the Z-isomer of diethyl 3-hydroxycyclobutanephosphonate 
pro due e d b Y h Y d r 0 g e nat ion 0 f E / Z -diethyl 
3-(benzyloxy)cyclobutanephosphonate (132). This can be explained by 
chelation of the lithium in the intermediate (136) by both the alkoxide and the 
phosphonate, holding these two groups cis to each other. A similar situation 
has been described in the reaction of 4-phenyl-4-(phenylsulfonyl)-l,2-
epoxybutane (137) with two equivalents of methylmagnesium bromide 
(Figure 2.9). This reaction produces only one isomer of phenyl 3-phenyl-l-
hydroxycyc1obutanesulfonate (138), which has been unambiguously shown to 
be the Z -isomer by X-ray structure determination. In this case the cis 
relationship is proposed to occur due to chelation of the magnesium by the 
alkoxide ion and the sulfone, in a system that is analogous to the alkoxide-
lithium-phosphonate system described above. 88 
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Ph 
Ph02S~ 
(137) 
(i) MeMgBr /THF / -78°C to RT 
(138) 
Z- isomer only 
Figure 2.9: Synthesis of Z-3-Phenyl-3-phenylsulfonylcyclobutanol 
2.4. Conclusion 
The synthesis of the previously unknown compound, diethyl 
3-oxocyclobutanephosphonate (134) has been described. This compound is a 
versatile synthetic intermediate which can be further functionalised to provide 
a range of 3-substituted-cyclobutanephosphonic acids and related compounds. 
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Chapter 3 
Synthesis of Aminoacid Cyclobutanephosphonic Acids 
3.1. Introduction 
Ketones are versatile synthetic intermediates that can undergo 
conversion into a number of other functional groups, including amines (via 
oximes), amino acids, cyanohydrins, a-hydroxy acids, epoxides and olefins. 
Ketones can also be transformed to their homologous aldehydes by Wittig-
Horner type reactions. 
Having prepared the key intermediate diethyl 
3-oxocyclobutanephosphonate (134), the synthesis of a number of interesting 
compounds became possible via elaboration of the 3-oxo functionality. In 
particular, the synthesis of 3-amino-3-carboxycyclobutanephosphonic acid and 
related phosphonic acids could now be attempted. There are two well known 
methods for the conversion of a carbonyl group into an a -amino acid 
functionality. The first and perhaps the most widely used is the Strecker 
reaction and the second is the Bucherer-Bergs reaction.94,95 
3.1.1. The Strecker Reaction 
The original Strecker synthesis (Figure 3.1) involved the reaction of an 
aldehyde or ketone (139) with sodium or potassium cyanide and ammonium 
chloride in an aqueous environment to give an a-aminonitrile (140) via an 
iminium ion intermediate. The a-aminonitrile is then hydrolysed to the amino 
acid (141). The main problem with this reaction is its sensitivity to the 
substituents on the ketone. In a number of cases, competing condensation 
reactions, long reaction times and low yields are observed. 
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J NaCN/NH4G .. NCX NH2 R R' ---H-2-0~---i~ R R' It" /H20. ro2~NH2 
R R' 
(139) 
R=alkyt aryl 
R'=alkyl, aryl, H 
(140) 
Figure 3.1: The Strecker Amino Acid Synthesis 
(141) 
Several modifications of the Strecker reaction have now been reported. 
These include: the use of ultrasonic irradiation to catalyse the reaction in a 
non-aqueous environment;96, 97 the use of substituted amines in place of 
ammonium chloride; 98 and the use of diethyl phosphorocyanidate in place of 
inorganic cyanide.99 All these modifications are reported to give higher yields 
than the original Strecker reaction, but again there are limits to the range of 
ketone and aldehyde substrates. 
3.1.2. The Bucherer-Bergs Reaction 
The Bucherer-Bergs amino acid synthesis (Figure 3.2) involves the 
reaction of a ketone or aldehyde (139) with sodium cyanide and ammonium 
carbonate to give a hydantoin intermediate (142). The hydantoin is then 
hydrolysed to the amino acid (141). The Bucherer-Bergs reaction is reported to 
give higher yields and, in some cases, different isomeric mixtures of products 
to the Strecker reaction.95 
NaCN/NH4C03 • 
H20 
(139) 
R=alkyl, aryl 
R'=alkyl, aryl, H 
o 1t 
O-'RXR
I 
(142) 
Figure 3.2: The Bucherer-Bergs Amino Acid Synthesis 
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R R' 
(141) 
Our initial attempts at the synthesis of E- and Z-3-amino-3-carboxy-
cyclobutanephosphonic acids (78) concentrated on the Strecker reaction of 
diethy13-oxocyc1obutanephosphonate (134) since we felt that this would give 
rise to a more equal mixture of the diastereoisomers. We also thought that the 
easiest way to separate a mixture of the diastereoisomers would be via a 
derivative of the amino nitrile. 
3.2. Synthesis of Diethyl 3-Amino-3-cyanocyclobutane-
phosphonate 
3.2.1. Reaction of Diethy13-0xocyclobutanephosphonate Under 
Standard Strecker Conditions 
The standard Strecker reaction conditions have been reported to be an 
acceptable method of converting a number of cyc1obutyl, cyc10pentyl and 
cyc10hexyl compounds to the corresponding amino nitriles. Diethyl 
3-oxocyc1opentanephosphonate and diethyl 3-oxocyc1ohexanephosphonate 
were transformed to amino nitriles in 89 % and 88 % yields respectively.77 
Ethyl 3-oxocyclobutanecarboxylate, the carboxylic analogue of diethyl 
3-oxocyclobutanephosphonate, was converted directly to 1-amino-
cyc1obutane-1,3-dicarboxylic acid in 48 % yield without isolation of the 
intermediate amino nitrile. 44 As these compounds are all similar to diethyl 
3-oxocyclobutanephosphonate (134), we attempted the synthesis of diethyl 
3-amino-3-cyanocyclobutane phosphonate under the standard Strecker 
reaction conditions. 
Reaction of diethyl 3-oxocyclobutanephosphonate (134) In 
concentrated ammonium hydroxide solution with sodium cyanide and 
ammonium chloride (Scheme 3.1), for 24 hours in the dark at room 
temperature, resulted in the formation of a number of products as shown by 
tIc. Work-up of the reaction, followed by analysis of the IH and 13e nmr 
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spectra of the crude reaction mixture, suggested that although some of the 
desired aminonitrile (135) « 15 0/0) had formed, large amounts of condensation 
products, some cyanohydrin (136) and some starting ketone were also present. 
o 
=()- II NaCN/NH4Cl o P(OEt)2 -----=-----l.~ NH40H 
(135) 
<15% 
+ 
Condensation products 
+ 
o (134) (134) HOX)-II 
,.. P(OEt)2 
NC" 
(136) 
Scheme 3.1. 
3.2.2. Synthesis of Diethyl 3-Cyano-3-hydroxycyclobutanephosphonate 
As the standard Strecker reaction conditions were obviously 
unsuitable for a high yielding preparation of diethyl 3-amino-3-
cyanocyclobutanephosphonate (135), our attention turned to reports in the 
literature of high yielding modifications of the Strecker synthesis using 
ultrasonic irradiation. A number of 4-piperidone derivatives that could not be 
converted to a-aminonitriles in even moderate yields under normal conditions 
were converted quantitatively to amino nitriles by reaction with potassium 
cyanide and an amine in acetic acid under ultrasonic irradiation. 96 A 
procedure in which involves the heterogeneous reaction of a ketone with 
potassium cyanide, ammonium chloride and alumina in acetonitrile under 
ultrasonic irradiation has been reported to give high yields of amino nitriles, 
while suppressing the formation of cyanohydrins and condensation 
products.97 This method has been used successfully in the synthesis of a 
number of l-amino-3-cyanocyclopropanealkylphosphonates.79 
62 
Reaction of diethyl 3-oxocyclobutanephosphonate (134) with sodium 
cyanide, ammonium chloride and alumina in acetonitrile under ultrasonic 
irradiation (Scheme 3.2) for 12 hours resulted in a much cleaner reaction as 
indicated by tIc analysis. Further investigation of the crude product by 1H and 
13e nmr indicated that only one compound, as a mixture of two isomers, (2:1 
ratio), had been formed with less than 10 % of the starting material remaining. 
Infrared spectroscopy indicated that these compounds were not the 
aminonitriles (135) but the cyanohydrins (136). The infrared spectrum showed 
a weak absorbance at 2221 cm-1 corresponding to the nitrile functionality and 
a strong broad absorbance at 3382 cm-1 corresponding to a hydroxyl group, 
rather than doublet in the region 3300 to 3400 cm-1 that would indicate the 
presence of an amino group. This was confirmed by elemental analysis of the 
phenyl acetyl derivative (138). 
(134) 
Scheme 3.2. 
o HOX>-II 
,.' P(OEt)2 
NC'" 
(136) 
85% 
Z:E 2:1 
As the cyanohydrin (136) is similar to the a-aminonitrile (135) we 
decided to use this compound as a model compound for studies on the 
separation and identification of the isomers. Separation of the Z- and 
E-cyclopentaneaminonitriles was achieved by chromatography of the N-acetyl 
derivatives on silica gel. A sample of the cyanohydrin (136) was converted to 
the O-acetyl derivative (137) (Scheme 3.3). Analysis by tIc using a variety of 
solvent systems gave only poor separation. However, conversion of the 
cyanohydrin to the phenyl acetyl derivative (138) facilitated rapid separation of 
the isomers by silica gel chromatography. 
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o 1-0>0- 11 
,. •• , P(OEth 
NC" 
(136) 
R( O)Cl / pyridine 
CH202 
o 0 
II II 
o 
II 0 
RC~II 
NC 
,..... P(OEth 
(137)R=CH3 
(138) R=PhCH2 
Silica gel chromotograpy 
1 % MeOH/CH20 2 
o 
PhCH2ro~P(OEth + 
NC' .. ···V 
II 
PhCH2ro~ 
NC .... ···V···" P(OEt)2 
II 
(138a) 
54% 
Scheme 3.3. 
(138b) 
30% 
o 
3.2.2.1 Assignment of Configurations of DiethyI3-(Phenylacetoxy)-3-
cyanocyclobutanephosphonate 
Separation of the isomers allowed assignment of the configurations 
using 13C nmr spectroscopy and X-ray crystallography. The major isomer 
from the crude reaction mixture was identified as the Z-isomer (138a) and the 
minor component as the E-isomer (138b). Comparison of the 13C nmr spectra 
of the two isomers showed a singlet for the peak at 117.93 ppm (Figure 3.3) for 
the isomer that eluted from the column first (138a) I and a doublet (J=3.2 Hz) at 
117.12 ppm (Figure 3.4) for the compound that eluted second (138b). These 
peaks correspond to the signal from the nitrile carbon indicating the 
compound that eluted from the column first is the Z-isomer (138a)and the 
second compound is the E-isomer (138b). In the E-isomer the configuration of 
NC-C3-C2-C1-P is such that it forms a "w"-shape (Figure 3.5) and thus the 
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coupling between the phosphorus and the nitrile carbon is large enough to be 
seen (Figure 3.4), however in the Z-isomer (139a), in which the phosphorus 
and the nitrile are on opposite faces of the cyclobutane ring, the configuration 
is such that no coupling will be observed (Figure 3.3). 
NC~ 
PhCH2CO~P(OEth 
II II 
o 0 
(138a) 
o 
II 
NC~P(OEt)2 
PhCH 2OO/V' II 
o 
(138b) 
Figure 3.5: Configuration of Z- and E-DiethyI3-(Phenylacetylamino)-3-cyano-
cyclobutanephosphonate 
There is also a considerable difference between the coupling constant 
of C3-P for each of the isomers. The Z-isomer has a value of 3Jcp=34.2 Hz 
which is significantly larger than the value for the E-isomer of 3J cp=19.6 Hz. 
This suggests a difference in the ring conformation between the two isomers. 
The isomer identified as the Z-isomer was isolated as a white powder and 
crystallised slowly from a mixture of pentane, ether and toluene to give 
colourless crystals which were suitable for X-ray diffraction. This allowed the 
X-ray crystal structure of isomer 1 to be determined, thus confirming it as the 
Z-isomer (Figure 3.6). Bond lengths and angles associated with the 
cyclobutane ring (13Ba) are significantly strained, as is typical of four-
membered rings. The dihedral angle C1-C2-C3-C4 is -14.7° illustrating the 
typical ring puckering of a cyclobutane. 
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Figure 3.6: Ortep plot of Z-Diethyl 3-(Phenylacetoxy)-3-cyano-cyclobutanephosphonate 
3.2.3. Reaction of Diethyl 3-0xocyclobutanephosphonate under Bucherer-
Bergs Conditions 
Since attempts at preparing the desired amino nitrile by the Strecker 
reaction had been unsuccessful, we decided to attempt the synthesis of the 
spirohydantoin via the Bucherer-Bergs procedure. Analysis by 13C and 31p 
nmr spectroscopy of the crude reaction mixture after diethyl 
3-oxo-cyclobutanephosphonate (134) was treated with sodium cyanide and 
ammonium carbonate in aqueous methanol at reflux for 6 hours (Scheme 3.4), 
indicated that spirohydantoin (139) formation had occurred with the ratio of 
the two isomers being approximately 4:1. This is in accordance with the ratio 
of products obtained by Bucherer-Bergs reactions on similar substrates. 44, 100 
o 
=0-- II NaCN/"Ammoniumcarbonate" o P~~2 • Aq. MeOH/Reflux 
(134) 
Scheme 3.4. 
HN~~(OEth 
O}-~ 
(139) 
65% 
Z:E4:1 
In the case of cyclobutane and cyclopentane compounds separation of 
the isomers was achieved by ion exchange chromatography and fractional 
crystallisation, respectively, of the amino acid. 44, 100 Hydrolysis of a sample of 
the hydantoin (139) (Scheme 3.5) and attempts at separation using these 
methods failed with our amino phosphonic acid (78). Acetylation of the 
spirohydantoin (139), to give the di-N-acetate (140) (Scheme 3.5) and analysis 
of the products by tIc using a variety of solvent systems indicated that the 
isomers were not separable by silica gel chromatography. 
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(78) 
o 
~o II HN P(OEt)2 O)--~ 
o 
(139) ~o II AcN P(OEt)2 )--NAC 
o 
(140) 
Scheme 3.5. 
3.2.4. Synthesis of DiethyI3-(Benzylamino)-3-cyanocyclobutane-
phosphonate 
A simple, mild one pot procedure for the synthesis of a-amino nitriles 
using benzyl amine and potassium cyanide in methanol and glacial acetic acid 
has been described. This reaction proceeds under non-aqueous conditions and 
the yields appear to be independent of the nature of the substituents on the 
precursor ketones. This method is reported to give high yields and no by-
products.98 
Reaction of diethyl 3-oxocyclobutanephosphonate (134) with 
benzylamine, sodium cyanide in methanol and acetic acid at reflux for 15 
hours (Scheme 3.6) was successful as a method of forming diethyl 
3-(benzylamino)-3-cyanocyclobutanephosphonate (141). Analysis of the 31p 
and 13C nmr spectra of the crude reaction mixture indicated the formation of 
just two products, which were identified as the two isomers (3:2 ratio). 
Separation of the Isomers of diethyl 3-(benzylamino)-3-
cyanocyclobutanephosphonate (141) was more difficult than the separation of 
the O-phenylacetyl (138) compound. However, separation can be achieved by 
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careful silica gel chromatography with hexane and iso-propanol as solvent 
(Scheme 3.6). 
o 0 
=0- II NaCN/PhCH2NH2 PhCH2NH><r II o P(OEt) 2 •. P(OEt) MeOHI AcOHI Reflux NC , .. " 2 
(134) 
o 
II 
(141) 
82% 
Z:E 3:2 
Silica gel 
chromatography 
20 % i-PrOH/hexane 
PhCH2NH~ PhCH 2NH)-/VP(OEt) 2 
NC''''''V + NC''''··V···'' P(OEt)2 
(141a) 
45% 
Scheme 3.6. 
(141b) 
30% 
II 
o 
The success of this method of preparing a-aminonitriles is probably 
due to the stabilising influence of the benzyl group on the intermediate 
iminium ion. The Strecker reaction proceeds via formation of the iminium ion 
(142) followed by attack of this intermediate by the cyanide ion (Figure 3.7). 
Thus the formation, and hence, stability of this intermediate is of utmost 
importance to the reaction. The unsubstituted iminium ion (142a) formed 
under standard Strecker reaction conditions is going to be considerably less 
stable than the benzyliminium ion (142b) and thus less likely to form. This 
allows simple nucleophilic attack of the carbonyl centre by the cyanide ion and 
subsequent cyanohydrin formation to be the dominant reaction. 
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o=<>-- ~OEt) 2 __ N_a_C_N_/_RNH_....::2:....-..-I .. ~
(134) 
(l42a) R=H 
(l42b) R=CH2Ph 
o 
RHN'-.A ___ II 
./V---P(OEt)2 
NC 
(136) R=H 
(141) R=CH2Ph 
Figure 3.7: Mechanism of the Strecker reaction 
The I3C nmr spectrum of the crude reaction mixture of the 
benzylaminonitrile (141) is similar to the I3C nmr spectrum of the 
O-phenylacetylcyanohydrin (138) in most respects. The major difference is the 
position of the signal due to C-3. In the spectra of the 
O-phenylacetylcyanohydrin this signal occurs between 65 and 67 ppm, 
(depending on the isomer) and in the spectrum of the N-benzylamino nitrile 
the signal due to C-3 occurs between 51 and 53 ppm, this suggests that the 
amino nitrile has formed in this case rather than the cyanohydrin which has 
the signal due to C-3 shifted downfield due to the greater electronegativity of 
the hydroxyl substituent compared to that of the amine substituent. The 
formation of the benzylaminonitrile was confirmed by infrared spectroscopy 
which showed absorbances at 2220 em-I, characteristic of the nitrile group and 
a strong absorbance at 3273 em-I, characteristic of the NH of a benzyl amine.98 
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No sign of any cyanohydrin or any unreacted ketone was detected by either 
runr or IR spectroscopy. 
3.2.4.1 Attempted Removal of the N-Benzyl Group 
It has been reported that N-benzyl groups are easily removed by 
hydrogenolysis at room temperature and atmospheric pressure in methanol 
using 5 % palladium on carbon as catalyst, whilst leaving the cyano group 
untouched. However, under these conditions the benzyl group of our 
compounds was not removed from either the Z- or the E-isomer (141). The 
benzyl group also remained intact after hydrogenolysis over 10 % palladium 
on carbon in methanol at room temperature at a pressure of three atmospheres 
(Scheme 3.7). Room temperature hydrogenation at three atmospheres, of 
diethyl 3-(benzylamino )-3-cyanocyclobutanephosphonate (141) in methanol 
and acetic acid using 10 % palladium on carbon as a catalyst resulted in 
reduction of the nitrile to the amine (143). However, the benzyl group was still 
left intact. Hydrolysis of the nitrile and concurrent removal of the 
phosphonate ester groups to give 3-(benzylamino )-3-carboxycyclobutane-
phosphonic acid (144) and subsequent hydrogenolysis of this compound also 
failed to deprotect the amine. Other unsuccessful methods for removal of the 
benzyl group include the use of Pearlman's catalyst (wet Pd(OHh on 
carbon)101 and wet palladium on carbon, both of which are reported to be 
effective for removal of benzyl groups. Attempts to remove the N-benzyl 
group using lithium in liquid ammonia resulted in a mixture of unidentified 
non-cyclobutane products, with no starting material or product isolated. 
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o 
PhCH2HNX>- II 
.' P(OEt)2 ~, NC~ 
(141) 
cat. = Pd/C, wet Pd/C, Pd(OHh/C 
Scheme 3.7. 
Catalytic transfer hydrogenation has been successfully applied as a 
method for removal of an N-benzyl group from a variety of compounds. 102-104 
Transfer hydrogenation is reported have greater selectivity and considerably 
shorter reaction times than traditional hydrogenolysis. Reactions are carried 
out at atmospheric pressure in the presence of a catalyst (usually palladium on 
carbon or palladium black) and a hydrogen donor. A number of hydrogen 
donors have been studied in the removal of benzyl groups, of these 
ammonium formate 102, 104 and 1,4-cyclohexadiene103 appear to be the most 
effective for debenzylation. Attempts to deprotect diethyI3-(benzylamino)-3-
cyanocyclobutanephosphonate (141) and 3-(benzylamino)-3-carboxy-
cyclobutanephosphonic acid (144) (Scheme 3.8) with ammonium formate or 
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l,4-cyclohexadiene in the presence of 10 % palladium on carbon or freshly 
prepared palladium black were all unsuccessful. 
o 
PhCH2HNX>- II 
\,0' P(OEt)2 
NC" 
(141) 
or 
o 
PhCH2HNX>- II 
..... P(OH)2 
1-I02C'" 
(144) 
cat. = Pd/C or palladium black 
MeOH/reflux 
H2 donor = NH4HC02 or l,4-cyclohexadiene 
Scheme 3.8. 
3.2.5. Synthesis of DiethyI3-(p-Methoxybenzylamino)-3-cyano-
cyclobutanephosphonate 
As it appeared that the N-benzyl group could not be removed from E-
or Z-diethyl 3-(benzylamino )-3-cyanocyclobutanephosphonate under any 
reaction conditions, we decided to repeat the Strecker synthesis using 
p-methoxybenzylamine. The p-methoxybenzyl (PMB) group has been removed 
from amines under a variety of mild oxidative conditions, of which the most 
practical is reaction with eerie ammonium nitrate (CAN).105, 106 
Synthesis of diethyl 3-(p-methoxybenzylamino )-3-amino-
cyclobutanephosphonate (145) (Scheme 3.9) was carried out in a manner 
similar to, and in comparable yield to that described above for the synthesis of 
diethyl 3-(benzylamino )-3-cyanocyc1obutanephosphonate (141). The 
diastereoisomers were again separated by silica gel chromatography using an 
iso-propanol/hexane solvent mixture. 
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o 0 
=<>--
II NaCN/PMBNH2 PMBHNX>-II o P(OEt) 2 ------~--l.~ , .. ,., P(OEt)2 
MeOHI AcOHI Reflux NC 
(134) 
o 
II 
PMBHN~P(OEt)2 
NC''''''V' 
(145a) 
53% 
Scheme 3.9. 
(145) 
85% 
cis :trans 3:2 
Silica gel 
chromatography 
20 % i-PrOH/hexane 
+ 
(145b) 
31 % 
3.2.5.1. Removal of the N-p-Methoxybenzyl Group 
The p-methoxybenzyl group was removed quantitatively by reaction 
with CAN in acetonitrile and water (Scheme 3.10). Interestingly, 
hydrogenolysis over palladium on carbon also facilitated the removal of the p-
methoxybenzyl group. The crude amino nitriles (135) were then hydrolysed to 
give the amino phosphonic acids (78) which were purified by ion exchange 
chromatography. 
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o 
PMBHNX>-II 
.... P(OEth 
NC'''' 
(145) 
(135) 
98% 
(i) 6M HCl/reflux 
(ii) Ion exchange 
chromatography 
Scheme 3.10. 
o H2X>-1I 
.... P(OEt)2 
NC'''' 
(135) 
97% 
(i) 6M HCl/reflux 
(ii) Ion exchange 
chromatography 
o H2X>-1I 
...... P(OH)2 
H02C'''' 
(78) 
76% 
3.2.5.2. Assignment of Configurations of Diethyl 3-(p-Methoxybenzyl-
amino)-3-cyanocyclobutanephosphonate 
The configuration of the isomers was again assigned using 13C nmr 
spectroscopy and X-ray crystallography of diethyI3-{p-methoxybenzylamino)-
3-cyanocyclobutanephosphonate (145). The signal at 121.36 ppm in the 13C 
nmr spectrum (Figure 3.8) due to the nitrile carbon of the Z-isomer (145a) is a 
singlet whereas the signal due to the nitrile carbon of the E-isomer (145b) (in 
which the nitrile and phosphonate functionalities are cis to one another) at 
120.26 ppm is a doublet (J=4.8 Hz) (Figure 3.9) due to the long-range 
W-coupling of the nitrile carbon to the phosphorus. It is interesting to note 
that this long-range coupling between the phosphorus and the nitrile carbon is 
not seen in the 13C nmr spectrum of either diethyl 3-(acetylamino)-3-
cyanocyclopentanephosphonate or 3-{acetylamino)-3-cyanocyclohexane 
phosphonate?7 
There is a significant difference in the chemical shift of the signal due 
to C-1 of each of the isomers. The C-1 signal of the Z-isomer (145a) (23.75 ppm) 
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Figure 3.9: 13C Nmr Spectrum of E-DiethyI3-(p-Methoxybenzylamino)-3-cyanocyc1obutanephosphonate 
(Figure 3.8) shows an upfield shift of 2.4 ppm relative to the C-1 signal of the 
E-isomer (145b) (26.13 ppm) (Figure 3.9), suggesting that the phosphorus atom 
of the Z -isomer (145a) is less electron rich than that of the other 
diastereoisomer. One possible explanation for this is that an intramolecular 
hydrogen bond exists between the amine proton and phosphonate moieties. 
An oxygen atom that is doubly bonded to a phosphorus is known to 
participate in hydrogen bonding. 107 The phosphonate would be less electron 
rich if it was donating electrons for a hydrogen bond. Such intramolecular 
hydrogen bonding would only be possible in the Z-isomer in which the amine 
and phosphonate moieties are cis to one another. The signal due to the 
phosphorus of the Z-isomer (145a) (29.17 ppm) in the 31p nmr spectrum also 
shows an upfield shift relative to the E-isomer (145b) (29.49 ppm). 
The E-isomer of diethyl 3-(p-methoxybenzy lamino )-3-cyano-
cyclobutanephosphonate (145b) was isolated as colourless crystals. Slow 
recrystallisation from a mixture of ether, toluene and pentane provided 
crystals suitable for X-ray diffraction. The X-ray structure of E-diethyl 
3-(p-methoxybenzylamino )-3-cyanocyclobutane phosphonate was obtained 
(Figure 3.10). The dihedral angle C1-C2-C3-C4 is -5.7°, which is considerably 
less than that of Z-diethyl 3-(phenylacetoxy)-3-cyanocyclobutanephosphonate 
(138a). However, it has been reported that this folding can be significantly 
affected by solid-state effects, with different crystals of the same compound 
showing different amounts of ring puckering. 44 
The 13C nmr spectra of the free amino acids (78) show similar shifts 
and coupling constants for the signals due to the cyclobutane ring to those in 
the spectra of the protected amino nitriles. The signal due to the carboxylic 
acid functionality of the E-isomer at 176.94 ppm is a doublet (J=2.9 Hz) due to 
the long-range coupling with the phosphorus. 
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Figure 3.10: Ortep Plot of E-Diethyl 3-(p-Methoxybenzylamino)-3-cyanocyclobutanephosphonate 
3.3. Synthesis of Z-3-Aminocyclobutanephosphonic Acid 
Diethyl 3-oxocyclobutanephosphonate (134) can be rapidly converted 
to 3-aminocyclobutanephosphonic acid (148) by a simple synthetic route 
(Scheme 3.11). Treatment of diethyl3-oxocyclobutanephosphonate (134) with 
hydroxylamine hydrochloride in water at reflux for 12 hours produces the 
oxime (146) in good yield with a small amount (-10 %) of starting material 
remaining. lOB The crude oxime (146) was converted to the amine by 
hydrogenolysis at 3 atmospheres of hydrogen with rhodium on alumina as the 
catalyst. The crude amine (147), contaminated by some diethyl 
3-hydroxycyclobutanephosphonate (134) was hydrolysed to the amino 
phosphonic acid (148) and purified by ion exchange chromatography 
(Dowex-SO H+ form), removing any of the ketone present. 
o 
~II 
0-v- P(OEt)2 
(134) 
(148) 
o 
=0-- 11 NH 20H.HClIH 20.. N_ P(OEt)2 reflux /-10 .r 
(i) 6M HClI reflux 
(ii) Ion exchange 
chromatography 
Scheme 3.11. 
(146) 
H2/Rh/ Alumina 
MeOH 
(147) 
Only one of the two possible diastereoisomers is formed. This was 
suggested to be the Z-isomer by the following argument. The carbonyl of 
cyclobutanones is known to prefer to be distorted toward the inner endo 
face.109,110 Thus it is plausible to assume that the oxime (146) will adopt a 
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similar conformation (Figure 3.11). It is also likely that the bulky phosphonate 
group will prefer to be in the psuedoaxial position to minimise steric 
interactions. In this conformation it is likely that hydrogenation will occur 
from the substantially less hindered top side of the cydobutane ring than from 
the more hindered bottom side, leading to the Z-isomer. 
H 
H~ H 4/ rH \ 
HO""" N ~ P(OEt) 2 
o 
(146) 
Figure 3.11: Lower energy conformation of Diethyl 3-hydroxylamine 
cyc1obutanephosphonate 
3.4. Synthesis of Diethyl 3-Hydroxy-3-methylcyclobutane-
phosphonate 
Treatment of diethyl 3-oxocydobutanephosphonate (134) with 
methylmagnesium bromide at -78°C results in the formation of only the 
Z-isomer of diethyl 3-hydroxy-3-methylcydobutanephosphonate (149) 
(Scheme 3.12). The Z-isomer was identified by the lack of coupling between 
the methyl carbon and the phosphorus in the 13C nmr spectrum. No evidence 
of the other diastereoisomer was found. 
==<>- ~ MeMgBr/THF/-78°C o P(OEt)2 .. 
(134) 
Scheme 3.12. 
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II 
o (148) 
This can be explained in a similar fashion to the formation of only the 
Z-isomer of diethyl 3-aminocyclobutanephosphonate (148). The lower energy 
conformation (134a) of the cyclobutanone is the one in which the ketone is 
distorted toward the inner endo-face and the phosphonate is in the 
pseudo axial position (Figure 3.12).109,110 Molecular modelling studies using 
Quanta indicate that there is approximately a 4.5 kcal difference between the 
two possible conformations (60.8 kcal versus 56.3 kcal), indicative of a ratio in 
the region of 99:1. Thus the nucleophilic attack occurs at the requisite angle (0 
::::: 110°) from the exo-face to provide a trans-selective addition. A similar 
selective addition has been observed in the addition of (l-phenylvinyl)lithium 
to a substituted cyclobutanone.111 
Nuc-
\ , 
\ 
\ 
"Trans" addition "Cis" addition 
Nuc-
H 
\ HI H \~/ 0FH \ 
o ~P(OEt)2 
o 
(134a) (134b) 
Figure 3.12: Nucleophilic Addition to the Low and High Energy Conformations of 
Diethy13-oxocyclobutanephosphonate 
3.5. Homologation of the Ketone Functionality 
Diethyl 3-formylcydobutanephosphonate was investigated as a 
potential intermediate in the synthesis of homologues of 3-amino-3-carboxy-
cyclobutanephosphonic acids (78). Homologation techniques for the formation 
of aldehydes form a considerable body of methodology. Among these 
techniques are the Darzen's method and the use of alkoxymethylene-112 and 
aryloxymethylene triphenylphosphoranes,113 diethyl methylthiomethyl-
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phosphonate,114 methoxymethyl diphenylphosphine oxide115 and a-methoxy-
a-trimethylsilyl carbanions. 116 Two major shortcomings are associated with 
Wittig (and similar) reactions: the first is the unreactivity of some reagents 
towards various substrates; the second is the formation of side-products from 
to enolizable ketones. 
3.5.1. Attempted Syntheses of Diethyl 3-Formylcyc1obutanephosphonate 
The lithium derivative of diethyl (l-methylthio)methylphosphonate 
has been reported as an effective reagent for the conversion of ketones to the 
homologous aldehydes via vinyl sulfide intermediates.114 The vinyl sulfide 
intermediates are readily converted to the aldehydes by a mercury(II)-
promoted hydrolysis. Reaction of diethyI3-oxocyclobutane-phosphonate (134) 
with a-lithio diethyl (l-methylthio)methyl phosphonate (150) (Scheme 3.13) 
did not result in the formation of the desired vinyl sulfide. A mixture of 
starting material and conjugation products were isolated. Similar results were 
obtained on reaction of diethyl 3-oxocyclobutanephosphonate (134) with both 
diphenyl methoxymethylphosphine oxide (151) and diethyl 
methoxyethoxymethylphosphonate (152) (Scheme 3.13). 
THF =<>-~ o P(OEt)2 "Wittig reagent" 
(134) 
"Wittig Reagent" =(150) MeSCH2P(O)(OEth 
(151) MeOCH2P(O)(Phh 
(152) MeOCH2CH20CH2P(O)(OEt)2 
Scheme 3.13. 
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The lithium salt of methoxymethyltrimethylsilane (153) has been 
described as a useful formyl anion equivalent,116 which is effective in cases 
where a variety of other Wittig-type reagents are unsuccessful.117 Treatment of 
a ketone with the anion of methoxymethyltrimethylsilane (153) gives the 
intermediate alcohol, which does not immediately undergo syn-elimination of 
-OSiMe3 in situ, but upon treatment with potassium hydride in 
tetrahydrofuran at room temperature, leads to the corresponding enol ethers. 
Treatment with formic acid gives the aldehydes in high yields. 116 Reaction of 
the lithium salt of methoxymethyltrimethylsilane (153) with diethyl 
3-oxocyclobutanephosphonate (134) results in the formation of the 
intermediate alcohol (154) (Scheme 3.14). However, reaction of this 
intermediate with potassium hydride at room temperature or in refluxing 
tetrahydrofuran yields only the ~-methoxy alcohol (155). Again, only one of 
the possible diastereoisomers is formed. Presumably, reaction with potassium 
hydride results in a l,3-migration of the silicon functionality. However, no 
elimination occurs and the silyloxy group is then hydrolysed in the work up. 
o - M o:)oSiMe3 
=0- 11 (i)MeOCHSiMe3 (153) /THF e o P(OEt) 2 -(i1-·)H-20----.;;~----l .. ~ HO ,..... "'" P(OEt) 2 
(134) 
Scheme 3.14. 
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II 
(154) 0 
MeO~ 
HO , .. ···V··", P(OEt) 2 
II 
(155) 0 
3.5.2. Synthesis of Diethyl 3-Formylcyc1obutanephosphonate 
The anion of diethyl isocyanomethylphosphonate (156) reacts with 
aldehydes and ketones via a Wittig-Horner reaction to form a,~-unsaturated 
isocyanides which can then be hydrolysed to give homologous aldehydes 
containing one extra carbon atom. Since the reaction between cyclobutanone 
and the lithium salt of diethyl isocyanomethylphsophonate (156) was 
successful,118 this appeared to be a promising Wittig reagent for reaction with 
our phosphonate substituted cyclobutane. Diethyl 3-oxocyclobutane-
phosphonate (134) was treated with a -lithio diethyl 
isocyanomethylphosphonate (156) in tetrahydrofuran at -78-0 °C for 
approximately 2 hours (Scheme 3.15) after which time the reaction was 
quenched with water and the tetrahydrofuran was removed. The residue was 
redissolved in diethyl ether, 6M hydrochloric acid was added and the reaction 
stirred at room temperature for 12 hours. The reaction was carried out in 
tetrahydrofuran due to the low solubility of the phosphonate in diethyl ether. 
However, when the hydrolysis of the intermediate unsaturated isocyanide 
(157) is carried out in tetrahydrofuran the resulting aldehydes have a tendency 
to trimerise, hence the redissolution In ether. 118 Diethyl 
3-formylcyclobutanephosphonate (158) was isolated in good yield as a 1:1 
mixture of the two isomers as determined by 31p nmr. 
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o 0 O=<>-~(OEt) CNCHP(O)(OEt)2 (156) CN~ II 
2 THF/-78 0 C • ~P(OEth 
(134) 
Scheme 3.15. 
° 
(157) 
EtzO 
H+/lliO 
II Ao-0 H P(OEt)2 
(158) 
86% 
E:Z 1:1 
Extensive analysis of the isomeric mixture of aldehydes (158) by tIc 
indicated that it would not be possible to separate the two isomers by 
chromatography. As the mixture was otherwise extremely pure, we decided to 
proceed to the next stage, when separation of the diastereoisomers was likely 
to be more facile. 
3.6. Synthesis of 3-<Amino-carboxymethyl)cyclobutane-
phosphonic Acid 
3.6.1. Synthesis of DiethyI3-(Phenyladetylamino)-cyanomethyl)-
cyclo butanephosp honate 
Reaction of diethyl 3-formyIcyclobutanephosphonate (158) with 
sodium cyanide and ammonium chloride in aqueous methanol resulted in the 
formation of large amounts of undesired condensation products. However, 
reaction of the aldehyde (158) (Scheme 3.16) with sodium cyanide and 
ammonium chloride in ammonIum hydroxide for 12 hours, with light 
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excluded, produced a high yield of the desired amino nitrile (159). Little or no 
formation of condensation products occurred under these conditions. Longer 
reaction times resulted in hydrolysis of the phosphonate esters. 
As it was hoped that the enantiomers of these compounds could be 
separated by enantioselective enzymatic hydrolysis the amino nitriles were 
converted to the N-phenylacetyl derivatives (160). The diastereoisomers were 
easily separated by silica gel chromatography using iso-propanol and hexane 
as a solvent mixture. The assignment of the isomers was again made using the 
characteristic coupling of the phosphorus to the carbon attached to the C-3 
position of the Z-isomer, which was found to be the second isomer that eluted 
from the column. 
o 
~o II H P(OEt)2 
(±)-(158) 
o 
o II 
II ./VP(OEt)2 
PhCH,GNH),,····V 
CN 
(±)-(160a) 
48% 
(±)-(160b) 
45% 
o 
II 
P(OEt)2 
H~2N 0 
II 
NC P(OEt)2 
(±)-(159) 
78% 
PhCH2C(O)CI/pyridine 
CH20 2 
o 
II 
Silica gel PhCH2CNH 0 
chromatography ~ II 
.. NC P(OEt)2 
hexane:i-PrOH 7:3 
Scheme 3.16. 
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(±)-(160) 
95% 
3.6.2. Enzymatic Separation of Enantiomers 
There are two general approaches to the synthesis of optically active 
amino acids: asymmetric synthesis of enantiomers and the resolution of 
racemates by chemical or enzymatic means. Of these methods, resolution of a 
racemate using enzymatic hydrolysis is a mild, highly enantioselective method 
that procedes with good yields. Penicillinacylase (Ee 3.5.1.11) from Escherichia 
coli is known to show L directed stereochemical preference in the hydrolysis of 
phenylacetylamino acids. Further investigation has shown that 
penicillinacylase is capable of hydrolysing a variety of phenylacetylamino 
compounds, including phenylacetylamino nitriles.119 A number of 
1-aminoalkylphosphonic acids have been prepared with high 
enantioselectivity via penicillinacy lase ca tal ysed hydrolysis of the 
phenylacetylamino phosphonic acids.1 2o These studies indicate that 
penicillinacylase has a high substrate tolerance and would thus be of use in the 
resolution of the enantiomers of (±)-E - and (+)-Z-diethyl 
3-(phenylacetylamino)-cyanomethyl)cyclobutanephosphonate. Enzymatic 
hydrolyses of the racemic phenylacetylamino nitriles (Scheme 3.17 and scheme 
3.18) were carried out using penicillinacylase immobilised on Eupergit under 
the conditions described by Rossi. 119 The reactions were monitored by tIc until 
there ceased to be an obvious increase the amount of phenylacetic acid 
produced, (approximately 6 hours). Acidification of the reaction mixture to pH 
4 with 6 M hydrochloric acid followed by extraction with dichloromethane 
yielded the unhydrolysed phenylacetylamino nitrile. Neutralisation of the 
aqueous layer and re-extraction with dichloromethane yielded the hydrolysed 
aminoni trile. 
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o 
o II 
o II y<YP(OEt)2 o II PhCH 2CNH 
II PP(OEt)2 PhCH2CNH Penicillinacylase 27°C 
CN 
(±)-(160a) 
a.alM Phosphate buffer pH 7/MeOH .. NC (-}-(160a) 
Scheme 3.17. 
o 
II 
43% 
NC (+)-(159a) 
41% 
95%ee 
PhCHJNH 0 PhCH2CNl /'.. ~~(OEt)2 
NC.J... /'... .. ~(OEt12 Penieillinaeyl.se 27 0C • NC- "<J 
- 'V a.OlM Phosphate buffer pH 7/MeOH 
(160b) 
Scheme 3.18. 
(-}-(160b) 
45% 
o 
II 
~P(OEt)2 
NC ~ 
(+)-(159b) 
43% 
95%ee 
The absolute configuration of the isomers is not known. However, it is 
likely that the isomer hydrolysed by the enzyme has R stereochemistry. 
Penicillinacylase is known to preferentially hydrolyse the L-isomer of amino 
acids and extensive efforts have been made to determine factors that influence 
the stereoselectivty of the hydrolysis of other phenylacetylamino 
compounds. 119 These studies have shown that when a nitrile, rather than a 
carboxylic acid functionality, is present on the carbon ex to the 
phenylacetylamino group and the third substituent is larger than an ethyl 
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group for example, an iso-propyl or phenyl group, then the R-isomer is the one 
which is preferentially hydrolysed. As the cyc10butane ring can be thought of 
as iso-propanol group that has a bond between the two methyl groups, then it 
is plausible to expect a similar stereoselectivity in the the hydrolysis of these 
cyc10butane compounds. 
3.6.3. Determination of Enantiomeric Excesses 
The enantiomeric purities of the compounds were determined by 19F 
runr analysis of the Mosher's amides. 121 Reaction of samples of the hydrolysed 
isomer with a-methoxy-a-trifluoromethylphenylacetyl chloride provided the 
Mosher's amide of the amino nitrile. On comparison ,of the 19F nmr spectrum 
of the single enantiomer from the enzymatic hydrolysis with the 19F runr 
spectrum of a sample of the Mosher's amide of the racemic compound, no 
evidence of a signal in the 19F nmr spectrum corresponding to the opposite 
enantiomer was found in either of the two diastereoisomers. However, given 
that the sample converted to the Mosher's amide was in the region of 3-4 mg, 
it would be unwise to say that the enantiomeric purity was greater than 95 %. 
3.6.4. Synthesis of 3-(Amino-carboxymethyl)cyclobutanephosphonic Acids 
The amino nitriles (159) and phenylacetylamino nitriles (160) were 
treated with 6 M hydrochloric acid at reflux to produce the aminophosphonic 
acids as their hydrochloride salts (Scheme 3.19). Purification of the 
aminophosphonic acids by ion exchange chromatography (Dowex 50W, H+ 
form) provided the enantiomerically pure aminophosphonic acids (79). 
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o 
o II 
II '" ~P(OEt)2 
PhCH2CNH Y V' 
o 
II 
NC 
NC 
(-)-(160a) 
(+)-(159a) 
(i) 6M HCl reflux 
(ii) Ion exchange Dowex 50 H+ 
(i) 6M HCl reflux 
(ii) Ion exchange Dowex 50 H+ 
PhCH2C~NH ~ (i)6MHClreflux 
P(OEt)2 • NC (ii) Ion exchange Dowex 50 H+ 
(-)-(l60b) 
NH2 0 
: II (i) 6M HCl reflux ~P(OEt)2 • 
NC"V (ii) Ion exchange Dowex 50 H+ 
(+)-(159b) 
Scheme 3.19. 
3.7. Conclusion 
o 
II 
'" ~P(OHb 
H2N Y V' 
!-02C 
(-)-(79a) 
[a]D= -17.9 
o 
II 
N .A.,;P(OH)2 
H2'~ 
H02C (+}-(79a) 
[a]D= +18.7 
12 /'.. ~~OH)2 
H02C' ~ 
(-)-(79b) 
[a]D= -12.9 
(+}-(79b) 
[a]D=+13.6 
The key intermediate diethyl 3-oxocyclobutanephosphonate (134) has 
been used in the synthesis of a variety of cyclobutane phosphonic amino acids. 
Both diastereoisomers of 3-amino-3-carboxycyclobutanephosphonic (78) acid 
have been prepared via a modified Strecker reaction. In the synthesis of 3-
amino-cyclobutanephosphonic acid (149), the cyclobutane phosphonic acid 
analogue of y-aminobutyric acid (GABA), only the Z-isomer was obtained due 
to a diastereoselective hydrogenation of the intermediate hydroxylamine. The 
synthesis of E- and Z-diethy13-formylcyclobutanephosphonates (158) was also 
carried out and the products were transformed into E- and Z-3-(amino-
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carboxymethyl)cyc1obutanephosphonic acid (79) ,the homologue of 3-amino-
3-carboxycyc1obutane-phosphonic acid (78). In all cases the diastereoisomers 
were separable by column chromatography. The enantiomers of 3-(amino-
carboxymethyl)cyc1obutanephosphonic acids (79) were separated by 
enantioselective enzymatic hydrolysis of the intermediate dEftlyl 
3-(phenylacetylamino )-cyanomethyl)cyclobutanephosphonates (160). Using 
this method of resolution, high enantioselectivities were obtained. Thus 
diethyl 3-oxocyclobutanephosphonate (134) is a versatile intermediate in the 
synthesis of cyclobutane phosphonic acid analogues of amino acids. 
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Chapter 4 
Synthesis of Cycloalkane l-substituted-l-phosphonate 
Compounds via Phase-transfer Catalysed Alkylations 
4.1. Introduction 
4.1.1. Development of Antiviral Agents 
Extensive efforts have been made in recent years to develop drugs for 
the safe and effective treatment of viral diseases. However, the concept of 
selective toxicity, in which a treatment destroys an infection but is not 
injurious to the host has met with only limited success in the treatment of viral 
infections. This is largely due to the close relationship between the host 
organism and the invading virus. 
Viral infections differ in two respects from bacterial and fungal 
infections. The virion is entirely dependent on the host cells' biochemical 
machinery and the genetic material of the virus can exert its control on the 
host cell so as to wholly or partially divert its metabolism to the production of 
viral nucleic acid and viral protein. Hence viruses can not reproduce outside 
the host cell. They are completely dependent on the host cell for their energy 
and synthetic requirements. 
Viruses contain either RNA or DNA but not both. It is convenient to 
classify viruses according to the type of nucleic acid they contain. DNA 
viruses include Epstein-Barr virus, herpes viruses and hepatitis (both A and B) 
virus. Common RNA viruses include influenza, rhinovirus and polio virus. 
There is a third class of viruses, known as retroviruses. These contain RNA 
that is transcribed into a DNA hybrid which then serves as a template for the 
synthesis of double-stranded DNA which is integrated into cellular DNA prior 
to multiplication. This class of virus includes the human immunodeficiency 
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virus (HIV), which is the etiologic agent of acquired immune deficiency 
syndrome (AIDS). 
4.2. The Viral Life Cycle 
The exact replication cycle of a virus depends on the class of virus. 
However, the general replication cycle proceeds as follows. A virion becomes 
attached to the outside of the cell and penetrates the cell membrane. The 
protein coat of the virion is removed by lipases and peptidases and the viral 
nucleic acid is transported to its replication site. The virion now takes control 
of the host cells' nucleic acid and protein synthesis. A mRNA copy of the viral 
genome is synthesised (transcription), from which the viral proteins are 
synthesised on the cellular ribosomes (translation). The viral nucleic acid is 
replicated. The new viral proteins and nucleic acids are assembled into virions 
and the host cell finally ruptures to liberate large numbers of virions so that 
further infection occurs. 
Two additional features of the virus host interaction are latency and 
transformation. DNA copies of the genome of herpes viruses and oncoviruses 
are incorporated into the host's chromosomes and are replicated with them in 
perpetuity. Emotional or environmental factors can reactivate the latent gene 
and cause a new outbreak of disease, e.g. cold sores (herpes simplex virus) and 
the onset of acquired immunodeficiency syndrome (AIDS) from the HIV virus. 
Oncoviruses may lead to the transformation of the cell into a malignant cell, 
resulting in cancer. 122 
4.3. Herpes Viruses 
The group of human herpes viruses include herpes simplex virus 
(HSV) types 1 and 2, varicella-zoster virus (VZV), cytomeglavirus (CMV), and 
Epstein-Barr virus (EBV). These are all large, enveloped DNA viruses which 
share the unique characteristic of becoming latent in the body after a primary 
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infection and having the potential for subsequent reactivation after varying 
periods of time.122 
4.3.1. Herpes Simplex Virus 
Herpes simplex viruses are of two types, both of which are found 
worldwide, with humans as their only natural reservoir. Since the virus can 
not remain infectious for long outside the human body, direct contact with 
secretions is necessary for transmission of the virus. Generally HSV -1 is 
transmitted in oral secretions and is responsible for cold sores and herpes 
keratitis where as HSV-2 is transmitted genitally. 122 
Once transmission has occured, it is thought that the herpes virus 
particles enter the cell via fusion of the viral membrane with the plasma cell 
membrane and encorporation of naked nucleocapsids into the cytoplasm. One 
or more of the glycoproteins on the herpes virus envelope are thought to be 
responsible for this fusion which results in the formation of giant syncytia. 
Once the parental DNA is uncoated, it moves rapidly to the nucleus of the host 
cell where it begins replication after about four hours. Assembly of herpes 
virus nucleocapsid takes place in the nucleus of the cell. The enveloped herpes 
virus particles are transported through the cytoplasm and are released from 
the plasma cell membrane.122 
4.4. Antiviral Chemotherapy 
The intimate relationship between host cell and virus makes it difficult 
to find a substance which inhibits or destroys the virus without being toxic to 
the cell. Many classes of compounds have been investigated for antiviral 
activity. However, the number of compounds in clinical use remains very 
small. After ten years of intensive research into viruses in the wake of the 
acquired immune deficiency syndrome (AIDS) epidemic, there are still only a 
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relative handful of antiviral drugs in routine clinical use. This contrasts starkly 
with the vast range of antibacterial drugs currently available. 
It is important to recognise that many antiviral agents, including some 
that are in clinical use, have more than one apparent mechanism of action. 
Thus the issue of defining exactly which mechanism is antiviral and which is 
causing a toxic reaction can be difficult to determine. 123 There are still only a 
few antiviral drugs licensed for regular clinical use (Table 4.1). 
Table 4.1: Licensed Antiviral Drugs 124 
Step in the Viral Life Cycle Antiviral Agent Virus 
Attachment Deoxynojirimycin HIV-l 
Penetration Amantadine Influenza A 
Uncoating Amantadine and Rimantadine Influenza A 
Replication 
(DNA) AZT HIV-l 
ddI HIV-l 
Acyclovir HSV &VZV 
5-Iodo-2'-deoxyuridine HSV 
5-Trifluoromethyl-2'-deoxyuridine HSV 
Adenine arabinoside HSV 
5-Ethyl-2'-deoxyuridine HSV (Germany) 
5-Iodo-2'-deoxycytidine HSV (France) 
(RNA) Ribavirin Respiratory syncytial 
virus 
Two lipid soluble primary amines (Figure 4.1), amantadine (161) and 
rimantadine (162) are well established in the treatment of influenza. 
Amantadine (161) has been licensed for use in the USA since 1966 and 
rimantadine is available for clinical use in the former USSR.125,126 In high 
concentrations these compounds exert a non-specific activity which prevents 
viral penetration. In lower concentrations (0.1-0.5 ~M), they appear to prevent 
stages involved in either penetration or virus assembly. 127 
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(161) (162) 
Figure 4.1: The Structure of Amantadine and Rimantadine 
However, the clinical use of amantadine (161) has been restricted for 
several reasons. It is only really effective against enveloped viruses such as 
influenza and has side effects such as insomnia and hallucinations resulting 
from secondary effects on the central nervous system. Rimantadine (162) is 
reportedly more effective than amantadine (161) against influenza 128 and also 
demonstrates reduced side effects. 129 
4.4.1. Nucleoside Analogues 
Ribavirin (163) (Figure 4.2) exhibits a broad spectrum of activity 
against a range of viruses, including influenza, both in vitro and in vivo. 130,131 
It is known to inhibit the synthesis of viral mRNA in influenza. The active 
species in vivo is thought to be ribavarin 5' -O-triphosphate which is known to 
be an inhibitor of influenza virus RNA polymerase in vitro under conditions in 
which ribavirin and ribavirin 5'-O-monophosphate have no activity.132 
However, the clinical use of ribavirin is limited due to its teratogenicity. 
Most of the nucleoside analogues which have promise as antiviral 
agents act by interrupting nucleic acid synthesis. One of the most successful 
and effective nucleoside antiviral drugs is 9-(2-hydroxyethoxymethyl) guanine 
(acyclovir) (164). 133 Acyclovir is used for the treatment of herpes viruses. 
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(163) (164) 
Figure 4.2: The Structure of Ribavirin and Acyclovir 
Acyclovir (164) has low toxicity as it is only metabolised by cells that 
are infected with the herpes viruses, where it has a much higher affinity for 
the virus induced deoxythymidine kinase than for the corresponding kinase of 
the host cell. This enzyme phosphorylates the acyclovir, forming acyclovir 
monophosphate which is further phosphorylated to the triphosphate. Once 
again the DNA polymerase has a much higher affinity for acyclovir 
triphosphate than the cellular polymerase; hence it is added to viral DNA in 
preference to cellular DNA. Once the drug is incorporated in to the DNA it 
acts as a chain terminator due to the lack of a 3'-hydroxyl group. Furthermore, 
it is also known to act as a suicide substrate for the DNA polymerase.1341135 
In recent years, many nucleoside analogues (Figure 4.3) have been 
prepared in the hope that they will act as inhibitors of the reverse transcriptase 
enzyme of the HIV virus. These compounds act by competing as substrates 
with the normal nucleoside substrates. The most potent of these nucleoside 
analogues are 3'-azido-2',3'-dideoxythymidine (AZT) (165),136 2',3'-
dideoxycytidne (ddC) (166)137 and 2',3'-dideoxyinosine (ddI) (167)138. 
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Figure 4.3: The Structure of Some Nucleosides with Antiviral Activity 
The nucleosides must first be converted intracellularly to the 
corresponding 51-0-triphosphate before any interaction with reverse 
transcriptase can occur. There is no difference in the ability of uninfected and 
virus-infected cells to phosphorylate these nucleosides. Therefore, the 
selectivity of these nucleoside analogues must be based on their interaction 
with the reverse transcriptase, to which they have an affinity 100 times greater 
than their affinity for cellular DNA polymerase. This poor selectivity is 
responsible for many of the toxic effects of these drugs. 
4.4.2. Glucosidase Inhibitors 
Glucosidase inhibitors have been shown to reduce the infectivity of a 
number of viruses.139 However, these compounds, including the carbohydrate 
analogues (Figure 4.4) deoxynojirimycin (168) and castano spermine (169), 
have been most effective against HIV in vitro. They have been shown to alter 
the glycosylation of the HIV envelope glycoprotein (gp120), greatly reducing 
penetration of the virus into the cells. It has been suggested that a 
conformational change of the abnormal glycoprotein prevents cleavage of this 
protein, which is necessary for infection.140 
101 
01-1 
(168) (169) 
Figure 4.4: The Structure of Some Alkaloid Antiviral Compounds 
Since the initial discovery that castanospermine and DNJ are capable 
of reducing the infectivity of HIV, many analogues with increased activity and 
reduced toxicity have been prepared. The most effective compounds are 
N-alkyl analogues 141, 142. N-Butyl DNJ has recently been introduced into 
clinical trials in the USA. 
4.4.3. Metal Ion Chelators as Antiviral Agents 
The presence of metal ions in both RNA and DNA polymerases has 
been well documented. 143 Zinc ions, in particular, appear to play an important 
role in the activity of nucleic acid polymerases.144 The correlation between the 
concentration of zinc ions and the level of polymerase activity has been 
documented in several systems.145-147 The presence of these metal ions 
suggests the possibility of inhibiting viral enzymes by the use of chelating 
agents to coordinate to essential metal ions. In the case of the influenza virus, a 
correlation has been found between the ability of pyrophosphate analogues to 
bind zinc and their in vitro antiviral activity.148 
4.4.3.1. Thiosemicarbazones 
Thiosemicarbazones (Figure 4.5) have been shown to be active against 
DNA and RNA viruses as well as tumours, protozoa and fungi. However, 
there is usually little margin between effective dose levels and toxicity. The 
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p-aminobenzaldehyde compound (170) was the first thiosemicarbazone 
reported to have antiviral activity. 149 Structure activity studies prompted by 
this compound led to I-methylisatin ~-thiosemicarbazone (171), which when 
given orally, was successful in the prophylaxis of smallpox.1SO 
s 
N-N--< 
~ H NH2 
o 
(170) (171) 
Figure 4.5: Thiosemicarbazones with Antiviral Activity 
The inhibitory effects of isatin ~-thiosemicarbazone (171) and its 
derivatives on vaccinia virus are produced late in the viral cycle. The mode of 
action of these compounds possibly involves metal ion chelation. lSI 
a-{N)-Heterocyclic thiosemicarbazones are known to inhibit the growth DNA 
viruses from the herpes family.1S2 It is thought that this activity is occurs via a 
terdentate complex. lSI 
4.4.3.2. Pyrophosphate Analogues 
Analogues of inorganic pyrophosphate (172) such as phosphonoacetic 
acid (PAA) (173), phosphonoformic acid (PFA) (174) (Figure 4.6) are known to 
inhibit the DNA polymerase of herpes simplex virus 1 (HSV-l) and the RNA 
transcriptase of influenza virus A. Methylene bisphosphonic acid (175), 
although it is isosteric with inorganic pyrophosphate, has been found not to 
have this inhibitory activity. Interest in this class of compounds was initiated 
by the discovery that PAA (173) inhibited herpes viruses in animals. 1S3 
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o 
(172) 
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II II (HOhp-C-OH 
(174) 
o 0 
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(173) 
o 0 
II II 
(HOhP ............... P(OH)2 
(175) 
Figure 4.6: Pyrophosphate and Antiviral Pyrophosphate Analogues; Phosphonoformic 
Acid, Phosphonacetic Acid and Methylene Bisphosphonic Acid 
4.4. Mode of Action of Pyrophosphate Analogues 
Data indicate that pyrophosphate analogues inhibit the herpes-
induced DNA polymerases by acting on the enzymes without prior 
conversion to an active compound. l48 This activity appears to be related to the 
ability of these compounds to form stable chelates with a metal ion (probably 
zinc) at the active centres of the enzyme systems.154 In the case of influenza 
virus, initiation of mRNA synthesis does occur in the presence of PFA (174), 
but the elongation of the RNA chain does not occur. This indicates that PFA 
(174) inhibits the chain elongation of influenza virus mRNA during capping 
processes. 155 
4.5. Disadvantages of Pyrophosphate Analogues 
P AA is known to accumulate in bones and teeth when gIven 
intravenously. In fact, the high affinity for bones and teeth of some 
bisphosphonic acids (Figure 4.7) for example, dichloromethylene-
bisphosphonic acid (clodronate) (176), I-hydroxyethylidene-bisphosphonic 
acid (etidronate) (177) and 4-amino-l-hydroxybutylidene-bisphosphonic acid 
(alendronate) (178) for solid-phase calcium phosphate is used to therapeutic 
advantage.156-158 These compounds have been shown to be useful in the 
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treatment of variety of osteolytic bone disorders including Paget's disease, 
hypercalcaemia of malignancy, osteolytic bone tumours and more recently 
osteoporosis. 159 
o 0 
II II 
(HOhPy P(OHh 
CI CI 
(176) (177) (178) 
Figure 4.7: Clinically Used Bone Chelating Bisphosphonic Acids 
Bisphosphonates are also commonly complexed with technetium-99 
and used as bone imaging agents.160 Although these bone-seeking properties 
of bisphosphonic acids are therapeutically useful for the treatment of bone 
disorders they are not desirable properties for antiviral agents. 
A second major drawback is the inability of highly charged molecules 
such as PAA (173) and PFA (174) to penetrate the cell wall. Although P AA is a 
very potent inhibitor of viral DNA polymerase, concentrations of 200 f.lg/ml 
are required for activity in vivo. This is 100 times greater than is needed in 
vitro. 
4.6. Structure-Activity Studies on Pyrophosphate Analogues 
As can be seen, there are several opportunities for improving the 
efficacy of P AA and PFA in vivo. Extensive structure-activity studies have been 
carried out with a number of analogues of PAA and PFA against the herpes 
and influenza viruses. 161, 162 These demonstrate that there are strict structural 
requirements for antiviral activity. 
Esterification of either the carboxyl or the phosphoryl groups results in 
a marked reduction of antiviral activity in vitro. Blocking of the carboxylic 
105 
group with small alkyl esters such as methyl or ethyl only slightly decreased 
activity. However, larger esters resulted in a much greater loss of activity. The 
ionizability of the phosphono group appears to be much more important. 
Monophosphoryl esters retain some activity. However, the diethylphosphono 
ester is inactive, although, some activity is reported in vivo, probably due to 
hydrolysis of the ester in the cell liberating the free acid. 161 
The phosphonic group is a very specific requirement for activity and 
can not be replaced by a sulfono, phosphinic or phosphine moiety. However, 
arsenoacetic acid showed strong inhibition of polymerase at high 
concentrations, but is inactive in vivo. 
Replacement of the carboxyl group by a phosphoryl group gives rise 
to methylenebisphosphonic acid (175). While the parent compound is devoid 
of activity, replacement of the methylene hydrogens by electron withdrawing 
groups leads to compounds which are good inhibitors of the RNA 
transcriptase of the influenza virus but have little or no anti-herpes activity.162 
The use of the tetrazole moiety as an isostere for the carboxylic acid 
group is well accepted. A variety of heterocyclic analogues of P AA have been 
investigated (Figure 4.8). Both the tetrazole (179) and the triazole (180) 
analogues were found to have weak inhibitory activity against DNA 
polymerase induced by HSV -1. However, only the tetrazole compound (179) 
showed any activity against RNA transcriptase of influenza.163 
N-N 0 
II \\ II 
N, ~P(OH)2 
N 
H 
(179) 
F N 0 
_\ II 
HN, ~P(OH)2 
N 
(180) 
Figure 4.8: Tetazole and Triazole Analogues of Phosphonoacetic Acid 
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The distance between the phosphonic and the carboxylic group is 
extremely important. Only PAA (173), and PFA (174) which is in general a 
more active antiviral agent than P AA (173), show any antiviral activity. The 
homologue 3-phosphonopropionic acid has little antiviral activity. This is 
possibly due to the stability of the chelates that these compounds form with 
zinc (Figure 4.9). PFA forms a chelate with a five-membered ring (181) and 
P AA forms a chelate with six-membered ring (182), whereas the propionic 
analogue forms a seven-membered ring chelate (183). It is well known that the 
stability of cyclic metal chelates is 5>6>7.164 
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Figure 4.9: Metal Chelates of Phosphonoformic, Phosphonacetic, and 
Phosphonopropanoic Acids 
Although methylenebisphosphonic acid (175) is a good isostere of 
pyrophosphoric acid, it shows little activity against the influenza or herpes 
viruses. It has been suggested that the isopolar properties of pyrophosphate 
analogues are as important as their isosteric properties. 165 This theory is 
supported by the fact that methylenebisphosphonic acids, in which the 
bridging carbon is substituted by an electron withdrawing substituent such as 
a halogen are active against the RNA polymerase of the influenza virus. 
Substituting the bridging carbon by an electron withdrawing group reduces 
the dissociation constant of the methylenebisphosphonic acid, making it 
isopolar with inorganic pyrophosphate ion in solution. 
Thiophosphonoacetic acid (184) (Figure 4.10) exhibits greater activity 
than P AA against influenza 162 and appears to have a lower toxicity to cells.166 
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This increased activity is possibly related to the increased ability to bind zinc. 
The greater affinity of sulphur towards zinc, as predicted by Pearson rules for 
hard and soft acids and bases,167 results in the thiophosphonate analogues 
forming stronger complexes with zinc than the fully oxygenated compounds. 
s S 
II II 
(HObP ............... P(OH)2 
(184) 
Figure 4.10: Methylenebisthiophosphonic acid 
4.6.1. Cyc10alkane Pyrophosphate Analogues 
Alkylation of the bridging carbon of P AA does not significantly reduce 
its antiviral activity. 161 The cyclopropyl analogue of P AA and 
methylenebisphosphonic acid have been synthesised and their activity against 
influenza virus assayed. The cyclopropyl PAA analogue retained most of the 
activity of the parent compound, while the methylenebisphosphonic acid 
analogue remained inactive. 168 This suggests the possibility that including the 
bridging carbon in an cycloalkane ring of greater than three carbons may 
result in compounds that, whilst retaining their antiviral activity, exhibit more 
desirable pharmacokinetic properties, such as increased cellular uptake and 
less deposition in bones. 
The constraint of the P-C-C and the P-C-P bond angles by the 
cyc10alkane ring may also significantly effect the ability of these compounds to 
chelate zinc and thus yield further structure-activity information. However, 
none of the other cycloalkane analogues (C4-C6) have been investigated. 
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4.7. Synthesis of Cycloalkane Bisphosphonic and Cycloalkane 
Phosphonoacetic Acid Analogues 
Monoalkylations of tetraalkyl bisphosphonates and trialkyl 
carboxyphosphonates are well known. However, until recently, intramolecular 
alkylation to form cyc10alkane compounds has proved more difficult than 
with the corresponding dialkyl malonate compounds. Early attempts at the 
monoalkylation of both the potassium 169 and sodium 170 salts of tetraethyl 
methylenebisphosphonate were reported to give low yields. The alkylation of 
the sodium salt of tetraisopropyl methylenebisphosphonate was reported to 
give a slightly improved yield. 171 
Later authors l72 reported low yields when the alkylation of 
tetraisopropyl methylene- and halogenomethylene-bisphosphonates was 
attempted using sodium, sodium hydride and butyllithium to form the active 
anions. However, these authors also reported that good yields of 
monoalkylated products were obtained when the thallium(I) salt of 
tetraisopropyl methylene- or halogenomethylenebisphosphonate was treated 
with an excess of alkyl iodide. 
4.7.1. Synthesis of Cyclopropane Analogues 
The syntheses of both cyc1opropanebisphosphonic acid 173 (191) and 
l-carboxycyc1opropane-l-phosphonic acid8 (194) have been reported. 
4.7.1.1. Cyclopropanebisphosphonic Acid 
Cyc1opropanebisphosphonic acid (191) has been prepared VIa a 
multistep synthesis using the thallium(I) salt of tetraisopropyl 
methylenebisphosphonate (195) (Figure 4.11).173 3-Bis(di-iso-
propylphosphono )-l-iodopropane (190) could not be prepared by the direct 
alkylation of the thallium(I) salt of tetraisopropyl methylene bisphosphonate in 
the presence of excess l,2-diiodoethane. This necessitated the use of a stable 
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iodoalkane (186) with a substituent at the 2-position that could be converted 
into an iodo-substituent through a series of intermediate compounds (187-
189). Reaction with a second equivalent of thallium ethoxide and subsequent 
deprotection of the phosphonate esters afforded cyclopropanebispbosphonic 
acid (191). 
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Figure 4.11: Synthesis of Cyclapropanebisphasphonic Acid 
Attempts to use a similar strategy for the preparation of larger ring 
SIzes led to problems. 4-Iodobutan-l-ol rapidly cyclised to form 
tetrahydrofuran, even in the dark at -20 oC. It was envisaged that this would 
be a problem for iodoalcohols containing three or more carbon atoms. The 
corresponding bromoalcochols could be prepared, but conversion of the 
bromine to iodine before alkylation of the tetraalkyl methylenebisphosphonate 
could take place would be necessary, as only iodoalkanes were found to react 
with the thalli urn salt. 
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4.7.1.2. Cyclopropane Phosphonoacetic Acid Analogue 
The synthesis of diethyl 1-carbo-t-butoxycyc1opropanephosphonic 
acid (194) (Figure 4.12) was carried out by phase transfer catalysed alkylation 
of t-butyl diethyl phosphonoacetate (192).8 This method is simple and high 
yielding and has been used in the synthesis of several 1-substituted-1-
carboxycyclopropanes. 174 However, it was reported to be unsuccessful as a 
method for the preparation of dialkyl cyc1opropanebisphosphonate 173 
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Figure 4.12: Synthesis of Diethyl1-Carboxycyc1opropanephosphonic Acid 
4.8. Phase-transfer Catalysed Alkylations 
The use of phase-transfer catalysis is well known as a method of 
alkylation and a variety of alkylations both intermolecular and intramolecular 
have been carried out.175, 176 Compounds with a sufficiently acidic hydrogen 
can be conveniently alkylated by reaction with the desired alkyl halide in the 
presence of concentrated solution of sodium hydroxide and a suitable catalyst 
such as benzyltriethylammonium chloride. The main advantage of phase-
transfer catalysed alkylations over more traditional methods using sodium 
hydride or butyl lithium is that there is no need to ensure that the reactions are 
carried out under anhydrous conditions. 
The phase transfer method has also been described as extractive 
alkylation.l77 It is thought that the tetraalkylammonium halide (195) is 
converted to the tetraalkylammonium hydroxide salt (196) in the aqueous 
III 
layer which is which is taken up in to the organic phase. The ammonium 
hydroxide salt (196) is then able to extract the acidic hydrogen from the 
substrate (197) to form the reactive intermediate (198) which remains in the 
organic phase and reacts with the alkylhalide (199) to give the monoalkylated 
product (200) (Figure 4.13).177 However, other authors have suggested that, as 
the catalysts employed are all essentially detergents, the reaction may occur 
either at the interface178 or in the micellar phase.179 
NR +X- lIo NR +OH- X 
Aqueous phase 
+ OH- , + 4 4 
(195) (196) 
Interface 
[NR4+ OH-] + HSub lIo [NR4+ Sub-] + H2O "' 
(196) (197) (198) Organic phase 
[NR4+ Sub-] + R'X lIIo [NR4+ X-] + R'Sub , 
(198) (199) (195) (200) 
Figure 4.13: Suggested Mechanism for Extractive Alkylation 
4.8.1. Phase-transfer Catalysed Synthesis of Tetraalkyl Cycloalkane-
bisphosphonates and Trialkyl1-Carboxycycloalkane-
phosphonates 
The simplicity of alkylation and intramolecular alkylation by phase-
transfer catalysis and the complication of the multistep synthesis using 
thallium(I) anions, not to mention the hazards of working with thallium salts 
encouraged us to investigate the use of phase transfer catalysis as a general 
means of preparing a range of trialkyl1-carboxycycloalkanephosphonates and 
tetraalkyl cycloalkanebisphosphonates. 
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4.9. Discussion 
4.9.1. Synthesis of 1-Carboxycycloalkanephosphonic Acids 
t-Butyl diethyl phosphonoacetate (192) was prepared in good yield by 
the Arbuzov reaction of triethyl phosphite with t-butyl bromoacetate.8 
Treatment of the resulting ester (192) with the required l,ro-dibromoalkane 
(n=3-5), 50 % sodium hydroxide and benzyltriethylammonium chloride 
produced the desired cycloalkane compounds in moderate yields (201-203) 
(Scheme 4.1). 
o 
II 
<P(OEtl2 
002t-Bu 
(192) 
TEBACI/50 % ag. NaOH 
BrCH2(CH2) nGI 2Br 
Scheme 4.1. 
(201) n=l, 42 % 
(202) n=2, 65 % 
(203) n=3, 43% 
Reaction times for maXImum yields ranged from 24-48 hours, 
depending on the ring size being formed. The cyclobutane and cYclopentane 
rings formed more rapidly than the cyclohexane ring. If the reaction of 
l,5-dibromopentane and t-butyl diethyl phosphonoacetate (192) was stopped 
after only 24 hours, the monoalkylated product predominated. Presumably the 
initial alkylation occurs at a similar rate with all the alkyl halides, but the 
longer alkyl chain of the intermediate 6-(t-butylcarboxy)-6-
(diethylphosphono)-l-bromohexane allows more freedom of movement to the 
alkyl chain, thus making the cyclisation more entropically disfavoured. 
Although the l,oo-dibromoalkane was used as both reactant and solvent no 
evidence of alkylation by two molecules of the alkyl halide was seen. The 
excess dibromoalkane and unreacted tetra alkyl methylenebisphosphonate 
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were removed by Kugelrohr distillation. Final purification was carried out by 
chromatography on silica gel. 
Hydrolysis of the t-butyl esters (201-203) (Scheme 4.2) was readily 
accomplished by treatment with trifluoroacetic acid at 0 °e. 8 Residual TFA 
was removed by washing a dichloromethane solution of the crude product in 
dichloromethane with brine. The diethyl l-carboxycycloalkanephosphonates 
(204-206) were of sufficient purity to be used without further purification. 
Dealkylation of the phosphonate ester groups was carried out with 
trimethylsilyl bromide.172 Although dealkylation of the cyclopropane 
analogue using this method was reported to result in significant amounts (20 
%) of side products arising from the opening of the cyclopropane ring,173 in 
the case of the four, five and six membered rings the only product resulting 
from this reaction was the desired l-carboxycycloalkanephosphonic acids 
(204-206). The occurrence of side reactions in the deprotection of the 
cyclopropane compound is probably a reflection of the increased ring strain 
and different electronic character of the cyclopropane ring in comparison to 
the larger ring sizes. 
The title compounds (207-209) were dissolved in ethanol and 
precipitated as their dicyclohexylamine salts (210-212). Recrystallisation of the 
white powder yielded analytically pure samples of the target compounds. 
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II 
~P(OEt)2 (CH2)n TFA • CO2 ~Bu 30 min 0 °c 
(201) n=l 
(202) n=2 
(203) n=3 
o 
II 
O<P(OEt)2 (CH 2)n TMSBr/CHzOz• C0 2H 
(204) n=l 
(205) n=2 
(206) n=3 
(210) n=l 
(211) n=2 
(212) n=3 
Scheme 4.2. 
o 
II 
('vP(OH)2 
(CH2~j 
C02H 
(207) n=l 
(208) n=2 
(209) n=3 
4.9.2. Synthesis of Cycloalkanebisphosphonic Acids 
Treatment of tetraethyl methylenebisphosphonate or tetraisopropyl 
methylenebisphosphonate (Scheme 4.3) with the required I, co-dibromoalkane 
(n=3-5), 50 % sodium hydroxide and triethylbenzylammonium chloride and 
purification in a manner analogous to that described above produced the 
desired tetraalkyl cycloalkane-bisphosphonates (214-216) in moderate yields. 
o 
II 
< 
P(OR)2 TEBACl/50 % ag. NaOH 
P(OR)2 
II 
o 
(213) R=Et 
(185) R=i-Pr 
Scheme 4.3. 
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o 
II 
0<P(OR)2 • (CH~n P(OR)2 
II 
o 
(214) R=Et, n=l, 37 % 
(215) R=i-Pr, n=2, 50 % 
(216) R=i-Pr, n=3, 48 % 
Although tetraethyl methylenebisphosphonate (213) was used as the 
substrate for the preparation of the cyclobutane compound (214), use of the 
tetraethyl ester to prepare the corresponding cyclopentane compound resulted 
mainly in hydrolysis of the ester groups with only low yields « 10 0/0) of 
diethyl cyclopentanebisphosphonate. Using the more hindered tetraisopropyl 
methylenebisphosphonate (185) led to much higher yields of the cyclopentane 
compound (215). However, the use of tetraisopropyl 
methylenebisphosphonate (185) for the preparation of the cyclobutane 
analogue resulted in only monoalkylated compound. This may be due to the 
bulk of the four isopropyl groups and the bromine interacting in such a way 
that the intermediate can not adopt a conformation which is suitable for 
nucleophilic displacement of the bromine by the carbanionic centre. 
The considerably longer reaction times of all these reactions compared 
to those of the malonate analogues8,174 is possibly due to the increased bulk of 
the phosphonates compared to the carboxylates. Reaction times for the 
malonates are of the order of one hour compared to one to two days for the 
corresponding phosphonates. A second factor that could account for the 
increased reaction time is that the phosphonates are more electron 
wtihdrawing than malonates, thus the anions of the bisphosphonates will be 
more stable and hence less reactive, than the anions of malonates. 
It is interesting that, of the six compounds produced by this method, 
only in the case of the reaction between tetraethyl methylenebisphosphonate 
and 1,3-dibromopropane to form tetraethyl cyclobutanebisphosphonate (213) 
was there any evidence of by-product (219) resulting from alkylation by a 
second molecule of the alkylbromide (Scheme 4.4). In this case elimination of 
HBr also occurred to form tetraethyl diprop-2-enemethylenebisphosphonate 
(219), which occurred in yields of less than 10 %. The fact that only 
monoalkylation occurs when the tetraisopropyl ester is used as a substrate 
indicates that there is also considerable strain on the tetraethyl intermediate to 
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adopt a conformation favourable to intramolecular displacement of bromide. 
The first elimination of HBr most likely occurs from the intermediate 
compound (217) before the intermolecular alkylation of (218) by the second 
molecule alkyhalide, thus both reducing steric hindrance and preventing 
intramolecular alkylation. 
o 
II 
P(OEt)2 < TEBACl/SO % ago NaOH. 
P(OEt) BrCH2C2CH2Br 
II 2 
o 
(214) 
o 0 
II II n P(OEtb ~ P(OEt) 2 Br~ ----I~ 
H P(OEt)2 P(OEt)2 
II II 
Ho-) (217) o (218) 0 
(219) 
Scheme 4.4. 
All the cycloalkane rings were found to be stable under the conditions 
of dealkylation of the phosphonate ester groups, which was mediated with 
trimethylsilyl bromide as described above. l72 The crude bisphosphonic acids 
(220-222) (Scheme 4.5) were obtained as viscous oils, treatment of which with 
dicyclohexylamine and ethanol, in a manner identical to that described for the 
l-carboxycycloalkanephosphonic acids, yielded analytically pure samples of 
the title compounds as bisdicyclohexylamine salts (223-225). 
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(CHvn 1MSBr/CH2C12 O<P(OR)2 .. O<P(OH)2 (CH~n P(OR)2 II 
o 
(214) R=Et, n=l, 37 % 
(215) R=i-Pr, n=2, 50 % 
(216) R=i-Pr, n=3, 48 % 
(220) n=l 
(221) n=2 
(222) n=3 
P(OH)2 
II 
o 
EtOH 
o 
II 
Dicyclohexy lam.ine 
O<P(OH)2 (CHVn • P(OH)2 
II 
Scheme 4.5. 
o 
(223) n=l 
(224) n=2 
(225) n=3 
2 
Despite earlier reports of the unreactivity of the anions of tetraalkyl 
methylenebisphosphonates prepared by conventional means,169-172 during the 
course of the work described above, two papers reporting the preparation of 
various l-substituted-cycloalkanephosphonates appeared in the literature.9, 180 
Tetraethyl cyclopentane- (228) and cyclohexanebisphosphonates (229), 
as well as diethyl 1-cyanocyclohexane- (230) and diethyl 
1-carboethoxycyclohexanephosphonates (231) (Figure 4.14), were prepared in 
30-50 % yield by the reaction of the required substituted 
methylenephosphonate with an excess of sodium hydride and dibromoalkane 
in THF.180 
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o 
II 
P(OEt)2 
( :'k 
R 11 ijJf/l', 
(213) R=PO(OEth ~YC~),?IP 
(226) R=C 02Et "$'/)r 
(227) R=CN 
o 
II OP(0 Et) 2 
P(OEt)2 
II 
(228) 0 
53% 
(229) R=PO(OEth 39 % 
(230) R=C 02Et 54 % 
(231) R=CN 53 % 
Figure 4.14: Synthesis of 1-Substitutedcycloalkanephosphonates 
Reaction of tetrakis(bromomethyl)benzene or 2,2'-bis(bromomethyl) 
biphenyl with tetraethyl methylenebisphosphonate or triethyl 
phosphonoacetate and sodium hydride affords aromatic bisphosphonates and 
carboxyphosphonates (232-234) (Figure 4.15) in moderate yield. 100 
o 
II 
(EtO)2P. 
(EtO)~ 
o 
(232) 
56% 
o 
II 
P(OEt) 2 
P(OEt)2 
II 
o 
o 
II 
P(OEt)2 
R 
(233) R=PO(OEth 56 % 
(234) R=C02Et 46% 
Figure 4.15: Aromatic 1-Substituedcycloalkanephosphonates 
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Diethyl 1-isocyanocycloalkanephosphonates (236-238) (Figure 4.16) 
were prepared by the reaction of two equivalents of potassium t-pentoxide 
and the required dibromoalkane with diethyl isocyanomethylphosphonate 
(235) in dichloromethane at -70 0C in yields of 35-60 %.9 
o 
II 
P(OEt)2 
< NC 
(235) 
o 
II 
P(OEt)2 
t-CsHnOK/CH2Ch 0 
Br-CH2(CH2)n+lCHz-: (CH2)n NC 
(236) n=l, 60 % 
(237) n=2, 62 % 
(238) n=3,35 % 
Figure 4.16: Synthesis of Diethy11-Isocyanocycloalkanephosphonates 
In light of the earlier reports that indicated the difficulty of alkylating 
sodium and potassium salts of substituted methyl phosphonates,169, 170, 172 it 
can only be assumed that the low yields were due to side reactions caused by 
impurities in the starting materials. 
4.10. Antiviral Activity of 1-Carboxycycloalkane phosphonic 
Acids and Cycloalkanebisphosphonic Acids 
The inhibitory effect of our PAA analogues upon (HSV-1) replication 
was analyzed using the plaque reduction assay as described by Mao et al.161 
The assay was performed in triplicate, using 100~g of compound per cm3. 
Inhibition of virus replication was determined by comparing the number of 
herpes virus-induced plaques in the presence and absence of the compound. 
The results of these assays are shown in table 4.2 below. 
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Table 4.2: Antiviral Activity of Cyc10alkane Compounds 
Compound 0/0 Inhibition of PFU 
0 
99.5161 II 
<P(OH)2 
C02H 
0 
99.5161 (I (OH)~ HN-to) 
C02H 2 
0 
II <1 o<P(OH12. ffl-to) 
C02H 2 
0 
II <1 o.P(OH12. ffl-to) 
C02H 2 
0 
II 8.5 C::(OH)2 . ffl-to) 
C02H 2 
0 
<1 0<~(OH)2 [ -to) 1 f,(OH)2· ffl 2 2 
0 
0 
<1 0. ~(OH)2 [ -to) 1 ~(OH)2 . ffl 2 2 
0 
<1 ~(OH)2 [ -to)] 0" I;(OH)2 . ffl 2 2 
0 
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4.11. Conclusion 
We have shown that phase transfer catalysed alkylation is an 
acceptable method of preparing cycloalkane 1-substitued-1-phosphonate 
compounds. 181 Although alternative methods have been proposed for the 
inter- and intramolecular alkylation of 1-substituted-1-
methylenephosphonates, we believe our method to be superior as it does not 
require anhydrous conditions. Furthermore, the phase transfer catalysed 
reaction is the only reported route to I-substituted cyclobutane-1-
phosphonates. 
Of the cycloalkane P AA analogues tested, only the cyclohexane 
compound showed significant activity as an inhibitor of HSV-1 activity, being 
10-100 times less active than P AA. None of the other P AA analogues, nor the 
alicylic methylene bisphosphonic acids showed activity against HSV-l. We 
propose that, due to the greater flexibility of the cyclohexane ring in 
comparison to the smaller ring compounds, the P-C-C bond angle of the 
cyclohexyl compound is closer to that of P AA than the P -C-C bond angle of 
the cyclobutane or the cyclopentane compounds. Although the compounds 
were essentially inactive against HSV-1, it is interesting to note that they were 
less toxic toward the host cells than P AA in all cases. 
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Chapter 5 
a-Phosphoryl Sulfoxides and Related Compounds as 
Potential Asymmetric Catalysts 
5.1. Introduction 
The property of chirality often determines the behaviour of molecules 
in many ways. It is responsible for the ability of a compound to interact with 
other chiral compounds at a molecular level. This in turn determines a number 
of characteristics of a compound, for example its taste, its smell and its 
medicinal activity. As chemicals, both natural and synthetic, find wide use in 
our everyday life, from medicines and food additives to pesticides and 
perfumes, it is understandable that for the production of these compounds it is 
preferable to secure them in an optically active form.182 
Since the thalidomide tragedy of the late 1950s, where one enantiomer 
of the drug was a harmless sedative and the other a potential teratogen, 
various drug approval agencies are now increasing their requirements for the 
approval and registration of drugs capable of showing optical isomerism. In 
the worst case, e.g. Thalidomide, the opposite antipode of a compound with 
desirable activity can cause severe side-effects. Even in the best case scenario, 
where the opposite enantiomer is simply devoid of any activity, it means that 
50 % of the dose of a drug is inactive. Thus, the stereoselective synthesis of 
compounds remains one of the greatest challenges facing synthetic chemists. 
5.1.1. Methods for the Preparation of Enantiomerically Pure Compounds 
One of the oldest methods for the preparation of enantiomerically 
pure compounds involves resolution of the enantiomers. The target compound 
is prepared as a racemic mixture and then the isomers are separated, usually 
via a diastereomeric salt derivative. The major disadvantage of this method is 
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that a maximum of 50 % yield can be obtained and unless the unwanted 
isomer can be epimerised, it often ends up as waste. Despite this, 
crystallisation of diastereomeric derivatives is common practice, even on an 
industrial scale.182 
A more economic approach is to design a synthetic route involving an 
asymmetric transformation to deliver the desired chirality. There are now a 
number of methods available to the organic chemist for asymmetric synthesis 
of chiral compounds. Asymmetric synthesis can be defined as any synthetic 
operation that produces a new chiral centre in an enantiomerically enriched 
form. 
The use of chiral starting materials from the chiral pool provides a 
valuable method of controlling the stereochemistry of subsequent reactions 
and thus the overall stereochemistry of the product. The synthesis of 
(+)-vincamine (239) (Figure 5.1) utilised the chiral centre of L-aspartic acid (29) 
as the sole source of chiral information in the construction of the three chiral 
centres of the target compound.183 
(29) (239) 
Figure 5.1: Synthesis of (+)-Vincamine from L-Aspartic Acid 
Another possibility is to introduce a chiral centre in to a molecule as a 
chiral auxiliary. The express purpose of this initial chiral centre is to control 
the stereochemistry of subsequent reaction(s). The chiral originator is removed 
from the molecule when its stereodirecting effect is no longer needed. The 
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inherent drawback of this technique is that two extra synthetic steps are 
required: one to introduce the chiral auxiliary and one to remove it. In some 
cases another disadvantage is the loss of the chiral auxiliary, although non-
destructive methods for the removal of chiral auxiliaries are becoming 
popular. The classic example of this method of asymmetric synthesis is the use 
of Evans' chiral oxazolidone auxiliaries (Figure 5.2).184 
o 0 o 
O),.N~ H 
LJ 
., 
,~ 
Bn 
Figure 5.2: Evans Chiral Oxazolidone Auxiliary 
The final group of asymmetric reactions involves processes where the 
chiral information is brought transiently in to the reaction system, usually 
through the transition state. These processes are catalytic with respect to the 
chiral moiety.182 External asymmetric inductions are economically the most 
desirable, since only a catalytic amount of the chiral originator is required and 
this can later be recovered in its original form. One of the most intriguing and 
synthetically valuable examples of a catalytic enantioselective reaction involve 
the addition of organometallic reagents to carbonyl compounds.185 
5.2. Enantioselective Addition of Organometallic Reagents to 
Carbonyl Compounds 
The organometallic alkylation of aldehydes or ketones is a simple and 
common synthetic operation. The development of a chiral version of this 
reaction, leading to optically active alcohols is obviously desirable because of 
its high synthetic utility. Enantioselective addition of organometallic reagents 
to aldehydes affords optically active secondary alcohols, which are 
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components of many naturally occurring compounds, biologically active 
compounds and materials such as liquid crystals. 
The two main methods for the enantioselective synthesis of optically 
active secondary alcohols are the enantioselective alkylation of aldehydes and 
the enantioselective reduction of ketones. The former reaction can achieve 
formation of optically active alcohols with concurrent carbon-carbon bond 
formation. Despite the advantage of this reaction, the enantioselective addition 
of organometallic reagents to aldehydes had, until recently, only been 
achieved with low to moderate enantioselectivities. l86 
A non-racemic chiral environment can be introduced to 
organometallic compounds by (1) co-ordination of an aprotic chiral 
complexing agent or solvent to the metallic centre or (2) modification of 
organometallics by protic auxiliaries such as optically active hydroxy or amino 
compounds, giving organometallic alkoxides or amides, respectively. Several 
highly enantioselective additions to prochiral aldehydes have now been 
reported. For example, optical yields of >90% were reported by the use of a 
chiral 1 ,2-diamine/ alkylithium, diamino alcohol/ alkylithium, 
~-sulfononamido alcohol/ alkyltitanium combined system or Li/Mg binary 
organometallic agents modified by optically active 2,2' -dihydroxy-1,1'-
binapthol. However, in most of these reactions, stoichiometric or even excess 
amounts of chiral reagent to organometallic reagent or carbonyl substrate are 
required. This limits the economic and practical usefulness of these 
reactions. 185 
5.2.1. Desirable Characteristics for Asymmetric Catalysts of 
Enantioselective Addition of Organometallic Reagents to Carbonyl 
Compounds 
In order to obtain a high degree of enantioselectivity, the chiral anionic 
ligand must possess a suitable 3-dimensional structure which clearly 
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differentiates between the diastereomeric transition states of the alkyl delivery 
step. In addition to this the rate of alkylation of the chirally modified 
organometallic should substantially exceed that of the original achiral reagent 
and the chiralligand must be readily detached from the initially formed metal 
alkoxide by the action of the alkyl donor or carbonyl substrate to establish the 
catalytic cycle. 185 
Of the various available organometallic compounds, dialkylzinc acts 
as an ideal alkyl donor for catalytic asymmetric alkylation. In most solvents 
dialkylzinc compounds do not react with aldehydes, forming instead a 
reversible donor-acceptor complex. Even at elevated temperatures alkylation 
takes place only very slowly.185 However, it is know well known that in the 
presence of certain asymmetric catalysts, e.g. ~-amino alcohols, this reaction 
proceeds rapidly and in many cases with high enantioselectivity. 
5.3. Enantioselective Addition of Organozinc Reagents to 
Aldehydes 
Until recently the addition of dialkylzincs to aldehydes was rarely 
utilised in organic synthesis, because the reaction is extremely sluggish and 
because side-reactions such as reduction usually occur. The clean nucleophilic 
addition of diethylzinc to benzaldehyde in the presence of a ~-amino alcohol 
derived from (S)-proline, was first reported by Mukaiyama. The ~-amino 
alcohol accelerates the carbon-carbon bond forming reaction to afford 1-
phenyl-propanol in 76 % yield.187 Although no asymmetric induction was 
observed in this reaction, the formation of a carbon-carbon bond from a 
dialkylzinc and an aldehyde suggested the possibility of asymmetric induction 
using an appropriate ~-amino alcohol. Oguni and ami used (S)-leucinol as a 
chiral catalyst and obtained optically active I-phenyl-propanol (241) from 
benzaldehyde (240) with moderate optical purity (49 % ee).188 Two years later 
Noyori and co-workers realised the first highly enantioselective alkylation of 
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aldehydes by diethylzinc, catalysed by (-)-3-exo-(dimethylamino)isoborneol 
(( -)-DAIB) (244) leading to a I-phenylpropanol (241) in up to 99 % ee (Figure 
5.3).189 
o 
(240) 
(-)-DAIB 
(241) 
99%ee 
Figure 5.3: Asymmetric Catalysis by (-)-DAIB 
OH 
Since the work of Noyori a number of bidentate protic auxiliaries and 
aprotic ligands have been screened, and this enantioselective alkylation has 
been extended to a range of alkylating agents and aldehyde substrates. 
Homogenous chiral catalysts that have been utilised include amino alcohols, 
piperazines, transition metal salts with diols, quarternary ammonium salts, 
diols and oxazaborolidines, some examples of highly enantioselective 
co-catalysts are given below (242-247) (Figure 5.4).189 
(242) 
Me Ph 
H 
." N, ",0 
Me B 
(245) 
Ph 
NH I 
01 ~Ph 
(243) 
W 
Me 01 
(246) 
(244) 
9"1 
Me / N'1.o"Me 
Me I 
->'" Ph 
(247) 
Figure 5.4: Highly Enantioselective Asymmetric Catalysts for the Addition of 
Dialkylzincs to Aldehydes 
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5.3.1. Mechanism of Addition of Dialkylzinc to Aldehydes 
The catalysis of this reaction by compounds such as ~-amino alcohols 
may be explained as follows. Monomeric dialkylzincs have a sp-hybridised 
linear geometry with approximately 1.95 A bond length between the zinc and 
the carbon atoms and are inert to carbonyl compounds because the alkyl-metal 
bond is relatively non-polar. Dimethyl zinc is known to form a complex with 
1,3,5-trimethylhexahydro-1,3,5-triazine. X-ray analysis revealed that the co-
ordination chemistry of the zinc atom changes to become tetrahedral with a 
1450 carbon-zinc-carbon bond angle and the bond length between the zinc and 
the carbon atoms increases (1.98 A). The overall result of this is an increase in 
the energy of the zinc-carbon bond and an increase in the nucleophilicity of 
the methyl group of the dimethyl zinc. 189 
The exact mechanism of the alkyl transfer reaction remains to be 
elucidated. However, the enantioselective alkylation is thought to proceed via 
a series of dinuclear complexes. Three possible transition state complexes have 
been postulated.185 The folded bicyclic transition state (248) as illustrated by 
the diastereomeric structure (Figure 5.5) is the most favoured. This mixed 
ligand dinuclear complex, in going from the ground state to the transition 
state increases both the electrophilicity of the aldehyde and nucleophilicity of 
the alkyl group as is necessary for this reaction. 
(248a) 
Figure 5.5: Proposed Transition State Complex for the Reaction Between Diethylzinc 
andBenzaldehyde in the Presence of (-)-DAIB 
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In the case of the catalyst DAIB, the more Lewis acidic DAIB-chelated 
Zn(A) accommodates the aldehyde substrate, increasing the electrophilicity at 
the carbon atom, and the bridging alkyl rather than the terminal alkyls act as 
the migrating group (248a). Although the electron density of the bridging 
alkyl in the ground state is slightly lower than that of the terminal alkyl, the 
Zn-Rbridging bond is more polarisable than the Zn-Rterminal linkage. 18S The 
stereochemical bias is thought to be provided by non-bonded repulsion of the 
carbonyl substituents from the terminal alkyl group attached to ZnB. In this 
case (Figure 5.6), the 5-geometry (248a) is obviously favourable over the 
R-generating transition state (248b).189 The alkyl group is then added to the 5i 
face of the aldehyde to afford a chiral alkyl zinc alkoxide.186 
(248a) (248b) 
5 -generating R -generating 
Figure 5.6: Stereocontrol of the Reaction Between Diethylzinc and Benzaldehyde 
The sense of asymmetric induction may be conceived as controlled by 
the chirality of the 5/ 4-fused bicyclic structures. The (5 )-configured zinc 
alkoxide is derived from the enantiomer having (5 )-Zn and (5)-0 
configurations (Figure 5.6), while the (R)-alkoxide is derived from the (R)-Zn 
and the (R)-O enantiomer. Configurations of the catalyst of a-5 or I3-R has 
been reported to give preference to formation of the (S)-enantiomer whilst the 
(R)-enantiomer is stabilised by a-R or 13-5 configurations. 
A good correlation is observed between reactivity and 
enantioselectivity. Higher enantioface selection is generally obtained along 
130 
with faster reactions. The degree of enantioselectivity depends primarily on 
the bulkiness of the substituents at the a-carbon. Direct interaction between 
the carbonyl substituents and the a- or the ~-substituents of ~-amino alcohols 
is unimportant.18S 
Reaction of benzaldehyde (240) and diethylzinc does not occur at 0 °C 
in the abscence of a catalyst (e.g. DAIB) and, notably, no alkylation occurs 
when equimolar amounts of catalyst and diethylzinc are present. This 
indicates that a complex formed from a 1:1 ratio of catalyst and diethylzinc can 
not alkyl ate benzaldehyde despite the presence of an alkyl-zinc bond, 
suggesting that two zinc atoms per aldehyde are responsible for the alkyl 
transfer reaction. 18S 
The bicyclic transition state (249) (Figure 5.7) could give an alternative 
explanation for the stoichiometry and stereochemistry of the organozinc 
reaction. Such a mechanism involving the transfer of a terminally located alkyl 
group to the electrophilically activated, bridged carbonyl carbon has also been 
suggested for the reaction of trimethylalluminium and benzophenone. A third 
possibility is the monocyclic six-centred transition state (250), analogous to 
that proposed for the reaction of trimethylaluminium and propiophenone, 
which is also in accordance with experimental findings. 18S 
(249) (250) 
Figure 5.7: Alternative Transition State Complexes for the Reaction Between Diethylzinc 
and Benzaldehyde in the Presence of (-)-DAIB 
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5.3.2. Recent Developments in the Search for Asymmetric Catalysts for the 
Addition of Dialkylzincs to Aldehydes 
Most of the known asymmetric catalysts for the addition of dialkylzinc 
to aldehydes are from three main classes: ~-amino alcohols, diamines and 
diols.18S, 186 More recently, it has been found that a wider range of compounds 
can catalyse, enantioselectively, this type of reaction. 
~-Hydroxy sulfoximides (251) (Figure 5.8) are reported to accelerate 
the addition of diethylzinc to aldehydes with high enantiocontrol.190 The 
asymmetric induction was found to be highly dependent on the structure of 
the catalyst. The best selectivities were found with compounds having two 
alkyl substituents at the hydroxy bearing ~-carbon. In the absence of an 
aldehyde, a dimeric zinc alkoxide complex was found to form between the 
~-hydroxy sulfoximide and the diethylzinc. In this dinuclear zinc complex two 
zinc alkoxides are bridged via their zinc and oxygen atoms to form a four-
membered Zn202 heterocycle. 190 Similar complexes have been reported for 
other known catalysts, suggesting that the catalytic mechanism of this 
compound is similar to that reported for those catalysts. 
(251) 
Rl= Me, Et, Tos, TBS 
R2=(CH2)J1 (CH2)9' Me 
Figure 5.8: ~-Hydroxy Sulfoximides 
Chiral dialkyl thiophosphoramidates (252) (Figure 5.9) derived from 
norephedrine have been shown to be highly enantioselective catalysts for the 
addition of dialkylzincs to aldehydes. Treatment of benzaldehyde (240) with a 
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diethylzinc in the presence of titanium iso-propoxide and a dialkyl 
thiophosphoramidate (252) afforded I-phenyl-propanol (241) in high yield and 
enantioselectivity (74-97 % ee).191 
Ph Me 
>---< ~R HO N-P 
I II'R 
H 8 
(252) 
R=OMe, ~Et, Me 
Figure 5.9: Dialkyl thiophosphoramidate 
These findings encouraged us to investigate the role of other types of 
compounds as potential catalysts for the addition of dialkylzinc to aldehydes. 
In particular, we were interested in examining the activities of substituted 
chiral sulfoxides (Figure 5.10) such as a-phosphoryl sulfoxides (253) and 
p-hydroxy sulfoxides (254). Although both these types compounds have 
played significant roles in asymmetric synthesis, as yet no investigation of 
these compounds as asymmetric catalysts by exploiting their ability to 
complex metal ions has been undertaken. 
o 
11~~3 
....... 8 R 
R 3 R 
(253) (254) 
Figure 5.10: a-Phosphoryl Sulfoxides and B-Hydroxy Sulfoxides 
5.4. Discussion 
5.4.1. Synthesis of a-Phosphoryl Sulfoxides 
Enantiopure dialkyl phosphorylmethyl p-tolyl sulfoxides (Scheme 5.1) 
are easily prepared by reaction of a-lithio diethyl methanephosphonate with 
the commercially available, desired diastereoisomer of menthyl 
p-toluenesufinate (255) .192 The reaction proceeds with inversion of 
stereochemistry at the sulfoxide centre. Using this one step synthesis (Scheme 
5.1), (R)-diethyl phosphorylmethyl p-tolyl sulfoxide (256) and (+ )-(R)-di-iso-
propyl phosphorylmethyl p-tolyl sulfoxide (257) were prepared. 
o 
II 
". S." Tol OMen 
(255) 
Scheme 5.1. 
(256) R=Et, 75 % yield, >95 % ee 
(257) R=i-Pr, 69 % yield, >95 % ee 
As we were interested in the effect that substituents at the sulfoxide 
centre would have on the stereocontrolling action of a-phosphoryl sulfoxides 
as catalysts, the bulky t-butyl group seemed an obvious choice as a 
substituent. Although a-phosphoryl p-tolyl sulfoxides are readily prepared 
due to the commercial availability of menthyl p-toluenesufinate, the synthesis 
of other optically active a-phosphoryl sulfoxides is more difficult. The most 
versatile method for the synthesis of enantiomerically pure sulfoxides is that 
described by Kagan and Rebiere. This route involves the reaction of 
organometallic reagents with an enantiomerically pure cyclic sulfite (260). This 
sulfite was found to react cleanly with many organometallics to give sulfinates 
with very high regioselectivity. Addition of a second organometallic 
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transforms the sulfinate in to a chiral sulfoxide with 100 % enantiomeric 
purity.193 This route is particularly convenient for the preparation of t-butyl 
sulfoxides. 
Enantiomerically pure (2R,5S)-trans-4,4-diphenyl-5-methyl-l,3,2-
dioxathiolane 2-oxide (260) was prepared in two steps from (S)-ethyllactate 
(258) (Scheme 5.2).193, 194 Reaction of the cyclic sulfite (260) with t-
butylmagnesium chloride afforded pure 2,2-diphenyl-l,2-dihydroxy-propyl 2-
0- t-butylsulfinate (262) after one recrystallisation. 193 
H Me~OEt 
HO 0 
(258) 
H Ph 
3PhMgBr 
Me~Ph 
o OH 
tv1e H 
+ HO>l+~h t-BuMgBr 
'S- t-Bu 
O~ ""'-
(262) 
68% 
". 
• 
9:1 
t-8u .. s./ 0 ....... f---THF-.....;_7:;:;...8-oC-
O~ ""'-" . • 
(263) 
Separated by recrystallisation 
Scheme 5.2. 
H Ph 
tv1e~Ph 
(260) 
64% 
HO OH 
(259) 
78% 
CH20 2 -40°C 
SOC12/ Et3N 
(261) 
9:1 
Separated by recrytsallisation 
The t-butyl sulfinate (262) (Scheme 5.3) was first reacted with one 
equivalent of n -butyl lithium to remove the hydroxyl proton. Subsequent 
treatment with two equivalents of ex -lithio dialkyl methanephosphonate 
yielded the desired dialkyl phosphorylmethyl t-butyl sulfoxides (263-264) in 
good yield and high enantiomeric excess. This reaction is known to proceed 
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with inversion of stereochemistry, resulting in the formation of products with 
the S-configuration at the sulfur atom. 193 
H Ph Me¥Ph 
o OH 
's- t-Bu 
O~ ..... ~, . 
• 
(262) 
(i) n-BuLi/THF / -78°c 
Scheme 5.3. 
.. 
o 0 
II II OR 
,~., S....... ~ R,-
t-Bu~ '" OR 
(263) R=OEt, >95 % ee 
(264) R=Oi-Pr, >95 % ee 
Enantiomeric purities of the a-phosphoryl sulfoxides were determined 
by the use of the chiral lanthanide shift reagent tris-[3-
(trifluoromethylhydroxymethylene-d-camphorato ]-europium(III) (TFMC), 
which is known to be suitable for the separation of enantiomeric resonances in 
a-phosphoryl sulfoxides. 89 All of the a-phosphoryl sulfoxides were 
determined to be greater than 95 % enantiomerically pure. 
The synthesis of S-(R),l-(R) diethyl a-methylphosphorylmethyl p-tolyl 
sulfoxide (265) (Scheme 5.4) was undertaken so that the effect of a catalyst that 
is chiral at the a-carbon as well as the sulfur could also be investigated. 
Quenching the lithium salt of (+ )-(S)-diethyl phosphorylmethyl p-tolyl 
sulfoxide (256) with iodomethane gave the a-methylated compound in 65 % 
yield as a 2.7:1 mixture of the diastereoisomers as determined by 31p nmr 
spectroscopy. This is in accordance with a 2.5:1 ratio of diastereoisomers 
prepared from a similar reaction of ( +) -( S)-dimethyl phosphorylmethyl p-tolyl 
sulfoxide with methyl iodide. Isolation of the major isomer (265) was achieved 
by silica gel chromatography. This isomer was identified as the S-(R),l-(R) 
isomer by comparison with the dimethyl phosphonate analogue prepared by 
Mikolajczyk. 195 
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5.4.2. Attempted Synthesis of Cyclic a-Phosphoryl Sulfoxides 
In an attempt to investigate the effect of restricting the rotation around 
the C-S and C-P bonds on the catalytic action of a-phosphoryl sulfoxides, the 
synthesis of cyclic a-phosphoryl sulfoxides was attempted. As already 
described in chapter 2, a-phosphoryl sulfoxides can not to be used as malonate 
analogues in the synthesis of cyclic compounds due to the low reactivity of 
their a-carbanions under these conditions. However, we have found that the 
corresponding a-phosphoryl sulfides react with alkyl halides yielding cyclic-
l,l-phosphoryl sulfides (Scheme 5.5). Treatment of diethyl phosphorylmethyl 
phenyl sulfide (120) with n-butyllithium and a l,co-dibromoalkane in THF, 
followed by a second equivalent of n-butyllithium, resulted in high yields of 
diethyll-phenylthiocycloalkane-I-phosphonates (121, 266-267). 
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It was hoped that asymmetric oxidation of the sulfides would afford 
the optically active sulfoxides. Although several procedures for the chemical 
asymmetric oxidation of sulfides to give sulfoxides are known, the degree of 
asymmetric induction is often highly dependent on the nature of the 
substituents on the sulfur atom. 196 One of the most effective methods for the 
asymmetric oxidation of sulfides is that described by Kagan et al. This 
procedure uses a modification of the Sharpless epoxidation conditions, in 
which one equivalent of water is included in the reaction mixture. High 
enantiomeric excesses have been observed using these conditions.197 
Treatment of the cyclic-l,l-phosphoryl sulfides (121, 266-267) with 
titanium iso-propoxide, diethyl tartrate (DET), water and t-butyl 
hydroperoxide did not result in oxidation of the sulfide (Scheme 5.6). 
Sulfoxides are known to be good ligands for titanium iso-propoxide,198 and 
this oxidation reaction is known to be inhibited when one equivalent of a 
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sulfoxide is present.197 As phosphoryl oxygen atoms are also known to 
coordinate to metals,l99 we thought that one reason for the unreactivity of our 
sulfides might be the co-ordination of the titanium to the phosphoryl oxygen 
in a fashion to that which it co-ordinates to the sulfoxide. The addition of a 
second equivalent of titanium iso-propoxide or a second equivalent of titanium 
iso-propoxide and DET did not facilitate the oxidation. It is quite probable that 
the phosphoryl oxygen is co-ordinating to the titanium and sterically 
preventing any reaction from occurring at the sulfur atom. As a result, we 
were unable to prepare cyclic-I, I-phosphoryl sulfoxides. 
Ph 
\ 
(CH~~S Ti{Oi-Pr) /DET/H O/t-BuOOH 
V' 1.2.1.1 
(121) n=l 
(266) n=2 
(267) n=3 
P(OEt)2 
II 
o 
Scheme 5.6. 
5.4.3. Synthesis of ~-Hydroxy Sulfoxides 
Another class of compounds that we were interested in investigating 
were ~ -hydroxy sulfoxides. These compounds are direct analogues of 
~-hydroxy sulfoximides that have been reported as catalysts for the 
enantioselective ethyl transfer from diethylzinc to aldehydes. The synthesis of 
the ~-hydroxy p-tolyl sulfoxides (Scheme 5.7) was carried out via methyl 
p-tolyl sulfoxide (268), which was prepared by treatment of menthyl 
p-toluenesulfinate (255) with methylmagnesium iodide. Reaction of a-lithio 
methyl p-tolyl sulfoxide with the appropiate ketone produced the 
enantiomerically pure ~-hydroxy sulfoxides (269-270) in high yields. 
139 
o 
II 
......... 8., 
,rTol 'OMen 
(255) 
o 0 ~ 
MeMgBr II (i) n-BuLi/THF/-78 °C ~0 R 
.. .. T I ......... 
TIfF/-78·C p-Tol ....... S'" Me (ill Ry R ~ 0 R 
(268) 0 
65% 
>95%ee 
Scheme 5.7. 
(269) R=Me, 77 % 
(270) R=Ph, 73 % 
>95%ee 
5.4.4. The Use of Chiral Sulfoxides as Potential Asymmetric Catalysts 
The catalytic activity of the substituted chiral sulfoxides was 
investigated in the reaction between diethylzinc and benzaldehyde (Scheme 
5.8), as these substrates have been used as standard conditions for many 
investigations of this type. All the reactions were carried out at 0 °e, with a 2:1 
ratio of diethylzinc to benzaldehyde and 10 mole % catalyst. The exceptions to 
this were the control reaction in which there was no catalyst present and 
reaction 3 in which the ratio of diethylzinc to benzaldehyde to catalyst was 
1:1:1. The results of this study are summarised in table 5.1. 
o OH 
Catalyst 
(240) (241) 
Scheme 5.8. 
As expected, in the absence of any catalyst little alkylation occurs even 
after extended reaction times. All the chiral sulfoxides investigated have the 
ability to catalyse the ethylation of benzaldehyde (240) by diethylzinc. 
Unfortunately this catalytic activity shows no enantioselectivity in any of the 
cases examined. In the case of the a-phosphoryl sulfoxides, increasing the size 
of the substituent on the sulfoxide (from phenyl to t-butyl) has no effect on the 
lack of enantioselectivity, but does result in an increase of the reaction time. 
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Table 5.1: Catalytic Activity of Chiral Sulfoxides 
Reaction % % 
Catalyst Mol % Time (h) Yield ee 
1 None 
- >50 <5 0 
0 0 
2 II II OEt 10 12 100 0 S Po .... 
p-T 01 ~ "'-.,/ , 
OEt 
0 0 
3 II II OEt 100 >50 0 0 S Po .... 
p-T 01 ~ "'-.,/ , 
OEt 
0 0 
4 II II OEt 10 3 7 0 S Po .... 
p-Tol~ "'-.,/ , 
OEt 
0 0 
5 II II Oi-Pr 10 12 100 0 S P. .... 
p-Tol ~ "'-.,/ , . 
O/-Pr 
0 0 
6 II II .... OEt 10 18 95 0 ). ••. S"'-.,/ P, 
t-8u OEt 
0 0 
7 II II .... Oi-Pr 10 18 82 0 ). ••. S"'-.,/ P, 
t-8u Oi-Pr 
0 0 
8 II II .... OEt 10 18 95 0 
~SyP, p-Tol OEt 
Ii3C 
0 OH 9 II~Me 10 12 100 0 P-TOI~S 
Me 
0 OH 
10 II~Ph 10 15 100 0 P-TOI~S Ph 
0 OH 100 0 11 II~Me 10 12 P-TOI~S Me 
+ Ti(Oi-Pr)4 
0 0 100 0 12 II II OEt 10 12 S Po .... 
p-Tol~ "'-.,/ , OEt 
+ Ti(Oi-Pr)4 
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Similarly, increasing the size of the phosphonate esters (from ethyl to iso-
propyl) also increases the reaction time. In the case of the P-hydroxy 
sulfoxides, increasing the size of the substituents adjacent to the hydroxyl 
group again increases the reaction time. 
When the catalyst is present In equimolar amounts with the 
diethylzinc, no alkylation of the aldehyde occurs. The addition of a second 
equivalent of diethylzinc allows the reaction to proceed. Similar findings have 
been reported for other catalysts of this reaction,185, 190 suggesting that the 
mechanism of catalysis is identical to that described above for DAIB. 
Reaction of diethylzinc and benzaldehyde (240) with titanium 
iso-propoxide in the presence of a chiral dialkyl thiophosphoramidate results 
in highly enantioselective addition of the ethyl group.1 91 However, under 
these reaction conditions, in the presence of ex -phosphoryl sulfoxides or 
p-hydroxy sulfoxides no enantioselectivity was observed. 
Although all the ex -phosphoryl sulfoxides or P -hydroxy sulfoxides 
investigated were found to catalyse the reaction between diethylzinc and 
benzaldehyde, this catalytic action was in no case accompanied by 
enantioselectivity. One explanation for this lack of enantioselectivity results 
from comparison of the proposed transition state of these compounds with the 
transition state of other similar compounds that do show enantioselectivity in 
the catalysis of this reaction for example, p-hydroxy sulfoximides. Assuming 
that the mechanism of catalysis of p-hydroxy sulfoximides is identical to that 
proposed for DAIB (Figure 5.5), an analogous transition state complex (271-
272) for the action of p-hydroxy sulfoximides can be proposed. This transition 
state complex would involve the formation of a 6/4 fused bicyclic complex 
(Figure 5.11), similar to the 5/4 system (248) described for DAlB. 
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(271) 
Less sterically hindered transition state 
Lower Energy 
(272) 
More sterically hindered transition state 
Higher Energy 
Figure 5.11: Proposed Transition State Complex for the Action B-Hydroxy Sulfoximides 
In the case of p-hydroxy sulfoximides, the transition state will involve 
a 6-membered ring (271) which is likely to adopt a twisted chair conformation 
to minimise steric interactions. The phenyl substituent of the sulfur is likely to 
adopt the less hindered pseudo-equatorial position. The more stable complex 
(271a) (Figure 5.12) is most likely the one in which the nitrogen methyl is 
psuedo-equatorial and bulky zinc alkoxide (ZnB) co-ordinates to the nitrogen 
in the psuedo-axial position, thus minimising steric interaction between the 
phenyl group and the zinc alkyl groups. The stereocontrol of this reaction is 
then due to the non-bonded repulsion of the carbonyl substituents from the 
terminal alkyl group attached to ZnB, as described in the case of DAIB, the 
S-directing conformation (271a) being more stable than the R-directing (271b). 
This mechanism correctly accounts for the stereochemistry of the reaction 
diethylzinc and benzaldehyde in the presence of (S rP-hydroxy 
sulfoximides.190 
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Me 
Me -"""'--
(271a) 
S-directing 
Me 
(271b) 
R-directing 
Figure 5.12: Stereocontrol of the Reaction Catalysed by (S)-l3-Hydroxy Sulfoximides 
In the case of the p-hydroxy sulfoxides and a-phosphoryl sulfoxides, a 
similar transition state (273) can be proposed (Figure 5.13). However, in the 
case of these compounds there is no substituent on the oxygen atom that 
co-ordinates to ZnB that will interact sterically with the substituent on the 
chiral sulfur atom. Therefore, there is not likely to be a significant energy 
difference between the transition state complex (273) in which ZnB is axial and 
that in which ZnB is equatorial (274). As these two transition states would lead 
to the opposite enantiomers, a racemic mixture is formed. 
Me 
Me-~ 
(273) (274) 
Figure 5.13: Proposed Transition State Complexes for Catalysis by Chiral Sulfoxides 
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5.5. Conclusion 
Both a-phosphoryl sulfoxides and p-hydroxy sulfoxides have been 
shown to catalyse the reaction between diethylzinc and benzaldehyde. 
Unfortunately this catalytic action is not accompanied by enantioselection. It 
appears that for compounds which are likely to form a 6-membered transtion 
state in reactions of this type e.g. p-hydroxy sulfoximides, a-phosphoryl 
sulfoxides and p-hydroxy sulfoxides, the presence of a substituent on the co-
ordinating atom, such as the methyl of the p-hydroxy sulfoximides is essential 
for enantioselectivity. Further information on the mechanism of the reaction 
could be gained from the use of sulfimide analogues of the sulfoxides 
described above. 
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Chapter 6 
Experimental 
6.1. General Experimental 
Melting points were determined using a Stuart Scientific SMP 1 
melting point apparatus and are uncorrected. Optical rotations were recorded 
on an Optical Activity Ltd model AA-1000 polarimeter at 589 nm (Na D-line) 
with a path length of 2 dm. Concentrations (c) are quoted in g/100 cm3. 
Microanalyses were performed at the University of Warwick. Infra red spectra 
were recorded neat, or as nujol mulls, as indicated, on a Perkin-Elmer 1720X 
fourier transform spectrometer using sodium chloride plates. Only selected 
absorbances (vmax) are reported. 1 H nmr spectra were recorded at either 250 
MHz or 400 MHz on Bruker ACF 250 or Bruker ACP 400 instruments 
respectively. Chemical shifts (OH) are quoted in parts per million (ppm), 
referenced externally to tetramethylsilane (TMS) at 0 ppm. Coupling constants 
(J) are reported in Hertz. 13C nmr spectra were recorded at 62.9 MHz on a 
Bruker ACF 250 instrument or 100.6 MHz on a Bruker ACP 400 instrument. 
Chemical shifts (oc) are quoted in ppm, referenced externally to TMS. 
Coupling constants Ucp) are reported in Hertz. 31p nmr spectra were recorded 
at 162 MHz or 101 MHz on a Bruker ACP 400 or Bruker ACF 250 instrument, 
respectively. Chemical shifts (op) are quoted in parts per million (ppm), 
referenced externally to 85 % phosphoric acid at 0 ppm. 19F nmr spectra were 
recorded at 376.3 MHz on a Bruker ACP 400 instrument. Chemical shifts (OF) 
are quoted in parts per million (ppm), referenced to trifiuoroacetic acid at 0 
ppm. All mass spectra were recorded on Kratos MS 90 spectrometer with only 
molecular ions (M+) and major peaks being reported, with intensities quoted 
as percentages of the base peak. Chemicals were purchased from Aldrich, 
Fluka or Sigma at the highest available grade. All solvents were purchased 
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from Fisons Scientific Equipment at SLR grade and purified, when required, 
by literature methods. 2oo Anhydrous solvents were obtained as follows: 
dichloromethane, distilled from calcium hydride under nitrogen; THF and 
dioxan, distilled from sodium-benzophenone ketal under nitrogen; methanol, 
distilled from magnesium methoxide under nitrogen; DMF, distilled from 
calcium hydride under nitrogen; acetone, distilled from magnesium sulfate 
under nitrogen; pyridine, distilled from sodium hydroxide under nitrogen. TIc 
was performed on aluminium backed plates pre-coated with silica (0.2 mm, 
60F254) which were developed using one or more of the following agents: UV 
fluoresence (254 nm), iodine vapour, potassium permanganate solution (0.5 % 
v/v), ammonium molybdate (2.5 % w/v), p-anisaldehyde (2.5 % v/v) or 
ninhydrin (0.2 % w/v). Flash chromatography was performed on silica gel 
(Merck Kieselgel 60F 254, 230-400 mesh). 
X-ray crystallographic measurements were made with a Siemens P3R3 
four-circle diffractometer equipped with an Oxford Cryosystems Cooler 
(version 2.4). Graphite monochromated Mo-Ka radiation (A 0.71073 A) was 
used to collect the intensity data in the (J)-28 mode. Unit cell parameters and 
orientation were obtained by least-squares refinement of the setting angles of 
20 high angle reflections. The crystallographic program system was SHELXTL-
93. The structures were solved by direct methods and refined using full-matrix 
least-squares on F2. All non-hydrogen atoms were refined anisotropically. All 
hydrogen atoms were given isotropic thermal parameters equal to 1.2 (or 1.5 
for methyl groups) times the equivalent isotropic displacement parameter of 
the atom to which it is attached. A summary of the crystal data, refinement 
details, bond lengths and angles are given in the appendices. 
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6.2. Synthesis of Amino Cyclobutane Phosphonic Acids 
6.2.1. 1,3-Dibromoacetone-2,2-dimethoxypropane (92) 
Br~OMe 
Br~OMe 
(92) 
Acetone (30g, 0.52 mol) was added to methanol (250 cm3) in a 1 dm 3 
flask equipped with a dropping funnel and condenser. The reaction mixture 
was cooled in ice, and bromine (166g, 1.04 mol) was slowly added to the 
reaction mixture with stirring. After the addition was complete the reaction 
mixture was stirred for a further 12 h, producing colourless crystals of the 
desired product which were removed by filtration, washed with a small 
amount of water and dried under vacuum (112.68 g, 83 0/0). m.p. 65-67 °C 
(lit.,81 65-67 °C) BH (250 MHz; CDCh) 3.3 (4H, s, CH2Br), 3.55 (6H, s, OCH3); Be 
(63 MHz; CDCh) 30.12 (CH2Br), 49.13 (OCH3), 49.58 (C(OCH3)z)· 
6.2.2. DiethyI3,3-Dimethoxycyclobutane-1,1-dicarboxylate (95) 
Me0>O<C02Et 
MeO C02Et 
(95) 
Diethyl malonate (49 g, 0.306 mol) was added dropwise to a stirred 
suspension of NaH (10 g, 80 %oil emulsion, 0.31 mol) in anhydrous DMF (250 
an3) under an atmosphere of nitrogen. On cessation of hydrogen evolution, 
1,3-dibromoacetone-2,2-dimethoxypropane (92) (36 g, 0.138 mol) was added in 
one portion. The mixture was heated at 121-128 °C for 48 h. The cooled 
reaction mixture was poured into an saturated solution of ammonium chloride 
(100 em 3) and extracted with dichloromethane (5 x 100 cm3). The combined 
148 
organic extracts were washed with water (2 x 100 cm3), aqueous sodium 
bicarbonate (2 x 100 cm3) and brine (2 x 100 cm3), dried over anhydrous 
magnesium sulfate, filtered and the solvent removed under reduced pressure 
to give a yellow oil. The crude mixture was distilled under reduced pressure 
to give the desired compound (18 g,45 %). b.p. 108-110 °c, 0.1 mm Hg (lit.,75 
92°C, 0.5 mm Hg) t}rnax/ cm-1 (neat) 2984, 2959, 1736, 1466, 1447, 1283, 1196, 
1142, 1075; 8H (250 MHz; CDCI3) 1.32 (6H, t, OCH2CH3), 2.68 (4H, s, C(2)-H & 
C(4)-H), 3.24 (6H, s, OCH3), 4.3 (4H, q, J 5.3, OCH2CH3); 8c (250 MHz; CDCI3) 
13.94 (OCH2CH3), 39.46 (C-2 & C-4), 44.46 (C-1), 48.01 (OCH3), 60.79 
(OCH2CH3), 98.21 (C-3), 169.65 (C=O); (NH3 CI) m/z 278 ([M+18]+, 10 %),246 
(80),229 (100),214 (40), 187 (25), 155 (30), 113 (30),88 (100). 
6.2.3. DiethyI3-0xocyclobutane-l,1-dicarboxylate (96) 
(96) 
DiethyI3,3-dimethoxycyclobutandicarboxylate (95) (5 g, 16 mmol) was 
dissolved in dichloromethane (20 cm3) and trimethylsilyl iodide (4 g, 20 
mmol) was added to the solution under an atmosphere of nitrogen. The 
reaction was stirred at room temperature for 1 h at which time analysis by nmr 
spectroscopy indicated that the reaction had gone to completion. The reaction 
mixture was poured into methanol (10 cm3) and the solution was evaporated 
to dryness under reduced pressure. The residue was disolved in ether and 
washed with aqueous sodium bisulfite (3 x 15 cm3), saturated sodium 
bicarbonate solution (2 x 10 cm3) and brine (2 x 10 cm3). The organic solution 
was dried over anhydrous magnesium sulfate, filtered and the solvent 
removed in vacuo to yield the title compound (96) as a colourless oil which was 
purified by Kugelrohr distillation (4.05 g, 98 %). b.p. ISO-155°C, 0.1 mm Hg 
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(lit.,SO 112-113 ec, 3 mm Hg) i}max/ cm-1 (neat) 2985, 2940, 1806, 1736, 1449, 
1370, 1280, 1220, 1180, 1097; OH (250 MHz; CDCh) 1.28 (6H, t, J 5.5, OCH2CH3), 
3.65 (4H, s, C(2)-H & C(4)-H), 4.28 (4H, q, J 5.5, OCH2CH3); oe (63 MHz; 
COCb) 14.07 (OCH2CH3), 37.12 (C-1), 51.23 (C-2 & C-4), 60.71 (OCH2CH3), 
173.74 (C=O), 201.45 (C(3) C=O); (NH3 CI) m/z 232 (55, [M+18]+, 23 0/0), 215 
([M+H] +,80), 141 (20),79 (100). 
6.2.4. Diethyl 3-Hydroxycyclobutanedicarboxylate (97) 
(97) 
Diethyl 3-oxocyclobutanedicarboxylate (96) (4.1 g, 19 mmol) was 
dissolved in ethanol (20 cm3) and sodium borohydride (800 mg, 22 mmol) was 
added in one portion. The reaction was stirred at room temperature for 3 h. 
Analysis by tIc (petroleum ether/ethyl acetate 4:1) indicated no reaction had 
occurred. The reaction mixture was heated to reflux for 5 h at which time tIc 
indicated that no starting material remained. The reaction mixture was cooled 
to room temperature and quenched by the addition of saturated ammonium 
chloride solution (10 cm3). The ethanol was removed under reduced pressure 
and the aqueous solution extracted with ether (3 x 20 cm3). The combined 
ethereal layers were washed with water (2 x 20 cm3) and brine (2 x 20 cm3), 
dried over anhydrous magnesium sulfate, filtered and evaporated to dryness 
under reduced pressure to afford the crude compound which was purified by 
silica gel chromatography (petroleum ether / ethyl acetate 4:1) to yield the title 
compound (97) as a colourless oil (1 g, 25 0/0). (154-158 ec, 0.1 mmHg) (lit.,sO 
178-183 ec 3 mmHg) i}max/cm-1 (neat) 3462,2986,2947, 1733, 1424, 1271, 1181; 
OH (250 MHz; CDCh) 1.23 (6H, t, J 7.5, OCH2CH3), 2.43 (2H, C(2)-H & C(4)-H), 
2.85 (2H, m, C(2)-H' & C(4)-H'), 4.2 (4H, q, J 7.5, OCH2CH3), 4.35 (lH, m, C(3)-
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H); Be (250 MHz; CDCI3) 13.81 (OCH2CH3), 40.00 (C-2 & C-4), 45.63 (C-1), 
61.50 (C-3), 61.78 (OCH2CH3), 171.31 (C=O), 171.61 (C=O); (EI) m/z 216 (M+, 10 
%), 171 (33), 143 (43), 127 (58), 113 (16),97 (100), 86 (16),69 (44),43 (47). 
6.2.5. 1-Chloro-2-benzyloxy-3-bromopropane (91) 
Br \ ___ OCH2 Ph 
CIJ''''-
(91) 
Epichlorohydrin (102 g, 1.1 mol) was added to a solution of mercuric 
chloride (0.2 g, 0.74 mmol) in benzyl bromide (171 g, 1 mol). The reaction 
mixture was heated to 160 ec, with stirring, for 24 h and then cooled to room 
temperature. Distillation under reduced pressure yielded the desired 
compound (91) (140-145 ec, 0.2 mmHg) (lit.,BO 148-155 ec, 0.2 mmHg. (189 g, 
69 0/0). OH (250 MHz; CDCh) 3.56 (2H, m, CH2CI), 3.72 (2H, m, CH2Br), 3.81 
(lH, m, CH), 4.67 (2H, Broad s, PhCH2), 7.38 (5H, br. s, ArH); oe (63 MHz; 
CDCI3) 31.71 (CH2Br), 44.03 (CH2CI), 72.26 (CHOCH2Ph), 77.36 (CH2Ph), 
127.65, 128.09, 128.52, 137.19 (6C, Ar); (EI) m/z 263 (M+, 100 %), 182 (56), 146 
(31),91 (43), 77 (53), 65 (42). 
6.2.6. Diethyl-3-(Benzyloxy)cyclobutanedicarboxylate (98) 
(98) 
Diethyl malonate (80 g, 0.5 mol) was added dropwise to a suspension 
of sodium hydride (15 g, 80 % oil emulsion, 0.5 mol) in anhydrous dioxane 
(400 cm3) under an atmosphere of nitrogen. The reaction mixture was stirred 
until the evolution of hydrogen ceased. 1-Chloro-2-benzyloxy-3-
bromopropane (91) (132.2 g, 0.5 mol) was added dropwise to the reaction 
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mixture. After the addition was complete the reaction mixture was heated to 
reflux for 24 h. After cooling the reaction mixture to room temperature a 
further portion of sodium hydride (15 g, 0.5 mol) was added. The reaction 
mixture was heated to reflux for a further 48 h, then cooled to room 
temperature poured into water (600 cm3) and extracted with ether (4 x 100 
an3). The organic extracts were combined and washed with water (2 x 100 
an3) and brine (2 x 100 cm3), dried over anhydrous magnesium sulfate and 
the solvent removed under reduced pressure. The crude product was distilled 
under reduced pressure to yield the title compound (99) (81.2 g, 53 %) (150-160 
°c, 0.1 mmHg) (lit., BO 178-183 °c 0.2 mmHg) DH (250 MHz; CDCl3) 1.61 (6H, t, J 
7.5, OCH2CH3), 3.8 (4H, m, C(2)-H2 & C(4)-H), 4.22 (4H, q, J 7.5, OCH2CH3), 
4.36 (lH, m, C(3)-H), 4.45 (2H, s, ArCH2), 7.35 (5H, m, PhH); DC (63 MHz; 
CDCb) 13.81 (OCH2CH3), 38.07 (C-2 & C-4), 46.51 (C-1), 61.77 (OCH2CH3), 
61.93 (OCH2CH3), 69.85 (C-3), 77.48 (CH2Ph), 127.82, 128.57, 137.22 (6C, Ar), 
171.27 (C=O), 171.59 (C=O); (EI) m/z 306 (M+, 8%), 277 (19), 215 (24), 201 (91), 
173 (100). 
6.2.7. Diethyl3-Hydroxycyclobutanedicarboxylate (97) 
(97) 
A solution of diethyl3-benzyloxycyclobutandicarboxylate (99) (30.6 g, 
0.1 mol) in methanol was hydrogenated over and palladium on carbon for 6h 
(3 atmospheres). The catalyst was removed by filtration through celite which 
was washed with methanol (2 x 30 cm3). The solvent was removed under 
reduced pressure to afford diethyl 3-hydroxycyclobutanedicarboxylate (21.5 g, 
98 %). (154-158 °c, 0.1 mmHg) (lit.,BO 178-183 °c 3 mmHg) i}max/cm-1 (neat) 
3462,2986,2947, 1733, 1424, 1371, 1271, 1181; DH (250 MHz; CDCl3) 1.23 (6H, t, 
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J 7.5, OCH2CH3), 2.43 (2H, C(2)-H & C(4)-H), 2.85 (2H, m, C(2)-H' & C(4)-H'), 
4.2 (4H, q, J 7.5, OCH2CH3), 4.35 (lH, m, CHOH); DC (63 MHz; CDCI3) 13.81 
(OCH2CH3), 40.00 (C-2 & C-4), 45.63 (C-1), 61.50 (C-3), 61.78 (OCH 2CH3), 
171.31 (C=O), 171.61 (C=O); (EI) m/z 216 (M+, 10 %), 171 (33), 143 (43), 127 (58), 
113 (16),97 (100), 86 (16), 69 (44),55 (10),43 (47). 
6.2.8. DiethyI3-(Benzenesulfonyloxy)cyclobutane-l,1-dicarboxylate (99) 
(99) 
A solution of diethyl 3-hydroxycyclobutanedicarboxylate (97) (lOg, 46 
mmol) and benzenesulfonyl chloride (9.1 g, 52 mmol) under an atmosphere of 
nitrogen was cooled to 0 °c in an ice bath. Anhydrous pyridine (50 cm3) was 
added slowly, the reaction mixture was stirred at 0 °c for 2 h and then allowed 
to warm to room temperature with stirring for 12h. The reaction mixture was 
poured into water (100 cm3) and extracted with ether (3 x 50 cm3). The 
J 
ethereal extracts were washed with water (3 x 50 cm3), dilute hydrochloric 
acid (2 x 50 cm3) and brine (2 x 30 cm3). The organic fraction was dried over 
anhydrous magnesium sulfate, filtered and the solvent removed under 
reduced vacuum to yield the desired product (99) (15 g, 91%). i}max/cm-1 
(neat) 2984, 1731, 1370, 1273, 1191, 1112, 1096, 1022; DH (250 MHz; CDCI3) 1.22 
(6H, t, J 7.5, OCH2CH3), 2.74 (4H, m, C(2)-H & C(4)-H), 4.15 (4H, q, J 7.5, 
OCH2CH3), 4.93 (lH, quint, J 5.1, C(3)-H), 7.60 (3H, m, ArH), 7.85 (2H, m, 
ArH); DC (63 MHz; CDCI3) 13.97 (OCH2CH3), 37.43 (C-2 & C-4), 46.29 (C-1), 
61.72 (OCH2CH3), 61.92 (OCH2CH3), 69.05 (C-3), 127.64, 127.73, 129.26, 133.92 
(6C, Ar), 169.73 (C=O), 170.58 (C=O); (NH3 CI) m/z 374 ([M+N1f4]+, 100 0/0), 
357 ([M+H] +,55),283 (18),235 (12),224 (21), 199 (49), 141 (17). 
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6.2.9. DiethyI3-Bromocyclobutane-1,1-dicarboxylate (100) 
(100) 
DiethyI3-(benzenesulfonyloxy)cyclobutanedicarboxylate (99) (6g, 19.6 
mmol) was added to a solution of anhydrous acetone (100 cm3). Fused lithium 
bromide (4.2 g, 49 mmol) was added in one portion. The reaction mixture was 
heated to reflux, with stirring, for 48 h under an atmosphere of nitrogen. The 
solvent was removed under reduced vacuum and the residue was dissolved in 
ether (100 cm3) and washed with water (3 x 30 cm3) and brine (2 x 20 cm3). The 
organic fraction was dried over anhydrous MgSO 4, filtered and the solvent 
removed to yield the title compound as a colourless oil (100) (5.2 g, 95 %). 
itmax/ cm-1 (neat) 2983, 1733, 1272, 1177, 1157, 1121; 8H (250 MHz; CDCI3) 1.30 
(6H, t, J 7.5, OCH2CH3), 2.76 (2H, m, C(2)-H & C(4)-H), 2.94 (2H, m, C(2)-H' & 
C(4)-H'), 4.24 (4H, q, J 7.5, OCH2CH3), 5.02 (lH, m, CHBr); 8e (60 MHz; CDCb) 
13.92 (OCH2CH3), 38.37 (C-2 & C-4), 46.62 (C-1), 61.71 (OCH2CH3),61.98 
(OCH2CH3), 62.18 (C-3), 170.11 (C=O), 170.86 (C=O); (EI) m/z 281 (M+, 37 %), 
233 (39), 199 (100), 153 (40), 125 (26),97 (21), 53 (19). 
6.2.10. Diethyl 3-(Trifl uoromethanes ulfonyloxy)cyc1o butane-1,1-
dicarboxylate (106) 
(106) 
A solution of diethyl 3-hydroxycyclobutanedicarboxylate (97) (2 g, 9.2 
mmol) and pyridine (5 cm3) in dichloromethane (20 cm3) was cooled to -5°C 
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under an atmosphere of nitrogen. Trifluoromethanesulfonic anhydride (3.45 g, 
11.0 mmol) was added slowly, then the reaction mixture was gradually 
allowed to warm to room temperature with stirring. After 12 h, ice water (20 
an3) was added and the reaction mixture was extracted with dichloromethane 
(3 x 20cm3). The combined organic extracts were washed with water (2 x 30 
an3) and brine (2 x 30 cm3), dried over anhydrous magnesium sulfate, filtered 
and the solvent removed in vacuo to yield the desired product (106) as a 
colourless oil (2.85 g, 89 0/0). OH (250 MHz; CDCI3) 1.18 (6H, t, J 7.5, OC2CH3), 
2.81 (2H, m, C(2)-H & C(4)-H), 3.05 (2H, br m, C(2)-H' & C(4)-H'), 4.15 (q, J 7.5, 
4H, OCH2CH3), 5.3 (lH, quint, J 7.45, C-3); Oc (CDCI3) 13.67 (OCH2CH3), 37.67 
(C-2 & C-4), 45.70 (C-1), 61.94 (OCH2CH3), 62.14 (OCH2CH3), 75.87 (C-3), 
118.21 (q, J 319, S03CF3), 169.26 (C=O), 170.06 (C=O); (NH3 CI) m/z 366 
([M+18]+, 93), 349 ([M+H]+, 40 %),284 (21),235 (25), 199 (100), 148 (31),80 (35). 
6.2.11. Diethyl Phosphorylmethyl Phenyl Sulfoxide (115) 
o 0 
II II 
PhS.........,.... P(OEt)2 
(115) 
A solution of sodium metaperiodate (17.2 g, 80 mmol) in water (150 
em3) was added dropwise to a solution of diethyl phosphorylmethyl phenyl 
sulfide (20 g, 77 mmol) in acetone (100 cm3) at 0 °C. The reaction mixture was 
stirred at -5°C for 5 h and then at room temperature for 12 h. The acetone was 
removed under reduced pressure and the aqueous solution extracted with 
dichloromethane (2 x 100 cm3, 3 x 50 cm3). The combined organic extracts 
were washed with water (2 x 100 cm3) and brine (2 x 100 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent evaporated under 
reduced pressure. The crude compound was purified by silica gel 
chromatography (ethyl acetate/petroleum ether 4:1) to yield the title 
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compound as a colourless oil (16 g, 76 %). OH (250 MHz; CDC13) 1.19 (6H, m, 
OCH2CH3), 3.16 (2H, ABX system, JAB 14.53, JAX 16.35, JBX 14.9, SCH2P), 3.97 
(4H, m, OCH2CH3), 7.45 (3H, m, Ar), 7.65 (2H, m, Ar); DC (63 MHz; CDC13) 
16.08 (d, 3J CP 5.9, OCH2CH3), 53.62 (d, JcP 138.8, CH2P), 62.57 (d, 2Jcp 6.9, 
OCH2CH3), 124.08, 129.20, 131.53, 144.65 (6C, Ar); op (101 MHz; CDC13) 16.53; 
(EI) m/z 276 (M+, 52 %),248 (24),220 (53), 172 (21), 125 (100),95 (59),77 (48), 65 
(37). 
6.2.12. [1,1-2H1-Diethyl Phosphorylmethyl Phenyl Sulfoxide (lISa) 
o 0 
II II 
PhSX (OEt)2 D D 
(lISa) 
A solution of diethyl phosphorylmethyl phenyl sulfoxide (115) (100 mg, 0.36 
mmol) in dry THF (10 cm3) under an atmosphere of nitrogen at room 
temperature, was treated with n-butyllithium (0.29 cm3, 0.73 mmol) for 10 
min. The reaction mixture was quenched with deuterium oxide (1 cm3). The 
THF was removed by evaporation under reduced pressure. The aqueous 
solution was diluted with water (10 cm3) and extracted with dichloromethane 
(3 x 10 cm3). The combined organic extracts were washed with water (2 x 
10cm3) and brine (2 x 10 cm3), dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure. The crude 
compound was purified by silica gel chromatography (ethyl 
acetate/petroleum ether 4:1) to yield the title compound (lISa) (74 mg, 73 %). 
8H (250 MHz; CDC13) 1.18 (6H, m, OCH2CH3), 3.16 «0.2H, residual protons 
from SCH2P), 3.95 (4H, m, OCH2CH3), 7.43 (3H, m, Ar), 7.63 (2H, m, Ar); (EI) 
m/z 278 (M+,34 %), 250 (28), 222 (51), 174 (23), 125 (100), 95 (65), 77 (46), 65 
(35). 
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6.2.13. Diethyll-Phosphoryl(l-methylethyl) Phenyl Sulfoxide (118) 
(118) 
A solution of diethyl phosphorylmethyl phenyl sulfoxide (115) 
(100 mg, 0.36 mmol) in dry THF (10 cm3) at room temperature under an 
atmosphere of nitrogen, was treated with n-butyllithium (0.29 cm3, 0.73 mmol) 
for 10 min. The reaction mixture was cooled to -78°C and iodomethane (0.2 
crn3) was added. The reaction mixture was warmed to room temperature and 
quenched with a saturated solution of ammonium chloride (10 cm3). The THF 
was removed by evaporation under reduced pressure and the aqueous 
solution extracted with dichloromethane (3 x 10 cm3). The combined organic 
extracts were washed with water (2 x 10cm3) and brine (2 x 10 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent evaporated under 
reduced pressure. The crude compound was purified by silica gel 
chromatography (ethyl acetate/petroleum ether 4:1) to yield the title 
compound (118) (71 mg, 65 %). DH (250 MHz; CDCI3) 1.20 (3H, d, J 4.6, C(l)-
CH3), 1.23 (3H, d, J 4.6, C(1)-CH3), 1.27 (6H, m, OCH2CH3), 4.12 (4H, m, 
OCH2CH3), 7.23 (3H, m, Ar), 7.41 (2H, m, Ar); DC (63 MHz; CDCI3) 16.16 (d, 
3JCp 5.9, OCH2CH3), 22.35 (d, 2JCp 5.8, CHCH3), 22.87 (d, 2JCp 5.8, CHC"H3), 
53.54 (d, JcP 138.8, SCH2P), 62.57 (d, 2J cp 6.9, OCH 2CH3), 124.05, 129.48, 
131.51, 144.66 (6C, Ar); Dp (250 MHz; CDCI3) 25.14; (El) m/z 304 (M+, 48 %),276 
(26),248 (53),204 (23), 164 (26), 125 (100),95 (54), 77 (43), 65 (33). 
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6.2.14. Diethyl Phosphorylmethyl Methyl Sulfoxide (119) 
o 0 
II II 
H
3
C ............ S"-.,/ P(OEt)2 
(119) 
A solution of sodium metaperiodate (5.7 g, 26.5 mmol) in water (50 
an3) was added dropwise to a solution of diethyl phosphorylmethyl methyl 
sulfide (5 g, 25.3 mmol) in acetone (30 cm3) at 0 CC. The reaction mixture was 
stirred at -5 cc for 5 h and then at room temperature for 12 h. The acetone was 
removed under reduced pressure and the aqueous solution extracted with 
dichloromethane (3 x 50 cm3). The combined organic extracts were washed 
with water (2 x 50 cm3) and brine (2 x 50 cm3), dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude compound was purified by silica gel chromatography 
(ethyl acetate) to yield the title compound (119) (4.4 g, 81 %). OH (250 MHz; 
CDCI3) 1.01 (6H, m, OCH2CH3), 2.61 (3H, s, CH3S), 3.19 (2H, ABX system, JAB 
14.50, J AX 15.63, JBX 14.35, CH2P), 3.88 (4H, m, OCH2CH3); oc (63 MHz; 
CDCI3) 15.99 (d, 3Jcp 6.0, OCH2CH3), 40.84 (d, 3Jcp 4.2, CH3S), 51.94 (d, JcP 
138.8, SCH2P), 62.52 (d, 2Jcp 6.2, OCH2CH3); op (101 MHz; CDCI3) 16.18; (EI) 
m/z 214 (M+, 13 0/0), 197 (11), 169 (21), 152 (94), 125 (100), 108 (73), 97 (93), 81 
(61). 
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6.2.15. Diethyl Phosphoryl-[2H]-methyl [2H]-Methyl Sulfoxide (119a) 
o 0 
II II 
H C ............ SXP(OEt)2 
21 
o H 0 
(119a) 
A solution of diethyl phosphorylmethyl methyl sulfoxide (119) 
(100 mg, 0.47 mmol) in dry THF (10 cm3) under an atmosphere of nitrogen 
was treated with n-butyllithium (0.37 cm3, 0.94 mmol) at room temperature for 
10 min. The reaction mixture was quenched with deuterium oxide (1 cm3). The 
THF was removed by evaporation under reduced pressure. The aqueous 
solution diluted with water (10 cm3) and extracted with dichloromethane (3 x 
10 cm3). The combined organic extracts were washed with water (2 x 10cm3) 
and brine (2 x 10 cm3), dried over anhydrous magnesium sulfate, filtered and 
the solvent evaporated under reduced pressure. The crude compound was 
purified by silica gel chromatography (ethyl acetate) to yield the title 
compound (119a) (59 mg, 58 0/0). OH (250 MHz; CDC13) 1.02 (6H, m, 
OCH2CH3), 2.63 (2H, br. s, CH2[2H]S), 3.18 (lH, m, SCH[2H]P), 3.88 (4H, m, 
OCH2CH3); (EI) m/z 216 (M+, 11 0/0), 171 (28), 153 (94), 127 (100), 110 (73). 
6.2.16. Diethyl 3-Hydroxy-4-bromobutanephosphonate (128) 
o 
II 
(EtO)2P~Br 
OH 
(128) 
Diethyl trimethylsilylmethylphosphonate (500 mg, 2.2 mmol) in a 
solution of anhydrous THF (15 cm3) under an atmosphere of nitrogen at -78 
°C, was treated with n-butyllithium (0.9 cm3, 2.3 mmol). The reaction mixture 
was stirred at -78°C for 30 min and epibromohydrin (320 mg, 2.4 mmol) in 
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anhydrous THF (2 cm 3)was added. The reaction mixture was warmed to room 
temperature and then heated to reflux for 5 h. After cooling to room 
temperature the reaction was quenched with a saturated solution of 
ammonium chloride (10 cm3). The THF was removed by evaporation under 
reduced pressure and the aqueous solution extracted with dichloromethane (3 
x 10 cm3). The combined organic extracts were washed with water (2 x 10cm3) 
and brine (2 x 10 cm3), dried over anhydrous magnesium sulfate, filtered and 
the solvent evaporated under reduced pressure. The crude compound was 
purified by silica gel chromatography (ethyl acetate/petroleum ether 10:1) to 
afford the title compound (128) (262 mg, 40 %). OH (250 MHz; CDCh) 1.08 (6H, 
t, J 6.8, OCH2CH3), 1.64 (4H, m, C(2)-H & C(l)-H), 3.41 (2H, m, C(3)-H) 3.64 
(lH, m, C(4)-H2), 4.05 (4H, m, OCH2CH3); Oc (250 MHz; CDCI3) 13.24 (d, JcP 
137.3, C-1), 16.02 (d, 3Jcp 5.9, OCH2CH3), 28.61 (d, 2Jcp 4.8, C-2), 41.32 (C-4), 
62.31 (d, 2JCp 5.9, OCH2CH3), 69.81 (3Jcp 6.4, C-3); (EI) m/z 398 (M+, 46 %), 396 
(45),370 (23),342 (18), 217 (56), 189 (22), 125 (100),77 (25). 
6.2.17. Diethyl 3-Benzyloxy-4-chlorobutanephosphonate (130) 
o 
II 
(EtO)2P~CH3 
OCH2Ph 
(130) 
Diethyl methanephosphonate (500 mg, 3.3 mmol) in a solution of 
anhydrous THF (15 cm3) at -78°C under an atmosphere of nitrogen, was 
treated with n-butyllithium (1.3 cm3, 3.3 mmol). The reaction mixture was 
stirred at -78°C for 1 hand 1-chloro-2-benzyloxy-3-bromopropane (895 mg, 
3.4 mmol) in anhydrous THF (2 cm3) was added. The reaction mixture was 
warmed to room temperature for 1 h and then cooled to -78°C. A second 
equivalent of n-butyllithium (1.3 cm3, 3.3 mmol) was added and the reaction 
mixture was allowed to warm to room temperature and stirred for 12 h. The 
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reaction was quenched with a saturated solution of ammonium chloride (10 
an3). The THF was removed by evaporation under reduced pressure and the 
aqueous solution extracted with dichloromethane (3 x 10 cm3). The combined 
organic extracts were washed with water (2 x 10cm3) and brine (2 x 10 cm3), 
dried over anhydrous magnesium sulfate, filtered and the solvent evaporated 
under reduced pressure. The crude compound was purified by silica gel 
chromatography (ethyl acetate/petroleum ether 10:1) to afford the title 
compound (130) (384 mg, 38 0/0). OH (250 MHz; CDCh) 0.97 (3H, m, C-(4)-H), 
1.11 (6H, t, J 6.8, OCH2CH3), 1.43 (4H, m, C(I)-H & C(2)-H2), 3.47 (IH, m, 
C(3)-H), 3.95 (4H, m, OCH2CH3), 4.43 (2H, s, ArCH2), 7.33 (5H, m, ArH); Oc (63 
MHz; CDCb) 12.44 (d, JcP 137.3, C-l), 16.03 (d, 3Jcp 5.9, OCH2CH3), 20.98 (C-
4), 21.25 (d, 2Jcp 4.8, C-2,), 62.31 (d, 2Jcp 5.9, OCH2CH3), 65.79 (3Jcp 6.4, C-3), 
77.39 (CH2Ph), 127.84, 128.12, 128.55, 137.27 (6C, Ar). 
6.2.18. DiethyI3-(Benzyloxy)cyclobutane-1-phosphonate (132) 
o 
~AAAIl PhCH 20~vv P(OEt) 2 
(132) 
Diethyl methanephosphonate (5 g, 32.9 mmol) in a solution of 
anhydrous THF (150 cm3) at -78°C under an atmosphere of nitrogen was 
treated with n-butyllithium (13.2 cm3, 33 mmol). The solution was stirred at 
-78 oC for 30 min and then l-chloro-2-benxyloxy-3-bromopropane (4.3 g, 16.45 
mmol) was added. The reaction mixture was stired at -78°C for 1 h and then 
warmed to room temperature and stirred for a further 1 h. The reaction was 
quenched by the addition of saturated ammonium chloride solution. The THF 
was removed in vacuo and the aqueous layer extracted with dichloromethane 
(4 x 40 cm3). The organic fractions were combined washed with water (2 x 40 
an3) and brine (2 x 30 cm3), dried over anhydrous MgS04, filtered and the 
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solvent removed under reduced pressure. The excess diethyl 
methanephosphonate (40°C, 0.1 mmHg), unreacted 1-chloro-2-benxyloxy-3-
bromopropane (100°C, 0.1 mmHg) and some mono-substituted product (120-
135°C, 0.1 mmHg) are removed by distillation under reduced pressure. The 
residue was purified by Kugelrohr distillation (200-205 °C, 0.1 mmHg) to yield 
the desired products as a colourless oil (132) (2.4 g, 49 % yield) as a mixture of 
E- and Z-isomers in a 2:1 ratio. OH (250 MHz; CDCb) 1.23 (6H, t, J 7.3, 
OCH2CH3,), 2.84-3.83 (4H, br. m, C(2)-H & C(4)-H), 4.11 (4.7H, m, OCH2CH3 
and C(3)-H of E-isomer), 4.25 (0.3H, m, C(3)-H of Z-isomer), 4.35 (2H, br. s, 
PhCH20), 7.33 (5H, br s, ArH); Oc (63 MHz; CDCI3) 16.41 (d, 3Jcp 5.9, 2 x 
OCH2CH3), 20.9 (d, JcP 154.5, C-1 E-isomer), 22.6 (d, JcP 149.6, C-1 Z-isomer), 
30.67 (d, 2JCp 5.9, C-2 Z-isomer), 31.68 (d, 2JCp 4.9, C-2 E-isomer), 61.57 (d, 2JCp 
7.9, 2 x OCH2CH3), 69.81 (PhOCH2), 70.13 (d, C-3 E-isomer, 3JCp 35.4), 71.37 
(d, C-3 Z-isomer, 3JCp 4.9), 127.57, 127.68, 128.27, 137.79 (6C, Ar); op (162 MHz; 
CDCI3) 33.17 (E-isomer), 36.59 (Z-isomer); (NH3 CI) m/z 299 ([M+H]+, 40 %), 
209 (13), 192 (12), 163 (10), 91 (100), 79 (20);m/z calc'd for C16H2304P [M+H]: 
299.1408, found 299.1410. 
6.2.19. Diethyl 3-Hydroxycyc1obutane-1-phosphonate (133) 
o 
~AAAII HO~vvP(OEt)2 
(133) 
A solution of diethyI3-(benzyloxy)cyclobutanephosphonate (132) (20g, 
67.1 mmol) in methanol (150 cm3) hydrogenated (3 atmospheres) over 
palladium on carbon (200 mg) until the uptake of hydrogen ceased 
(approximately 3 h). The catalyst was removed by filtration through celite 
which was washed with methanol (3 x 20 cm3). Removal of the solvent in 
vacuo yielded the alcohols (133) as a colourless oil (13.9 g, 100 % yield), which 
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were used without further purification. '6max / cm-1 (neat) 3382, 2995, 2910, 
1445, 1235, 1163; 8H (250 MHz; CDCh) 1.25 (6H, m, OCH2CH3), 1.9-2.55 (5H, 
m, (C(l)-H, C(2)-H & C(4)-H), 4.05 (4H, m, OCH2CH3), 4.25 (0.7H, m, C(3)-H 
E-isomer), 4.45 (0.3H, m, C(3)-H Z-isomer); Bc (63 MHz; CDCI3) 16.31 (d, 3Jcp 
5.6, 2 x OCH2CH3), 19.14 (d, JcP 154, C-1 E-isomer), 20.71 (d, JcP 151, C-1 
Z-isomer), 33.35 (2J CP 6.2, C-2 & C-4 Z-isomer), 34.26 (2J CP 5.3, C-2 & C-4 
E-isomer), 61.61 (d, 3Jcp 5.4, 2 x OCH2CH3), 64.28 (d, 3Jcp 33, C-3 E-isomer), 
65.00 (d, 3JCp 5.6, C-3 Z-isomer); 8p (162 MHz; CDCI3) 32.2 (E-isomer), 35.0 
(Z-isomer); (EI) m/z 208 (M+, 10 0/0), 195 (10), 165 (25), 138 (45), 109 (60),91 (30), 
83 (100);m/z calc'd for CsH1804P [M+H]: 209.0940, found 209.0942. 
6.2.20. Diethy13-0xocyclobutane-1-phosphonate (134) 
o 
=<)- 11 o P(OEt)2 
(134) 
To a solution of RuCh (150 mg) in dichloromethane (50 cm3) was 
added a solution of Nal04 (2 g) in water (50 cm3). The biphasic mixture was 
stirred at room temperature for 12 h. The aqueous layer as separated and 
extracted with dichloromethane (2 x 10 cm3). The combined yellow organic 
layers were added to a solution of diethyI3-hydroxycyclobutane-phosphonate 
(133) (12 g, 57.7 mmol) in dichloromethane (20 cm3) and a solution of Nal04 
(24.7 g, 115.4 mmol) in water (100 cm3). The biphasic mixture was stirred 
vigourously (approximately 16 h) until the yellow colour persisted on 
standing. Sufficient water to dissolve the Nal03 was added to the reaction 
mixture. The two layers were separated and the aqueous layer extracted with 
dichloromethane (3 x 30 cm3). The combined organic layers were washed with 
water (2 x 50 cm3) and brine (2 x 40 cm3), dried over anhydrous magnesium 
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sulfate, filtered and the solvent evaporated in vacuo. The crude ketone 
containing RuCl3 was purified by Kugelrohr distillation (160-165 °C, 0.1 
mmHg) to yield the pure ketone (10.8 g, 90 %). i}max/cm-1 (neat) 2985, 1785, 
1228, 1054; OH (250 MHz; CDCh) 1.21 (6H, t, J 7.3, OCH2CH3), 2.55 (lH, m, 
C(l)-H), 3.11-3.37 (4H, m, C(2)-H & C(4)-H), 4.01 (4H, q, J 7.3 OCH2CH3); Oc 
(63 MHz; CDCI3) 16.31 (d, 3JCp 5.6, OCH2CH3), 20.47 (d, JcP 157.9, C-1,), 49.15 
(d, 2Jcp 4.6, C-2 & C-4), 62.13 (d, 2JCp 6.6, OCH2CH3), 202.8 (d, 3Jcp 18.4, C=O); 
op (162 MHz; CDCI3) 30.2; (NH3 CI) m/z 224 ([M+18]+, 22 0/0), 206 ([M+H]+, 
100), 178 (32), 165 (43), 138 (25), 109 (29);m/z calc'd for CsH 160 4P [M+H]: 
207.0784, found 207.0789. 
6.2.21. EIZ- Diethyl 3-Cyano-3-hydroxycyclobutane-1-phosphonate (136) 
o H)xr ll 
".. P(OEt)2 
NC" 
(136) 
Ammonium chloride (1.09g, 20 mmol), sodium cyanide (1 g, 20 mmol) 
and alumina (2.8 g, 34 mmol) were suspended in acetonitrile (60 cm3). The 
suspension was sonicated for 10 min and then a solution of diethyl 
3-oxocyclobutanephosphonate (134) (3.5 g, 17 mmol) in acetonitrile (5 cm3) 
was added and the reaction was sonicated for 15 h. The reaction mixture was 
filtered through a pad of celite which was washed with acetonitrile (50 cm3). 
The combined acetonitrile fractions were evaporated in vacuo and then taken 
up in dichloromethane (40 cm3) and washed with water (2 x 20 cm3) and brine 
(2 x 20 cm3), dried over anhydrous magnesium sulfate, filtered and 
evaporated to dryness to yield a colourless oil which was identified as a 
mixture of the two isomers of diethyl 3-cyano-3-
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hydroxycyclobutanephosphonate (136) (3.14g, 79 0/0). t3-max l cm-1 (neat) 3382, 
2221, 1164, 1052, 1023; OH (250 MHz; CDCI3) 1.24 (6H, t, J 7.2, OCH2CH3), 2.39-
2.89 (5H, br. m, C(l)-H, C(2)-H & C(4)-H), 4.08 (4H, m, OCH2CH3); Oc (63 
MHz; CDCI3) 16.23 (d, 3Jcp=5.6, 2 x OCH2CH3), 21.61 (d, JcP 158.6, C-1 minor 
isomer), 24.74 (d, JcP 156.1, C-1 major isomer), 36.23 (d, 2Jcp 5.7, C-2 & C-4 
minor isomer), 37.56 (d, 2JCp 4.9, C-2 & C-4 major isomer), 62.28 (d, 2JCp 6.7, 2x 
OC'H2CH3), 63.26 (d,3JCp 23.5, C-3 minor isomer), 64.35 (d, 3Jcp 33.7 C-3 major 
isomer), 121.71 (CN); (NH3 CI) mlz 233 ([M+H]+, 16 0/0), 205 (83), 165 (81), 138 
(100), 111 (69). 
6.2.22. EIZ-DiethyI3-(Acetoxy)-3-cyanocyc1obutane-1-phosphonate (137) 
o 
II 0 H3CC:>(r1l 
,." P(OEt)2 
NC~ 
(137) 
A solution of the semi-pure cyanohydrin (136) (100 mg, 0.43-mmol) 
and acetyl chloride (100 mg, 1 mmol) in dry pyridine (5 cm 3) was stirred at 
room temperature for 13 h. The reaction mixture was poured in to water (10 
an 3) and extracted with dicloromethane (3 x 10 cm3). The combined organic 
extracts were washed with dilute hydrochloric acid (2 x 10 cm3), saturated 
sodium bicarbonate solution (2 x 10 cm 3), water (2 x 10 cm3) and brine (2 x 10 
an 3), dried over anyhydrous magnesium sulfate, filtered and the solvent 
removed in vacuo. The crude compound was purified by silica gel 
chromatography (dichloromethane/methanol 95:5) to afford the title 
compound (137) as a mixture of the two isomers in a 2:1 ratio (96 mg, 81 %) 
t3-max/cm-1 (neat) 2986, 2223,1757,1216, 1025; oH (250 MHz; CDCh) 1.31 (6H, 
m, OCH2CH3), 2.03 (-lH, s, C(O)CH3 major isomer), 2.13 (-2H, s, C(O)CH3 
minor isomer), 2.51-3.02 (5H, br m, C(l)-H, C(2)-H & C(4)-H), 4.09 (m, 4H, 
OCH2CH3); oC (63 MHz; CDCh) 16.22 (d, 3Jcp 5.8, 2 x OCH2CH3), 20.17 
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(C(O)CH3 minor isomer), 20.34 (C(O)CH3 major isomer), 23.48 (d, JcP 158.7, C-
1 major isomer), 25.03 (d, JcP 156.5, C-1 minor isomer), 35.19 (d, 2Jcp 6.0, C-2 
minor isomer), 35.27 (d, 2J cp 5.2, C2 major isomer), 61.95 (d, 2Jcp 5.8, 2 x 
OCH2CH3), 62.11 (d, 3Jcp 34.2, C-3 minor isomer), 66.33 (d, 3J cp 20.1, C-3 
major isomer), 117.26 (CN), 117.92 (CN), 168.33 (C=O), 168.52 (C=O); 8P (162 
MHz; CDCI3) 27.7 (major isomer), 28.3 (minor isomer); (NH3 CI) m/z 293 
([M+ 18] +, 15 %),276 ([M+H]+, 100),234 (10), 205 (10), 165 (17), 138 (18). 
6.2.23. Z-Diethyl 3-(Phenylacetoxy)-3-cyanocyclo butane-1-
phosphonate (138a) 
o 0 
II II 
PhCH2ro~/'vP(OEt) 2 
NC""'V 
(138a) 
To a solution of the crude cyanohydrin (136) (3.0 g, 12.9 mmol) in 
dichloromethane (40 cm3) at 0 °c was added triethylamine (2.73 g, 27 mmol), 
and phenylacetyl chloride (2.1g, 13.4 mmol). The reaction mixture was stirred 
at room temperature for 12 h, after which time the solution was diluted to 100 
an3 with dichloromethane and washed with water (3 x 20cm3), dilute 
hydrochloric acid (2 x 20 cm3), saturated sodium bicarbonate solution (3 x 
20cm3), water (2 x 20 cm3) and brine (2 x 20 cm3). The organic solution was 
dried over anhydrous magnesium sulfate, filtered and the solvent removed 
under reduced pressure to yield the crude product as an orange oil. Separation 
of the isomers was achieved using silica gel chromatography 
(dichloromethane/methanol, 99:1) to give each isomer as a colourless oil. The 
isomer with the higher Rf value was crystalised by cooling an ethereal solution 
of the compound to -100 °c to give an off white solid (138a) (2.4 g, 54 %). Rf 
0.65 (99:1 dichloromethane/methanol) m.p. 43 °c (Found C, 57.76; H, 6.28; N, 
3.89; C17H23NOSP requires C, 58.10; H, 6.32; N, 3.99 %); i}max/cm-1 (CH2Clz) 
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3075,3068,3039,2140, 1752; BH (250 MHz; CDCI3) 1.24 (6H, t, J 7.7, OCH2CH3), 
2.55-2.71 (3H, m, C(l)-H, C(2)-H & C(4)-H), 2.85-2.95 (2H, m, C(2)-H' & 
C(4)-H'), 3.64 (2H, s, PhCH2CO), 4.01 (4H, m, OCH2CH3), 7.21 7.32 (5H, m, 
ArH); Bc (63 MHz; CDCI3) 16.33 (d, 3Jcp 5.9, OCH2CH3), 21.05 (d, JcP 154.8, 
C-1), 35.48 (d, 2Jcp 4.9, C-2), 40.33 (PhCH2), 62.12 (d,2Jcp 6.9, OCH2CH3), 65.48 
(d, 3JCp 20.95, C-3), 117.96 (CN), 127.41, 128.65, 129.06, 132.25 (6C, Ar), 169.18 
(C=O); Bp (162 MHz; CDCI3) 27.62; (EI) m/z 351 (M+, 27 0/0), 205 (46), 181 (31), 
169 (40), 118 (96),91 (50),83 (100); 
Xray Crystallography: Crystals were colourless plates of formula 
CI7H22N OsP grown from a saturated solution of pentane/ diethyl 
ether/toluene at ambient temperature; orthorhombic, space group Pcba, 
a 9.991(5), b 12.885(8), c 28.39(2) A, a 90, ~ 90, 'Y 90°, U 3655(4) A3, Z 8, Dc 1.277 
mg/ dm3, Mo-Ka radiation (A 0.71069 A), Jl(Mo-Ka) 0.84 mm-I, T 220 K, R 
0.0366 for 2405 unique reflections observed (I / o(l)~.O) reflections. 
6.2.24. E-Diethyl 3-(Phenylacetoxy)-3-cyanocyclobutane-l-
phosphonate (138b) 
o 
II 
PhCH200x> 
NC ",.- -"" P(OEt) 2 
II 
o 
(138b) 
The lower Rf isomer from above was isolated (138b) (1.3 g, 30 0/0). R£ 
0.55 (99:1 dichloromethane/methanol) (Found C, 57.92; H, 6.38; N, 3.87; 
CI7H22NOSP requires C, 58.10; H, 6.32; N, 3.99 %); i}max/cm-I (CH2C}z) 2984, 
2909, 1754, 2235; BH (250 MHz; CDCh) 1.30 (6H, t, OCH2CH3), 2.62 (3H, m, 
C(l)-H, C(2)-H & C(4)-H), 2.94 (2H, m, C(2)-H' & C(4)-H'), 3.63 (2H, s, PhCH2), 
4.07 (4H, m, OCH2CH3), 7.21-7.36 (5H, m, ArH); Bc (63 MHz; CDCh) 16.27 (d, 
3Jcp 5.9, OCH2CH3), 23.76 (d, J cp 155.5 C-1), 34.27 (d, 2J CP 4, C-2), 40.53 
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(PhCH2), 62.20 (d, 2JCp 6.9, OGI2CH3), 66.47 (d, 3JCp 12, C-3,), 117.13 (d, 4Jcp 
2.9 CN), 127.41, 128.48, 129.00, 132.31, (6C, Ar), 162.32 (C=O); op (162 MHz; 
CDCI3) 28.25; (EI) m/z 351 (M+, 31 0/0), 205 (38), 181 (32), 169 (48), 118 (93), 91 
(62),83 (100). 
6.2.25. EIZ-Diethy13-Spirohydantoincyc1obutane-1-phosphonate (139) 
o 
~o II HN P(OEt)2 o}-~ 
(139) 
To a solution of diethyl 3-oxocyc1obutanephosphonate (134) (1 g, 
4.88 mmol) in methanol (10 cm3) and water (10 cm3) adjusted to pH 7 (1M 
ammonium hydroxide solution) was added sodium cyanide (250 mg, 
5.1 mmol) and "ammonium bicarbonate" (771 mg, 9.76 mmol). The reaction 
mixture was heated to reflux for 15 h, cooled and extracted with 
dichloromethane (2 x 10 cm3) to remove any unreacted ketone. The aqueous 
layer was evaporated to dryness under reduced pressure. The crude 
compound (139) was used without further purification. OR (250 MHz; CD30D) 
1.32 (6H, m, OCH2CH3), 2.5-3.6 (5H, br. m, C(l)-H, C(2)-H & C(4)-H2), 4.26 
(4H, m, OCH2CH3); oc (63 MHz; CD30D) 17.10 (d, 3Jcp 6.9, 2 x OCH2CH3), 
20.04 (d, JcP 145, C-1 one isomer), 21.27 (d, JcP 148, C-1 other isomer), 30.36 
(2Jcp 5.8, C-2 & C-4 one isomer), 32.45 (3JCp 5.8, C-2 & C-4 other isomer), 60.05 
(3Jcp 14, C-3 one isomer), 64.29 (3JCp 17, C-3 other isomer), 65.34 (d, 3Jcp 5.9, 2 
x OGI2CH3), 179.87 (2 x C=O), 180.77 (2 x C=O). 
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6.2.26. EIZ-Diethyl 3-(N,N -Diacetylspirohydantoin)cyc1obutane_1_ 
phosphonate (140) 
o 
~o II AcN P(OEt)2 )--NAC 
o 
(140) 
To a solution of the crude spirohydantoin (139) (400 mg, 1.45 mmol) in 
dry pyridine (10 cm3) was added acetyl chloride (0.25 cm3). The reaction 
mixture was heated to reflux for 12 h, then poured into water (20 cm3) and 
extracted with dichloromethane (3 x 10 cm3). The organic extracts were 
washed with dilute hydrochloric acid (2 x 10 cm3), saturated sodium 
bicarbonate solution (2 x 10 cm3), water (2 x 15 cm3) and brine (2 x 15 cm3), 
then dried over anhydrous magnesium sulfate, filtered and evaporated to 
dryness under reduced pressure. The crude oil was further purified by 
filtration through a small plug of silica (dichloromethane/methanol 19:1) to 
afford diethyl 3-(N,N-diacetylspirohydantoin)cyclobutanephosphonate (140) 
as an inseparable mixture of the two isomers (339 mg, 65 0/0). OR (250 MHz; 
CDCI3) 1.08 (6H, m, OCH2CH3), 1.81 (s, --2.4H, C(O)CH3 major isomer), 1.95 (s, 
.... 0.6H, C(O)CH3 minor isomer), 1.98 (s, 3H, C(O)CH3 both isomers), 2.45-2.76 
(SH, m, C(l)-H, C(2)-H & C(4)-H), 3.99 (4H, m, OCH2CH3); oc (63 MHz; 
CDCI3) 16.13 (d, 3Jcp 6.9, 2 x OCH2CH3), 20.02 (C(O)CH3 major isomer), 20.12 
(C(O)CH3 minor isomer), 20.19 (C(O)CH3 minor isomer), 20.22 (C(O)CH 3 
major isomer), 20.35 (d, JcP 149, C-1 one isomer), 21.58 (d, JcP 153, C-1 other 
isomer), 30.02 (2Jcp 5.8, C-2 & C-4 one isomer), 32.35 (3Jcp 5.8, C-2 & C-4 other 
isomer), 60.85 (3Jcp 19, C-3 one isomer), 64.55 (3Jcp 23, C-3 other isomer), 62.34 
(d,3Jcp 5.9, 2 x OCH2CH3), 178.66 (C=O), 179.87 (C=O), 179.99 (C=O), 180.77 
(C=O). 
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6.2.27. EIZ-3-Amino-3-carboxycyc1obutane-1-phosphonic acid (78) 
o H)2C~ __ A II 
~--P(OH)2 
H2N 
(78) 
A solution of the crude spirohydantoin (139) (400 mg, 1.45 mmol) in 
sodium hydroxide solution (6 M, 10 cm3) was heated to reflux for 24 h. The 
solution was cooled to room temperature and evaporated to dryness under 
reduced pressure. The residue was dissolved in water (3 cm3) and applied to 
an ion exchange column (Dowex SOW, H+ form). The column was washed 
with water (100 cm3) and eluted with aqueous pyridine (1M, 200 cm3). 
Ninhydrin postive fractions were combined and evaporated to dryness under 
reduced pressure. Residual traces of pyridine were removed by repeated 
dissolution of the residue in water (5 cm3) and re-evaporation (3 times) to 
afford an inseparable mixture of E - and Z - 3-amino-3-
carboxycyclobutanephosphonic acids (78) (200 mg, 71 0/0). OH (250 MHz; 
CDCI3) 2.27-2.61 (3H, m, C(l)-H, C(2)-H & C(4)-H), 2.73 (2H, m, C(2)-H' & 
C(4)-H'); Oc (63 MHz; CDCh) 22.76 (d, JcP 141, C-1 E-isomer), 25.10 (d, JcP 142, 
C-1 Z-isomer), 31.65 (d, 2Jcp 4.8, C-2 & C-4 Z-isomer), 31.77 (d, 2Jcp 4.8, C-2 & 
C-4 E-isomer), 55.18 (d, 3JCp 16, C-3 E-isomer), 57.28 (d, 3JCp 14.5, C-3 Z-
isomer), 176.40 (C=O Z-isomer), 175.22 (d, 4JCp 3.1, C=O E-isomer); op (162 
MHz; CDCI3) 25.70 (Z-isomer), 26.51 (E-isomer). 
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6.2.28. Z-Diethyl 3-(Benzylamino )-3-cyanocyclobutane-1- phosphonate 
(141a) 
o 
II 
PhCH2HN~P(OEt)2 
NC"'··V 
(141a) 
To a solution of diethyl 3-oxocyclobutanephosphonate (134) (2 g, 9.7 
mmol) and sodium cyanide (480 mg, 9.8 mmol) in dry methanol was added 
benzylamine (1.2 g, 12.9 mmol). The solution was cooled to 0 °C and glacial 
acetic acid (1 cm3) was added dropwise. The reaction mixture was heated 
gradually with stirring to 60°C for 20 h. After cooling to room temperature the 
solution was neutralised with saturated sodium bicarbonate solution (5 cm3), 
the solvent was removed under reduced pressure and the residue taken up in 
dichloromethane (30 cm3) and water (20 cm3). The organic layer was separated 
and the aqueous layer was extracted with dichloromethane (2 x 15 cm3). The 
combined organic layers are washed with water (2 x 20 cm3) and brine (2 x 20 
an3), dried over anhydrous magnesium sulfate, filtered and the solvent 
removed in vacuo yielding the crude ex-benzylaminonitrile as a mixture of the 
two isomers in a 3:2 ratio. The crude product was purified by silica gel 
chromatography (dichloromethane/methanoI95:5). Separation of the isomers 
was achieved by silica gel chromatography (3 times) (hexaneliso-propano18:2) 
to afford pure Z-Diethyl 3-(benzylamino)-3-cyanocyclobutanephosphonate 
(141a) (1.4 g,45 0/0). R£ 0.55 (8:2 hexane:iso-propanol) 'i}max/cm-1 (CH2Cb) 3274, 
3033,2985,2953,2222, 1605, 1496, 1455; OH (400 MHz; CDCb) 1.21 (6H, t, J 7.0, 
OCH2CH3), 1.97 (IR, br. s, NH), 2.31 (2H, m, C(2)-H & C(4)-H), 2.57 (3H, m, 
C(I)-H, C(2)-H' & C(4)-H'), 3.70 (2H, d, J 4.6, PhCH2), 3.95 (4H, m, OCH2CH3), 
7.18 (5R, m, Ar); oc (100 MHz; CDCI3) 16.30 (d, 3JCp 6.4, OCH2CH3), 22.14 (d, 
JcP 154.8, C-l), 34.85 (d, 2JCp 4.5, C-2 & C-4), 48.80 (PhCH2), 52.50 (d, 3JCp 25.5, 
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C-3), 61.87 (d, 2JCp 4.5, OGl2CH3), 121.33 (CN), 127.31, 128.23, 128.32, 138.31 
6C (Ar); op (162 MHz; CDCh) 29.13; (NH3 CI) m/z 323 ([M+H]+, 5 0/0), 296 
(100),207 (11), 108 (22),91 (62). 
6.2.29. E- Diethyl 3-(Benzylamino)-3-cyanocyc1obutane-1- phosphonate 
(141b) 
PhCH 2HNX> 
NC ",., "'" P(OEt) 2 
II 
o 
(141h) 
The lower Rf isomer from above was isolated (141b) (930 mg, 30 %). Rf 
0.45 (85:15 hexane:iso-propanol) t}max/cm-1 (CH202) 3272, 3033, 2986, 2952, 
2222, 1608, 1496, 1455; OH (400 MHz; CDCh) 1.26 (6H, t, J 7.0, OCH2CH3), 1.86 
(lH, br. s, NH), 2.20 (2H, m, C(2)-H & C(4)-H), 2.65 (2H, m, C(2)-H' & C(4)-H'), 
2.88 (lH, m, C(l)-H), 3.74 (2H, br. s, PhCH2), 4.03 (4H, m, OCH2CH3), 7.21 (5R, 
m, Ar); Oc (100 MHz; CDCI3) 16.33 (d, 3J CP 6.4, OCH2CH3), 24.54 (d, J Cp 154.8, 
C-1), 33.12 (d, 2JCp 6.4, C-2 & C-4), 48.86 (PhCH2), 50.63 (d, 3Jcp 25.5, C-3), 
61.85 (d, 2Jcp 6.4, OCH2CH3), 120.16 (d, 4Jcp 4.8, CN), 127.36, 128.13, 128.41, 
138.386C (Ar); Op (162 MHz; CDCh) 29.50; (NH3 CI) m/z 323 ([M+R]+, 7 %), 
296 (100),207 (17), 108 (20),91 (54). 
6.2.30. E- Diethyl 3-(Benzylamino)-3-(aminomethyl)cyc1obutane-
phosphonate (143) 
(143) 
A solution of E-diethyl 3-(benzylamino)-3-cyanocyclobutane-
phosphonate (141b) (50 mg, 1.5mmol) in methanol (20 cm3) containing 3 drops 
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of concentrated hydrochloric acid, was hydrogenated over 10 % palladium on 
carbon (100 mg) at room temperature and 3 atmospheres for 12 h. The catalyst 
was removed by filtration through a pad of celite, which was washed with 
methanol (30 cm3). The solvent was removed under reduced pressure to afford 
a pale yellow oil which was identified as E-diethyl 3-(benzylamino )-3-
(aminomethyl)cyclobutanephosphonate (143) (42 mg, 86 0/0). OH (250 MHz; 
COCI3) 1.14 (6H, m, OCH2CH3), 1.87 (2H, br. s, CH2NH2), 2.03 (4H, m, C(l)-H, 
C(2)-H, C(3)-H & NH), 2.52 (2H, m, C(2)-H' & C(3)-H'), 3.93 (4H, m, 
OCH2CH3), 6.34 (2H, br. s, NH2), 7.05 (5H, m, Ar); Oc (63 MHz; CDCh) 16.23 
(d, 3Jcp 5.9, OCH2CH3), 20.68 (d, JcP 150.6, C-1), 30.38 (d, 2Jcp 5.9, C-2), 44.29 
(PhCH2), 45.95 (d, 4Jcp 3.4, CH2NH2), 61.66 (d, 2Jcp 5.8, OCH2CH3), 126.83, 
127.98, 128.23, 139.96 (6C, Ar); (NH3 CI) m/z 327 ([M+H]+, 8 %), 300 (16), 273 
(24), 190 (100),91 (32), 77 (13). 
6.2.31. Z-3-(Benzy lamino )-3-carboxycyc1obutanep hosp honic Acid (144a) 
(l44a) 
z-Diethyl 3-(benzylamino )-3-cyanocyclobutanephosphonate (141 a) 
(100 mg, 0.31mmol) was dissolved in hydrochloric acid (6M, 5cm3). The 
solution was heated to reflux for 24 h, cooled to room temperature and the 
solvent removed in vacuo. Any residual hydrochloric acid was removed by the 
repeated addition of water (3 x 10 cm3) and re-evaporation. The residue was 
dissolved in ethanol (5 cm3) and propane oxide (1 cm3) was added. The 
mixture was heated to reflux for 30 min, cooled and evaporated to dryness 
under reduced pressure to afford Z - ( ben z y I ami no) - 3 -
carboxycyclobutanephosphonic acid (144a) as an off white solid (81 mg, 92 0/0) 
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OR (250 MHz; CDCh) 2.42 (2H, m, C(2)-H & C(4)-H), 2.92 (3H, m, C(l)-H & 
C(2)-H', C(4)-H'), 3.83 (2H, hr. s, PhCH2), 4.87 (lH, hr. s, NH), 7.12 (5H, s, Ar); 
Oc (63 MHz; CDCI3) 17.88 (d, JcP 155.5, C-1), 43.76 (PhCH2), 49.22 (d, 2Jcp 3.0, 
C-2 & C-4), 64.47 (d, 3Jcp 6.9), 127.66, 129.53, 129.84, 133.10 (6C, Ar), 176.48 
(C=O); (NH3 CI) m/z 213 ([M+18]+, 34 0/0), 196 ([M+H]+, 18), 152 (100),91 (45), 
77 (22). 
6.2.32. E-3-(Benzylamino)-3-carboxycyclobutanephosphonic Acid (144b) 
E-Diethyl 3-(henzylamino )-3-cyanocyclohutanephosphonate (141b) 
(100 mg, 0.31mmol) was dissolved in hydrochloric acid (6M, 5cm3). The 
solution was heated to reflux for 24 h, cooled to room temperature and the 
solvent removed in vacuo. Any residual hydrochloric acid was removed hy the 
repeated addition of water (3 x 10 cm3) and re-evaporation. The residue was 
dissolved in ethanol (5 cm3) and propane oxide (1 cm3) was added, the 
mixture was heated to reflux for 30 min, cooled and evaporated to dryness 
under red uced pressure to afford E -3-(benzylamino)-3-
carhoxycyclohutanephosphonic acid (144b) as an off white solid (81 mg, 92 0/0) 
OR (250 MHz; CDCh) 2.55 (lH, m, C(l)-H), 2.87 (2H, m, C(2)-H & C(4)-H), 3.17 
(2H, m, C(2)-H' & C(4)-H'), 3.94 (2H, hr. s, PhCH2), 4.83 (lH, s, NH), 7.24 (5H, 
s, Ar); Oc (63 MHz; CDCI3) 19.08 (d, JcP 148.5, C-1), 43.63 (PhCH2), 49.06 (d, 
2Jcp 3.2, C-2 & C-4), 61.65 (d, 3Jcp 17.6, C-3), 127.36, 129.40, 129.84, 133.02 (6C, 
Ar), 171.25 (d, 4JCp 3.6, C=O); (NH3 CI) m/z 213 ([M+18]+, 26 0/0), 196 ([M+H]+, 
32), 152 (100), 91 (32), 77 (15). 
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6.2.33. Z- DiethyI3-(p-Methoxybenzylamino)-3-cyanocyc1obutane_ 
phosphonate (145a) 
o 
II 
PMBNH~P(OEt)2 
NC""'V 
(145a) 
To a solution of diethyl 3-oxocyclobutanephosphonate (134) (1.5 g, 
7.3 mmol) and sodium cyanide (430 mg, 8.74 mmol) in dry methanol was 
added p-methoxybenzylamine (1.2 g, 9.7 mmol). The solution was cooled to 0 
°C and glacial acetic acid (1 cm3) was added in a dropwise fashion. The 
reacton mixture was heated gradually with stirring to 60°C for 20 h. After 
cooling to room temperature the solution was neutralised with saturated 
sodium bicarbonate solution (5 cm3) and the solvent was removed under 
reduced pressure and the residue taken up in dichloromethane (30 cm3) and 
water (20 cm3). The organic layer was separated and the aqueous layer was 
extracted with dichloromethane (2 x 15 cm3). The combined organic layers are 
washed with water (2 x 20 cm3) and brine (2 x 20 cm3), dried over anhydrous 
magnesium sulfate, filtered and the solvent removed in vacuo yielding the 
crude a-p-methoxybenzylaminonitrile as a mixture of the two isomers in a 3:2 
ratio. The crude product was purified by silica gel chromatography 
(dichloromethane/methanoI95:5). Separation of the isomers was achieved by 
silica gel chromatography (3 times) (hexane/ iso-propanol 85:15) to afford pure 
Z-DiethyI3-(benzylamino)-3-cyanocyclobutanephosphonate (145a) (1.37 g, 53 
%). Rf 0.52 (8:2 hexane:iso-propanol) (Found C, 57.82; H, 7.08; N, 7.85; 
C17HzsN204P requires C, 57.76; H, 7.13; N, 7.93 0/0); 'i}max/cm-1 (CH202) 3278, 
2982,2839,2221, 1795, 1686; OH (400 MHz; CDCh) 1.23 (6H, t, J 7.0, OCH2CH3), 
2.06 (IH, br. s, NH), 2.32 (2H, m, C(2)-H & C(4)-H), 2.59 (3H, m, C(I)-H, C(2)-
H' & C(4)-H'), 3.68 (2H, s, PhCH2), 3.73 (3H, s, OCH3), 4.00 (4H, m, OCH2CH3), 
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6.78 (2H, d, J 8.7, Ar), 7.20 (2H, d, J 8.7, Ar); Be (100 MHz; CDCh) 16.31 (d, 3Jcp 
4.8, OCH2CH3), 22.20 (d, JcP 154.8, C-1), 34.87 (d, 2Jcp 6.4, C-2 & C-4), 48.29 
(PhCH2), 52.44 (d, 3JCp 27.1, C-3), 55.10 (OCH3), 61.92 (d, 2Jcp 6.4, OCH2CH3), 
113.73 (2C, Ar), 121.35 (CN), 129.50, 130.31, 158.85 (4C, Ar); op (162 MHz; 
COCb) 29.17; (NH3 CI) m/z 354 ([M+H]+, 5 %), 326 (71),207 (20), 136 (12), 121 
(100). 
6.2.34. E- Diethyl 3-(p-Methoxybenzylamino)-3-cyanocyclobutane-
phosphonate (145b) 
PMBNH>O 
NC ",., "'~ P(OEt) 2 
II 
(145b) 0 
The lower Rf isomer from above was isolated (145b) (801 mg, 31 %). Rf 
0.43 (85:15 hexane:iso-propanol) (Found C, 57.87; H, 7.19; N, 8.03; 
C17HzsN204P requires C, 57.76; H, 7.13; N, 7.93 %); t}max/cm-1 (CH202) 3276, 
2982,2909,2221, 1795, 1613, 1249, 1176; OR (400 MHz; CDCh) 1.33 (6H, t, J 7.0, 
OCH2CH3), 1.63 (lH, br. s, NH), 2.22 (2H, m, C(2)-H & C(4)-H), 2.68 (2H, m, 
C(2)-H' & C(4)-H'), 2.91 (lH, m, C(l)-H), 3.72 (2H, br. d, J 4.9, PhCH2), 3.76 (3H, 
s, OCH3), 4.07 (4H, m, OCH2CH3), 6.83 (2H, d, J 8.8, Ar), 7.23 (2H, d, J 8.8, Ar); 
Oc (100 MHz; CDCI3) 16.36 (d, 3Jcp 4.8, OCH2CH3), 24.58 (d, JcP 154.8, C-1), 
33.12 (d, 2Jcp 6.4, C-2 & C-4), 48.38 (PhCH2), 50.60 (d, 3JCp 23.9, C-3), 55.13 
(OCH3), 61.89 (d, 2Jcp 6.4, OCH2CH3), 113.84 (2C, Ar), 120.21 (d, 4JCp 4.8, CN), 
129.96, 130.36, 158.92 (4C, Ar); Op (162 MHz; CDCI3) 29.49; (NH3 CI) m/z 352 
([M+H]+, 6 0/0), 326 (28), 165 (13), 136 (22), 121 (100),95 (11), 81 (12). 
Xray Crystallography: Crystals were colourless plates of formula 
C17H22N OsP grown from a saturated solution of pentane/ diethyl 
ether/toluene at ambient temperature; triclinic, space group P-1, a 7.630(3), b 
9.882(5), c 13.604(6) A, ex 94.09(4), p 104.07(3), 199.27(4)°, U 975.4(8) A3, Z 2, Dc 
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1.200 mg/dm3, Mo-Ka radiation (A 0.71069 A), Il(Mo-Ka) 0.84 mm-1, T 220 K, 
R 0.0548 for 3443 unique reflections observed (I/o(l)~2.0) reflections. 
6.2.35. Oxidative Removal of the N-p- Methoxybenzyl Group 
Ceric ammonium nitrate (822 mg, 1.5 mmol) was added to a solution 
of the p-methoxybenzylaminonitrile (80 mgs, 0.23 mmol) in acetonitrile and 
water (6 cm3 , 9:1). The reaction was monitored by tlc 
(dichlomethane/methanoI19:1). After 2 h no starting material remained. The 
reaction mixture was diluted by the addition of water (20 cm3) and extracted 
with dichloromethane (3 x 15 cm3). The organic extrracts were then extracted 
with dilute hydrochloric acid (1 M, 2 x 15 cm3), the acidic fractions were 
adjusted to pH 8 and extracted with dichloromethane (3 x 10 cm3). The 
dichloromethane fractions were washed with water (2 x 10 cm3) and brine 
(2 x 10 cm3), dried over anhydrous magnesium sulfate, filtered and 
evaporated to dryness to afford the deprotected a-aminonitrile compund as a 
crude oil which was used in the next step without further purification. 
6.2.36. Removal of the N-p-Methoxybenzyl Group by Hydrogenation 
A solution of the p-methoxybenzylaminonitrile (100 mgs, 0.29 mmol) 
in methanol (15 cm3) was hydrogenated (3 atmospheres) over palladium on 
carbon for 4 h. The reaction mixture was filtered through a pad of celite which 
was washed with methanol (2 x 10 cm3). The combined filtrates were 
evaporated to dryness under reduced pressure. The residue was dissolved in a 
solution of dilute hydrochloric acid (1 M, 15 cm3) and extracted with 
dichloromethane (2 x 10 cm3). The aqueous fraction was adjusted to pH 8 with 
sodium hydroxide (1 M) and extracted with dichloromethane (3 x 15 cm3). The 
dichloromethane fractions were washed with water (2 x 10 cm3) and brine (2 x 
10 cm3), dried over anhydrous magnesium sulfate, filtered and evaporated to 
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dryness to afford diethyl 3-amino-3-cyanocyclobutanephosphonate as a crude 
oil which was used in the next step without further purification. 
6.2.37. Z- Diethyl 3-Amino-3-cyanocyc1obutanephosphonate (135a) 
o 
II 
H2~P(OEt)2 
NC"'··'V 
(135a) 
Z-J:Jethyl~methoxybenzy1amino)-3-cyanocycbbutanephosphonate (145a) was 
deprotected by either of the methods described above to afford Z-diethyl 3-
amino-3-cyanocyclobutanephosphonate (135a). OR (250 MHz; CDCh) 1.29 (6H, 
t, J 6.8, OCH2CH3), 2.16 (2H, br. S, NH2), 2.24 (2H, m, C(2)-H & C(4)-H), 2.32 
(3H, br. m, C(l)-H, C(2)-H' & C(4)-H'), 4.03 (4H, m, OCH2CH3); oc (63 MHz; 
CDCI3) 16.23 (d, 3JCp 6.4, OCH2CH3), 22.51 (d, JcP 143, C-1), 34.25 (d, 2Jcp 6.3, 
C-2 & C-4), 51.78 (d, 3JCp 24, C-3), 61.92 (d, 2JCp 6.5 OCH2CH3), 121.25 (CN). 
6.2.38. E- Diethyl 3-Amino-3-cyanocyc1obutanephosphonate (135b) 
H2X> 
NC ",.. ."" P(OEt) 2 
II 
(135b) 0 
E-J:Jethyl~methoxybenzy1amino )-3-cyanocycbbutanephosphonate (145b) was 
deprotected by either of the methods described above to afford E-diethyl 
3-amino-3-cyanocyclobutanephosphonate (135b). OR (250 MHz; CDCh) 1.27 
(6H, t, J 6.8, OCH2CH3), 2.18 (2H, br. s, NH2), 2.35 (3H, m, C(l)-H, C(2)-H & 
C(4)-H), 2.68 (2H, m, C(2)-H' & C(4)-H'), 4.03 (4H, m, OCH2CH3); oc (63 MHz; 
CDCI3) 16.33 (d, 3JCp 6.4, OCH2CH3), 24.02 (d, JcP 144, C-1), 32.85 (d, 2Jcp 6.3, 
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C-2 & C-4), 50.01 (d, 3JCp 17, C-3), 61.82 (d, 2Jcp 6.5 OCH2CH3), 120.06 (d, 4Jcp 
3.9,CN). 
6.2.39. Z-3-Amino-3-carboxycyc1obutanephosphonic Acid (78a) 
(78a) 
Crude Z-diethy13-amino-3-cyanocyclobutanephosphonate (135a) (100 
mgs, 0.43 mmol) was dissolved in hydrochloric acid (6M, 10 cm3) and the 
solution was heated to reflux for 48 h. After cooling the solution was 
evaporated to dryness under reduced pressure. The residue was dissolved in 
water (2 cm3) and applied to an ion exchange column (Dowex SOW, H+ form). 
The column was washed with water (100 cm3) and then eluted with aqueous 
pyridine (1 M, 200 cm3). Ninhydrin active fractions were combined and 
evaporated to dryness under reduced pressure. Residual traces of pyridine 
were removed by repeatedly dissolving the the compound in water (10 cm3) 
and re-evaporating (3-times) affording the title compound (78a) as an off white 
solid (62 mg, 74 0/0). OH (400 MHz; D20) 2.28 (2H, m, C(2)-H & C(4)-H), 2.56 
(lH, m, C(l)-H), 2.73 (2H, M, C(2)-H' & C(4)-H'); Oc (101 MHz; D20) 25.10 (d, 
JcP 142, C-1), 31.65 (d, 2Jcp 4.8, C-2 & C-4), 57.28 (d, 3Jcp 14.5, C-3), 176.40 
(C=O); op (162 MHz; D20) 26.51; (FAB) m/z calc'd for CSHlONOSP: 195.0296, 
found 195.0294. 
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6.2.40. E-3-Amino-3-carboxycyc1obutanephosphonic Acid (78b) 
Crude E-diethyl 3-amino-3-cyanocyclobutanephosphonate (135b) 
(100 mgs, 0.43 mmol) was dissolved in hydrochloric acid (6M, 10 cm3) and the 
solution was heated to reflux for 48 h. After cooling the solution was 
evaporated to dryness under reduced pressure. The residue was dissolved in 
water (2 cm3) and applied to an ion exchange column (Dowex SOW, H+ form). 
The column was washed with water (100 cm3) and then eluted with aqueous 
pyridine (1 M, 200 cm3). Ninhydrin active fractions were combined and 
evaporated to dryness under reduced pressure. Residual traces of pyridine 
were removed by repeatedly dissolving the the compound in water (10 cm3) 
and re-evaporating (3 times) affording the title compound (78b) as an off white 
solid (67 mg, 76 %). OH (400 MHz; D20) 2.33 (3H, m, C(l)-H, C(2)-H & C(4)-H), 
2.46 (2H, m, C(2)-H' & C(4)-H'); OC (101 MHz; D20) 22.76 (d, fcp 141, C-1), 
31.77 (d, 2JCp 4.8, C-2 & C-4), 55.18 (d, 3JCp 16, C-3), 175.22 (d, 4fcp 3.1, C=O); 
op (162 MHz; D20) 25.70; (FAB) m/z calc'd for CSHlONOSP: 195.0584, found 
195.0581. 
6.2.41. Diethyl 3-0ximinocyc1obutanephosphonate (146) 
o 
HOr =0--- 11 N- P(OEt)2 
(146) 
Hydroxylamine hydrochloride (520 mg, 8.1 mmol) was added to a 
solution of diethyl 3-oxocyclobutanephosphonate (134) (500 mgs, 2.43 mmol) 
in water (10 cm3) and the pH of the solution adjusted to 4 (1 M HCI). The 
180 
reaction mixture was heated to reflux for 15 h. After cooling the solution was 
adjusted to pH 8 (1 M NaOH) and extracted with dichloromethane (3 x 10 
an3). The organic extracts were washed with water (2 x 10 cm3) and brine (2 x 
10 cm3), dried over anhydrous magnesium sulfate, filtered and the solvent 
removed in vacuo to afford the title compound (146) (455 mg,85 0/0). ~rnax/cm-l 
(neat) 3851, 3274, 2965, 2359, 1651; BH (250 MHz; CDCh) 1.18 (m, 6H, 
OCH2CH3), 1.75 (lH, s, N-OH), 2.25 (lH, m, C(l)-H), 2.97-3.30 (4H, m, C(2)-H 
& C(4)-H), 3.99 (4H, m, OCH2CH3); Bc (63 MHz; CDCh) 16.21 (d, 3J Cp 5.9, 
OCH2CH3), 21.51 (d, JcP 152.6, C-1), 31.91 (d, 2Jcp 5.9, C-2 or C-4), 32.76 (d, 
2JCp 4.9, C-2 or C-4), 62.20 (d, 2JCp 5.9, OCH2CH3), 152.30 (d, 3Jcp 15.8, C-3); 
(NH3 CI) m/z 234 ([M+H]+, 16 %), 217 (65), 206 (18), 191 (100), 165 (43). 
6.2.42. Z-3-Aminocyc1obutanephosphonic Acid (148) 
Ii:! N""··O···" P(OH)2 
II 
(148) 0 
A solution of diethyl 3-oximinocyc1obutanephosphonate (146) 
(400 mg, 1.81 mmol) in methanol (containing 4 drops of concentrated 
hydrochloric acid) was hydrogenated (3 atmospheres) over rhodium on 
alumina (30 mg) for 15 h. The reaction mixture was filtered through a pad of 
celite which was washed with methanol (3 x 10 cm3). The combined filtrates 
were evaporated to dryness under reduced pressure. The residue was 
dissolved in water (3 cm3) and applied to an ion exchange column (Dowex 
SOW, H+ form). The column was washed with water (100 cm3) and eluted with 
pyridine (200 cm3). The ninhydrin positive fractions were combined and 
evaporated to dryness under reduced pressure, residual traces of pyridine 
were removed by repeated additon of water (5 cm3) and re-evaporation 
(3 times) to afford the title compound (148) (169 mg, 62 %). BH (250 MHz; D20 ) 
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2.26 (2H, m, C(2)-H & C(4)-H), 2.49 (lH, m, C(l)-H), 2.63 (2H, m, C(2)-H' & 
C(4)-H'), 3.03 (lH, m, C(3)-H); Oc (63 MHz; D20) 24.32 (d, JcP 144, C-1), 28.41 
(d, 2JCp 4.8, C-2 & C-4), 39.38 (d, 3JCp 4.8, C-3); op (162 MHz; D20 ) 26.36; (NH3 
CI) m/z 169 ([M+ 18]+,24 0/0), 152 ([M+H]+, 16), 135 (12), 118 (16), 107 (100). 
6.2.43. Z- Diethy13-Hydroxy-3-methylcyc1obutanephosphonate (149) 
:>0 .. ", P(OEt) 2 
II 
(149) o 
A solution of diethyl 3-oxocyc1obutanephosphonate (134) (100 mgs, 
0.49 mmol) in anhydrous THF (15 cm3) at -78°C under an atmosphere of 
nitrogen, was treated with a solution of methyl magnesiumbromide (0.17 cm3, 
3 Min diethyl ether). The reaction mixture was stirred for 2 h at -78°C then 
allowed to warm to room temperature and quenched with a saturated solution 
of ammonium chloride (15 cm3). The THF was removed in vacuo and the 
aqueous residue was extracted with dichloromethane (3 x 15 cm3). The 
combined organic fractions were washed with water (2 x 15 cm3) and brine (2 
x 15 cm3), dried over anhydrous magnesium sulfate, filtered and evaporated 
to dryness under reduced pressure to afford the title compound as a colouless 
oil (149) (88 mg, 81 0/0). OH (250 MHz; CDCI3) 1.24 (6H, t, J 6.9, OCH2CH3), 1.33 
(3H, s, CH3), 2.20 (3H, m, C(l)-H, C(2)-H & C(4)-H), 2.68 (2H, m, C-(2)-H' & 
C(4)-H'), 4.01 (4H, m, OCH2CH3); Oc (63 MHz; D20) 16.32 (d, 3Jcp 6.9, 
OCH2CH3), 18.86 (d, JcP 152, C-1), 26.36 (CH3), 38.30 (d, 2Jcp 4.9, C-2 & C-4), 
61.82 (d, 2Jcp 5.9, OCH2CH3), 70.27 (d, 3JCp 24.6, C-3); op (101 MHz; CDCh) 
32.15; (NH3 CI) m/z 223 ([M+H]+, 32 a/a), 205 (63), 177 (24), 149 (27), 122 (100), 
107 (21);m/z calc'd for C9H2004P [M+H]: 223.1096, found 223.1094. 
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6.2.44. Z- Diethyl 3-Methoxymethyl-3-hydroxycyc1obutanephosphonate 
(155) 
MeO~A 
HO "'··V··'I, P(OEt) 2 
II 
(155) o 
A solution of methoxymethyltrimethylsilane (113 mgs, 0.97 mmol) in 
anhydrous anhydrous THF (10 cm3) at -78°C was treated with sec-
butyllithium (0.75 cm3, 1.3 M in cyclohexane). The solution was stirred for 30 
min and then diethyl 3-oxocyclobutanephosphonate (134) (100 mgs, 0.49 
mmol) in anhydrous THF (1 cm3) was added. The reaction mixture was stirred 
at -78°C for 1 h and then potassium hydride (23 mg, 0.58 mmol) was added 
and the solution warmed to room temperature. The reaction mixture was 
stirred at room temperature for 15 h and then quenched with a saturated 
solution of ammonium chloride (10 cm3). The THF was removed in vacuo and 
the aqueous solution extracted with dichloromethane (3 x 15 cm3). The 
combined organic extracts were washed with water (2 x 15 cm3) and brine 
(2 x 15 cm3), dried over anhydrous magnesium sulfate and evaporated to 
dryness to afford the title compound (155) (93 mg, 73 %). OR (250 MHz; CDCI3) 
1.24 (6H, t, J 7.8, OCH2CH3), 2.20 (2H, m, C(2)-H & C(4)-H), 2.52 (3H, m, C(l)-
H, C(2)-H' & C(4)-H'), 3.32 (2H, s, CH30CH2), 3.35 (3H, s, CH3OCH2),4.01 
(4H, m, OCH2CH3); Oc (63 MHz; CDCI3) 16.11 (d, 3Jcp 6.9, OCH2CH2), 19.30 
(d, JcP 152, C-1), 33.99 (d, 2Jcp 5.5, C-2 & C-4), 59.08 (s, CH3OC'H2), 59.32 (s, 
CH3OCH2), 61.79 (d, 2Jcp 5.9, OCH2CH3), 71.36 (d, 3Jcp 24.3, C-3). 
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6.2.45. EI Z-Diethyl 3-Formylcyclobutanephosphonate (158) 
o 
o 
H 
II 
P(OEt)2 
(158) 
A solution of diethyl isonitrilemethylphosphonate (850 mg, 4.8 mmol) 
in anhydrous THF (25 cm3) at -78°C was treated with n-butyllithium (1.92 
an3, 4.8 mmol). The solution was stirred at this temperature for 30 min and 
then a solution of diethyl 3-oxocyclobutanephosphonate (134) (900 mg, 4.4 
mmol) in anhydrous THF (5 cm3) was added. The reaction mixture was stirred 
for a further 2 h at -78°C and then warmed to room temperature and 
quenched with water (5 cm3). The THF was removed in vacuo and the residue 
redissolved in ether (20 cm3) and hydrochloric acid (6 M, 10 cm3). The biphasic 
solution was stirred at ambient temperature for 15 h. The ether was removed 
by evaporation under reduced pressure and the aqueous residue was 
extracted with dichloromethane (3 x 20 cm3). The combined organic extracts 
were washed with water (2 x 15 cm3) and brine (2 x 15 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent removed under 
reduced pressure to afford a 1:1 mixture of the two diastereoisomers of the 
title compound (158) as a colourless oil (795 mg, 83 0/0) i}max/cm-1 (neat) 2984, 
2909, 2724, 1719, 1480, 1444, 1292, 1226; OH (250 MHz; CDCh) 1.14 (6H, m, 
OCH2CH3), 2.20-2.63 (5H, br. m, C(l)-H, C(2)-H & C(4)-H), 3.00 (lH, m, C(3)-
H), 3.94 (4H, m, OCH2CH3), 9.54 (...,O.5H, t, J 1.75, HC=O Z-isomer), 9.62 
( .... O.5H, d, J 1.2, HC=O E-isomer); Oc (63 MHz; CDCh) 16.23 (d, 3Jcp 5.9, 2 x 
OCH2CH3), 21.76 (d, 2Jcp 5.9, C-2 & C-4 of one isomer), 22.41 (d, 2Jcp 5.9, C-2 
& C-4 of other isomer), 24.59 (d, JcP 133, C-1 of one isomer), 24.59 Ucp lSI, C-1 
of other isomer), 42.09 (3Jcp 17.7, C-3 of one isomer) 42.67 (d, 3Jcp 11.8 of other 
isomer), 61.79 (d, 2Jcp 5.9, 2 x OCH2CH3), 200.99 (d, 4Jcp 2.9, C=O Z-isomer), 
201.11 (C=O E-isomer); op (162 MHz; CDCh) 29.99, 31.98; (NH3 CI) m/z 221 
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([M+H]+, 100 0/0), 191 (32), 165 (40), 152 (65), 138 (70), 109 (42),55 (31);m/z calc'd 
for C9H l704P [M+H]: 221.0940, found 221.0942. 
6.2.46. (+)-E/Z- Diethyl 3-(Amino-cyanomethyl)cyc1obutanephosphonate 
(159) 
H~2N 0 
II 
NC P(OEt)2 
(159) 
To a solution of the aldehyde (158) (400 mg, 1.8 mmol) in dry 
methanol (20 cm3) was added sodium cyanide (135 mg, 2.7 mmol) and 
ammonium chloride (244 mg, 4.6 mmol). The reaction was stirred at ambient 
temperature with light excluded for 15 h. The methanol was removed under 
reduced pressure and the residue dissolved in dichloromethane (20 cm3) and 
water (20 cm3). The organic layer was separated and the aqueous layer 
extracted with dichloromethane (2 x 20 cm3). The combined organic layers 
were washed with water (2 x 15 cm3) and brine (2 x 15 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent removed in vacuo to 
yield the title compound (159) as a pale orange oil which was used in the next 
step without any further purification (385 mg, 91 0/0). OH (250 MHz; CDCb) 
1.21 (6H, m, OCH2CH3), 1.56 (2H, hr. s, NH2), 2.11-2.74 (6H, br. m, C(l)-H, 
C(2)-H, C(3)-H & C(4)-H), 3.61 (lH, m, HC(CN)NH2), 3.99 (4H, m, OCH2CH3); 
oc (63 MHz; CDCb) 16.36 (3Jcp 5.9,2 x OCH2CH3), 23.79 (d, 2Jcp 7.9, C-2 or C-
4 of one isomer), 24.01 (d, JcP 137, C-1 of one isomer), 24.09 (d, JcP 149, C-1 of 
other isomer), 24.51 (d, 2Jcp 5.9, C-2 or C-4 of one isomer & C-2 or C-4 of other 
isomer), 25.36 (d, 2Jcp 5.9, C-2 or C-4 or other isomer), 36.37 (d, 3JCp 21.7, C-3 
of one isomer), 36.39 (d, 3JCp 29, C-3 of other isomer), 47.55 (C(CN) NH2, 
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E-isomer), 47.56 (d, 4JCp 3.2, C(CN)NH2 Z-isomer) 61.64 (d 2J 69 
, ,cp ., 
2 x OCH2CH2), 120.62 (CN of one isomer), 120.67 (CN of other isomer); op (250 
MHz; CDCh) 30.52, 32.28. 
6.2.47. (+)-E- DiethyI3-(Phenylacetylamino)-cyanomethyl)cyclobutane_ 
phosphonate (160a) 
~ ~ 
PhCH:Pi )'", .. V P(OE!) 2 
eN 
(160a) 
Triethylamine (1.5 cm3) was added dropwise to a solution of (±)-E/ Z-
diethyl 3-(amino-cyanomethyl)cyclobutanephosphonate (159) (360 mg, 1.46 
mmol) and phenylacetyl chloride (250 mg, 1.6 mmol) in dry dichloromethane 
(20 cm3) at room temperature. The reaction mixture was stirred for 15 h and 
then poured into water (20 cm3). The organic layer was separated and the 
aqueous layer was extracted with dichloromethane (3 x 15 cm3). The combine 
organic extracts were washed with water (2 x 15 cm3) and brine (2 x 15 cm3), 
dried over anhydrous magnesium sulfate, filtered and the solvent removed in 
vacuo to afford a crude product. The diastereoisomers were separated by silica 
gel chromatography to yield the title compound (214 mg, 80.5 %). Rf 0.48 (7:3 
hexane:iso-propanol) (Found C, 59.29; H, 6.89; N, 7.69; ClsH25N204P requires 
C, 59.31; H, 6.92; N, 7.72 0/0); i}max / cm-1 (neat) 3295, 2865, 2898, 2960, 2222, 
1655, 1490, 1465, 1045; OH (400 MHz; CDC h) 1.26 (6H, dt, J 7.02.8, OCH2CH3), 
1.96 (lH, br. s, NH), 2.04 (2H, m, C(2)-H & C(4)-H), 2.27 (2H, m, C(2)-H' & 
C(4)-H'), 2.49 (lH, m, C(l)-H), 2.79 (lH, m, C(3)-H), 3.57 (2H, s, PhCH2), 4.00 
(4H, m, OCH2CH3), 4.9 (lH, t, J 8.8, HC(CN)NHAcPh), 7.23 (3H, m, Ar), 7.29 
(2H, m, Ar); oe (101 MHz; CDCh) 16.33 (d, 3Jcp 6.4, OCH2CH3), 24.02 (d, JcP 
150, C-1), 24.10 (d, 2Jcp 4.8, C-2 or C-4), 24.30 (d, 2JCp 6.4, C-2 or C-4), 34.99 (d, 
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3Jcp 9.7, C-3), 42.78 (PhCH2), 44.17 (C(CN)NHAcPh), 61.97 (d, 2JCp 4.8, 
OCH2CH3), 117.35 (CN), 127.31, 128.81, 128.96, 134.19 (6C, Ar), 170.94 (C=O); 
Op (162 MHz; CDCh) 32.42; (NH3 CI) m/z 365 ([M+H]+, 100 %), 338 (8), 273 
(19), 165 (12), 136 (22),91 (32). 
6.2.48. (+)-Z-Diethyl 3-(Phenylacetylamino)-cyanomethyl)cyclobutane_ 
phosphonate (160b) 
o 
II 
PhCH2CHN 
NC 
(160b) 
o 
II 
P(OEt)2 
The lower Rf isomer from above was isolated (160b) (228 mg, 86 0/0). Rf 
0.40 (7:3 hexane:iso-propanol) (Found C, 59.28; H, 6.96; N, 7.77; C 18H2,5N20~ 
requires C, 59.31; H, 6.92; N, 7.69 0/0); Jrnax/cm-1 03295,2865,2898,2960,2222, 
1655, 1490, 1465, 1045; OH (400 MHz; CDCI3) 1.28 (6H, dt, J 7.0 2.8, OCH2CH3), 
2.06 (lH, br. s, NH), 2.11-2.46 (4H, br. m, C(2)-H & C(4)-H), 2.54 (lH, m, 
C(l)-H), 2.81 (lH, m, C(3)-H), 3.62 (2H, s, PhCH2), 4.04 (4H, m, OCHzCH3), 
4.78 (lH, dd, J 6.7 7.7, HC (CN)NHAcPh), 7.24 (3H, m, Ar), 7.29 (2H, m, Ar); Oc 
(101 MHz; CDCI3) 16.36 (d,3Jcp 6.4, OCH2CH2), 22.94 (d,2Jcp 6.5, C-2 or C-4), 
23.19 (d, JcP 148, C-1), 23.63 (d, 2Jcp 4.8, C-2 or C-4), 33.30 (d, 3Jcp 17.7, C-3), 
42.60 (PhCH2), 43.55 (d, 4JCp 3.2, C(CN)NHAcPh), 62.07 (d, 2Jcp 4.8, 
OCH2CH3), 117.29 (CN), 127.04, 128.61, 129.10, 134.32 (6C, Ar), 171.33 (C=O); 
op (162 MHz; CDCI3) 32.24; (NH3 CI) m/z 365 ([M+H]+, 100 %), 338 (11), 273 
(22), 165 (17), 136 (34), 91 (37). 
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6.2.49. Enantioselective Enzyme Hydrolysis of (±)-E-Diethyl 
3-(Phenylacetylamino )-cyanomethyl)cyc1obutanephosphonate (±)_ 
(160a) 
(+)-E-Diethy I 3-(phenylacetylamino )-cyanomethyl)cyclobu tane-
phosphonate (+)-(160a) (150 mg, 0.41 mmol) was dissolved in methanol (3 
cm3 ) and phosphate buffer (8 cm3, 0.01 M, pH 7). Penicillinacylase 
immobilised on Eupergit (-20 units) was added. The reaction mixture was 
incubated at 27°C and monitored by tIc (hexane/iso-propanol 7:3). After 
conversion had ceased (-6 h), the reaction mixture was filtered, adjusted to pH 
4 (1 M HCI) and extracted with dichloromethane (3 x 10 cm3). The combined 
organic fractions were washed with saturated sodium bicarbonate solution 
(2 x 10 cm3), water (2 x 10 cm3) and brine (2 x 10 cm3) and dried over 
anhydrous magnesium sulfate, filtered and the solvent removed in vacuo to 
yield crude (-) -E - diethyl 3-(phenylacetylamino )-cyano-
methyl)cyclobutanephosphonate (-)-(160a) (67 mg, 45 %). The acidic fraction 
from above was adjusted to pH 7 (1 M N aOH) and extracted with 
dichloromethane (3 x 10 cm3). The combined organic fractions were washed 
with saturated sodium bicarbonate solution (2 x 10 cm3), water (2 x 10 cm3) 
and brine (2 x 10 cm3) and dried over anhydrous magnesium sulfate, filtered 
and the solvent removed in vacuo to yield crude (+ )-E-diethyl 3-(amino-
cyanomethyl)cyclobutanephosphonate (+)-(159a) (42 mg,41 0/0). 
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6.2.50. (+ )-E-3-(Amino-carboxymethyl)cyc1obutanephosphonic Acid (+)_ 
(79a) 
H02C (+)-(79a) 
(+)-E-diethyl 3-(amino-cyanomethyl)cyclobutanephosphonate 
(+)-159a) (35 mg, 0.14 mmol) was dissolved in hydrochloric acid (6 M, 5 cm3) 
and the reaction mixture heated to reflux for 36 h. After cooling the solvent 
was removed by evaporation under reduced pressure and the residue 
dissolved in water (1 cm3), applied to an ion exchange column and washed 
with water (40 cm3). The column was eluted with pyridine (1 M, 90 cm3) and 
the ninhydrin active fractions were combined and evaporated to dryness. 
Residual traces of pyridine were removed by repeated dissolution in water 
and re-evaporation (3 times) to afford (+ )-E-3-(amino-
carboxymethyl)cyclobutanephosphonic acid (+)-(79a) (19 mg, 64 %) [ex ]D20 
+18.7° (c 0.8 in 1 M HCI), BH (400 MHz; D20) 2.09-2.27 (2H, br. m, C(2)-H & 
C(4)-H), 2.30-2.62 (3H, br. m, C(l)-H, C(2)-H' & C(4)-H'), 2.79 (lH, m, C(3)-H), 
4.14 (lH, m, CH(NH2)C02H); Bc (101 MHz; D20) 22.45 (d, 2JCp 5.9, C-2 or 
C-4), 22.62 (d, 2Jcp 5.2, C-2 or C-4), 23.32 (d, JcP 143, C-1), 33.28 (d, 2JCp 15.2, 
C-3), 49.29 (C(NH2)C02H), 176.38 (C=O); Bp (162 MHz; D20) 25.26; (FAB) m/z 
calc'd for C~12N05P: 209.0452, found 209.0454. 
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6.2.51. (-)-E-3-(Amino-carboxymethyl)cyc1obutanephosphonic Acid 
(-)-(79a) 
o 
II 
P(OH)2 
(-)-(79a) 
(-)-E-diethyl 3-(phenylacetylamino )-cyanomethyl)cyclobu tane-
phosphonate (-)-(160a) (67 mg, 0.18 mmol) was dissolved in hydrochloric acid 
(6 M, 5 cm3) and the reaction mixture heated to reflux for 36 h. After cooling 
the solvent was removed by evaporation under reduced pressure and the 
residue dissolved in water (1 cm3), applied to an ion exchange column and 
washed with water (40 cm3). The column was eluted with pyridine (1 M, 90 
crn3) and the ninhydrin active fractions were combined and evaporated to 
dryness. Residual traces of pyridine were removed by repeated dissolution in 
water and re-evaporation (3 times) to afford (- )-E-3-(amino-
carboxymethyl)cyclobutanephosphonic acid (-)-(79a) (24-mg, 62 %) [ex ]D20 
-17.9° (c 0.8 in 1 M HCI), OH (400 MHz; D20) 2.09-2.27 (2H, m, C(2)-H & 
C(4)-H), 2.30-2.62 (3H, br. m, C(l)-H, C(2)-H' & C(4)-H'), 2.79 (lH, m, C(3)-H), 
4.14 (lH, m, CH(NH2)C02H); Oc (101 MHz; D20) 22.45 (d, 2JCp 5.9, C-2 or 
C-4), 22.62 (d, 2JCp 5.2, C-2 or C-4), 23.32 (d, JcP 143, C-l), 33.28 (d, 2Jcp 15.2, 
C-3), 49.29 (C(NH2)C02H), 176.38 (C=O); op (162 MHz; D20) 25.26; (FAB) m/z 
calc'd for C6lI12NOSP: 209.0452, found 209.0454. 
6.2.52. Enantioselective Enzyme Hydrolysis of (±)-Z-Diethyl3-
(Phenylacetylamino)-cyanomethyl)cyc1obutanephosphonate 
(+)-160b) 
(+)-Z-DEthyl 3-(pheny1acety1amino }cyanomethyl)cycbbutanephosphonate 
(±)-160b) (150 mg, 0.41 mmol) was dissolved in methanol (3 cm3) and 
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phosphate buffer (8 cm3, 0.01 M, pH 7). Penicillinacylase immobilised on 
Eupergit (-20 units) was added. The reaction mixture was incubated at 27°C 
and monitored by tIc (hexane/ iso-propanol 7:3). After conversion had ceased 
(-6 h), the reaction mixture was filtered, adjusted to pH 4 (1 M HCI) and 
extracted with dichloromethane (3 x 10 cm3). The combined organic fractions 
were washed with saturated sodium bicarbonate solution (2 x 10 cm3), water 
(2 x 10 cm3) and brine (2 x 10 cm3) and dried over anhydrous magnesium 
sulfate, filtered and the solvent removed in vacuo to yield crude (-)-Z-diethyI3-
(phenylacetylamino)-cyano-methyl)cyclobutanephosphonate (-)-(160b) (63 mg, 
42 %). The acidic fraction from above was adjusted to pH 7 (1 M NaOH) and 
extracted with dichloromethane (3 x 10 cm3). The combined organic fractions 
were washed with saturated sodium bicarbonate solution (2 x 10 cm3), water 
(2-x 10 cm3) and brine (2 x 10 cm3) and dried over anhydrous magnesium 
sulfate, filtered and the solvent removed in vacuo to yield crude (+ )-Z-diethyl 
3-(amino-cyanomethyl)cyclobutanephosphonate (+)-(159b) (43 mg, 43 %). 
6.2.53. (+ )-Z-3-(Amino-carboxymethyl)cyc1obutanephosphonic Acid 
(+)-(79b) 
(+)-(79) 
(+}-Z-dEthyl3{anIDo-qranomethyl)cycbbutanephosphonate (+ )-(159b) (35 mg, 
0.14 mmol) was dissolved in hydrochloric acid (6 M, 5 cm3) and the reaction 
mixture heated to reflux for 36 h. After cooling the solvent was removed by 
evaporation under reduced pressure and the residue dissolved in water 
(1 cm3), applied to an ion exchange column and washed with water (40 cm3). 
The column was eluted with pyridine (1 M, 90 cm3) and the ninhydrin active 
fractions were combined and evaporated to dryness. Residual traces of 
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pyridine were removed by repeated dissolution in water and re-evaporation 
(3 times) to afford (+)-Z-3-(amino-carboxymethyl)cyclobutanephosphonic acid 
(+)-(79b) (18 mg, 61 0/0) [a]D20 +13.6° (c 1 in 1 M HCI), OH (400 MHz; D20 ) 2.23-
2.48 (4H, br. m, C(2)-H & C(4)-H), 2.55 (IH, m, C(I)-H), 2.87 (IH, m, C(3)-H), 
4.21 (IH, CH(NH2)C02H); Oc (101 MHz; D20) 22.61 (d, 2JCp 4.8, C-2 or C-4), 
22.87 (d, 2Jcp 4.2, C-2 or C-4), 25.15 (d, JcP 142, C-l), 31.43 (d, 3Jcp 13.8, C-3), 
48.92 (d, 4JCp 2.8, C(NH2)C02H), 176.21 (C=O); op (162 MHz; D20 ) 26.48; 
(FAB) m/z ca1c'd for C6H12NOSP: 209.0452, found 209.0453. 
6.2.54. (-)-Z-3-(Amino-carboxymethyl)cyc1o butanephosphonic Acid 
(-)-(79b)i 
o 
II 
P(OH)2 
(-)-(79b) 
(-)-Z-diethyl 3-((phenylacetylamino)-cyanomethyl)cyclobutane-
phosphonate (-)-(160b) (63 mg, 0.18 mmol) was dissolved in hydrochloric acid 
(6 M, 5 cm3) and the reaction mixture heated to reflux for 36 h. After cooling 
the solvent was removed by evaporation under reduced pressure and the 
residue dissolved in water (1 cm3), applied to an ion exchange column and 
washed with water (40 cm3). The column was eluted with pyridine (1 M, 90 
cm3) and the ninhydrin active fractions were combined and evaporated to 
dryness, Residual traces of pyridine were removed by repeated dissolution in 
water and re-evaporation (3 times) to afford (-)-Z-3-(amino-
carboxymethyl)cyclobutane-phosphonic acid (-)-(79b) (24 mg, 63 0/0) [a]D20 
-12.9° (c 0.9 in 1 M HCI), OH (400 MHz; D20) 2.23-2.48 (4H, br. m, C(2)-H & 
C(4)-H), 2.55 (IH, m, C(I)-H), 2.87 (IH, m, C(3)-H), 4.21 (IH, C(NH2)C0 2H); 
OC (101 MHz; D20) 22.61 (d, 2JCp 4.8, C-2 or C-4), 22.87 (d, 2JCp 4.2, C-2 or C-4), 
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25.15 (d, JcP 142, C-1), 31.43 (d, 3JCp 13.8, C-3), 48.92 (d, 4JCp 2.8, 
C(NH2)C02H), 176.21 (C=O); Bp (162 MHz; D20) 26.48; (FAB) m/z calc'd for 
C~12N05P: 209.0452, found 209.0454. 
6.2.55. Preparation of a-Methoxy-a-trifluoromethylphenylacetylamino 
Derivatives 
General procedure: To a sample of diethyl 3-(amino-cyano-
methyl)cyclobutanephosphonate (5 mg, 20 J1mol) in dichloromethane (1 cm3) 
was added triethylamine (50 J11) and a-methoxy-a-trifluoromethyl-
phenylacetylchloride (240 J11 of a 0.1 M solution in dichloromethane). The 
reaction mixture was stirred for 12 h at room temperature and then the solvent 
removed by evaporation under reduced pressure. The residue was dissolved 
in CDCh and the sample analysed by 19F nmr spectroscopy. 
(±)-E- Die thy 1 3 - ( (a -methoxy-a-trifluoromethylphenylacetylamino)-
carboxymethyl)cyclobutanephosphonate 
BF (376 MHz; CDCh) -71.89 & -72.84 
(+)-E-D i e t h yl 3 - «a-Methoxy-a-trifluoromethylphenylacetylamino)-
carboxymethyl)cyclobutanephosphonate 
BF (376 MHz; CDCh) -71.89 
(±)-Z - Die thy 1 3 - «a-Methoxy-a-trifluoromethylphenylacetylamino)-
carboxymethyl)cyclobutanephosphonate 
BF (376 MHz; CDCh) -69.85 & -71.91 
(+ )-Z-Die thy 1 3 - «a-Methoxy-a-trifluoromethylphenylacetylamino)-
carboxymethyl)cyclobutanephosphonate 
BF (376 MHz; CDCh) -71.91. 
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6.3. Synthesis of Cycloalkane l,l-Bisphosphonic and l-Carboxy-
1-Phosphonic Acids 
6.3.1. t-Butyl Diethyl phosphonoacetate (192) 
o 
II 
(EtO) 2P~ 00 2t-Bu 
(192) 
A solution of t-butyl bromoacetate (50 g, 0.26 mol) and triethyl 
phosphite (42.6 g, 0.26 mol) (freshly distilled from sodium) was heated gently 
(80°C). The solution was heated further until the ethyl bromide began to distil 
(oil bath temperature 110 °C). After 30 min the reaction was cooled and the 
product distilled under reduced pressure to yield the desired compound (57 g, 
87 0/0). (120-122 °C, 0.2 mmHg) (115°C, 0.2 mmHg) (lit.,B) 'i}max/cm-1 (neat) 
2982, 1729, 1259, 1211, 1117, 1054, 1028; OH (250 MHz; CDCh) 1.37 (6H, t, 17.3, 
OCH2CH3), 1.5 (9H, s, C(CH3b), 3.9 (2H, d, IHCP 22, PCH2), 4.2 (4H, dq, 17.3, 
7.3, OCH2CH3); (NH3 CI) m/z 253 ([M+H]+, 10 %), 197 (91), 179 (100), 151 (72), 
126 (64), 57 (84), 41 (31). 
6.3.2. General Procedure for Preparation of Diethyl t-Butyl-1-carboxy-
cyc1oalkanephosphonates (201-203) 
A suspension of benzyltriethylammonium chloride (2.0 g, 8.7 mmol) in 
50 % aqueous NaOH (20 cm3) was treated with a solution of t-butyl 
diethylphosphonoacetate (2.0 g, 7.9 mmol) in the appropriate 
l,ro-dibromoalkane (10 cm3). The reaction mixture was stirred at room 
temperature for 24-48 h, poured into dichloromethane (150 cm3), washed with 
water (7 x 100 cm3) and brine (2 x 100 cm3), dried over anhydrous magnesium 
sulfate filtered and the solvent removed under reduced pressure. The crude , 
product was distilled under reduced pressure (150°C, 0.2 mmHg). TIc 
(petroleum ether:ethanol, 97:3) indicated that the product was still impure. 
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The desired product was isolated by flash column chromatography on silica 
gel (petroleum ether:ethanol, 97:3). 
6.3.3. Diethyl t-ButyI1-Carboxycyc1obutanephosphonate (201) 
(201) 
Diethyl t-butyll-carboxycyclobutanephosphonate (201) was prepared 
as described above (970 mg, 42 %). t).max/cm-1 (neat) 2981, 1724, 1285, 1055; BH 
(250 MHz; CDCh) 1.32 (t, 6H, J 7.8, OCH2CH3), 1.48 (9H, s, C(CH3h), 2.00 (2H, 
m, C(3)-H), 2.62 (4H, m, (C(2)-H & C4-(H2)), 4.16 (4H, m, OCH2CH3); oc (63 
MHz; CDCh) 16.27 (d,3JCp 6, OCH2CH3), 17.14 (d,3JCp 14.3, C-3), 27.5 (d, 3Jcp 
1.7, C(2) & C-4), 27.92 (OC(CH3h), 46.27 (d, JcP 137, C-l), 62.55 (d, 2Jcp 16.5, 
OCH2CH3), 81.24 (OC(CH3h), 171.01 (C=O); op (101 MHz; CDCh) 25.2; (NH3 
CI) m/z 293 ([M+H]+, 30 %), 254 (50),237 (100). 
6.3.4. Diethyl t-ButyI1-Carboxycyc1opentanephosphonate (202) 
o 
\I 
~P(OEt)2 
U "C0 2t-Bu 
(202) 
Diethyl t-butyl l-carboxycyclopentanecphosphonate (202) was 
prepared as described above (1.57g, 65%). t).max/ cm-1 (neat) 2980, 2940, 1724, 
1455, 1254, 1220, 1029; OH (250 MHz; CDCh) 1.23 (6H, t, J 7.1, OCH2CH3), 1.37 
(9H, s, C( CH3)3), 1.55-1.75 (4H, br m, (C(3)-H & C(4)-H), 1.82-2.11 (2H, br m, 
(C(5)-H' & C(2)-H'), 2.21-2.39 (2H, br m, (C(5)-H' & C(2)-H'), 4.06 (4H, quint, J 
7.1, OCH2CH3); oc (63 MHz; CDCI3) 16.24 (d, 3JCp 7, OCH2CH3), 25.03 (d, 3Jcp 
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11.8, C-3 & C-4), 27.84 (OC(CH3h), 32.37 (C-2 & C-(5)), 53.83 (d, JcP 135.2, C-1), 
62.25 (d, 2JCp 16.9, OCH2CH3), 80.96 (OC(CH3h), 170.79 (C=O); op (101 MHz; 
CDCI3) 28.0; (NH3 CI) m/z 307 ([M+H]+, 40 %),268 (30),251 (100),206 (10). 
6.3.5. Diethyl t-ButyI1-Carboxycyclohexanephosphonate (203) 
o 
II r'I< P(OEt) 2 
V 002t-Bu 
(203) 
Diethyl t-butyl 1-carboxycyclohexanecphosphonate (203) was 
prepared as described above (1.72g, 43 %). t1max / cm-1 (neat) 2990,2940, 1730, 
1455, 1250, 1210, 1060; DB (250 MHz; CDCb) 1.23 (6H, t, J 7.1, OCH2CH3), 1.37 
(9H, s, C(CH3)3), 1.37-1.52 (2H, broad m, C(2)-H' & C(6)-H'), 2.02-1.61 (6H, 
broad m, C(2)-H', C(6)-H', C(3)-H & C(5)-H), 2.30-2.21 (2H, broad m, C(4)-H), 
4.16 (4H, quint, J 7.1, OCH2CH3); DC (63 MHz; CDCb) 16.22 (d, 3JCp 4,6, 
OCH2CH3), 22.36 (d, 3JCp 11.8, C-3 & C-5), 25.15 (C-4), 27.66 (C(CH3h), 29.49 
(d, 2JCp 4.5, C(2) & C-6), 56.78 (d, JcP 148.1, C-1), 62.23 (d, 2Jcp 6.9, OCH2CIfJ), 
80.86 (OC(CH3h), 170.72 (C=O); op (101 MHz; CDCI3) 28.7; (NH3 CI) m/z 332 
([M+H] +,45 0/0),293 (25),277 (100), 232 (15). 
6.3.6. General Procedure for the Preparation of 1-Carboxycycloalkane-1-
phosphonic Acids (207-209) 
The diethyl t-butyl 1-carboxycycloalkanephosphonate (201-203) (500 
mg, 1.7 mmol) was treated with an ice cold solution of trifluoroacetic acid 
(3 cm3) for 1 h. The acid was removed in vacuo. Residual traces of acid were 
removed by the repeated addition and evaporation of water (3 x 3 cm3). The 
crude residue was taken up in dichloromethane (4 cm3) and treated with 
bromotrimethylsilane (2.2 cm3, 17 mmol) for 48 h, lyophillised, shaken with 
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water and lyophillised again to yield the desired compounds (207-209), which 
was converted to the dicyc10hexylamine salts without further purification 
6.3.7. 1-Carboxycyclobutanephosphonic Acid (207) 
(207) 
1-Carboxycyclobutanephosphonic acid (207) was prepared as 
described above (260 mg, 85 %). OH (250 MHz; D20) 2.06-1.95 (2H, m, C(3)-H), 
2.63-2.54 (4H, m, C(2)-H & C(4)-H); oc (63 MHz; D20) 17.14 (d, 3fcp 14.3, C-3), 
27.5 (C-2 & C-4), 46.2 (d, fcp 137, C-1), 174 (C=O); op (162 MHz; D20 ) 25.1; 
(NH3 CI) m/z 181 ([M+H]+, 35 %) 137 (100), 119 (32), 101 (13). 
6.3.8. Dicyclohexylammmonium 1-Carboxycyclobutanephosphonic Acid 
(210) 
1-Carboxycyclobutanephosphonic acid (207) (200 mg, 1.1 mmol) was 
treated with ethanol (4 cm3) and dicyclohexylamine (283 mg, 1.1 mmol) to 
yield the crude title compound which was recrystalised from 
methanol/ diethyl ether to gIve dicyclohexylammonium 
1-carboxycyc1obutanephosphonic acid (210) as a white crystalline solid (318 
mg, 80 %). m.p. 230-233°C (Found C, 56.49; H, 8.85; N, 3.76; C17H32NOsP 
requires C, 56.47; H, 8.93; N, 3.88%). 
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6.3.9. 1-Carboxycyclopentanephosphonic Acid (208) 
(208) 
1-Carboxycyc1opentanephosphonic acid (208) was prepared as 
described above (250 mg, 81 %). OR (250 MHz; D20) 1.52-1.75 (4H, m, C(3)-H2 
& C(4)-H2), 1.82-2.15 (2H, m, (C(2)-H & C(5)-H), 2.24-2.31 (2H, m, (C(2)-H' & 
C(5)-H'); Oc (63 MHz; D20) 25.03 (d, 3Jcp 11.8, C(3) & C-4), 32.55 (C-2 & C-5), 
53.91 (d, JcP 132.8, C-1), 172.91 (C=O); op (162 MHz; D20) 25.0; (NH3 CI) m/z 
195 ([M+H] +,55 0/0), 151 (100) 133 (14), 115 (16),87 (31). 
6.3.10. Dicyclohexylammonium 1-Carboxycyclopentanephosphonic Acid 
(211) 
1-Carboxycyc1opentanephosphonic acid (208) (200 mg, 1.0 mmol) was 
treated with ethanol (4 cm3) and dicyclohexylamine (181 mg, 1.0 mmol). The 
crude compound was recrystallised from methanol/ diethylether to yield the 
desired compound (211) as a white crystalline solid (326 mg, 87%). m.p. 224-
226°C (Found C, 57.74; H, 9.30; N, 3.84; C1SH34NOSP requires C, 57.56; H, 
9.23; N, 3.73 0/0). 
6.3.11. 1-Carboxycyclohexanephosphonic Acid (209) 
(209) 
1-Carboxycyclohexanephosphonic acid (209) was prepared as 
described above (260 mg, 80 0/0). OR (250 MHz; D20) 1.24-1.40 (2H, m, C(2)-H' 
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& C(6)-H'), 1.64-1.87 (6H, m, C(2)-H', C(6)-H', C(3)-H, C(5)-H), 2.36-2.51 (2H, 
m, C(4)-H); oc (63 MHz; D20 ) 24.21 (d, 3JCp 12.6, C(3) & C-5), 26.86 (C-4), 31.58 
(d,2JCp 4.7, C(2) & C-6), 51.11 (d, JcP 127.2, C-1); op (162 MHz; D20 ) 25.1; 
(NH3 CI) m/z 209 ([M+1]+, 45 %), 161 (100) 143(14), 133 (10),. 
6.3.12. Dicyclohexylammonium l-Carboxycyc1ohexanephosphonic Acid 
(212) 
1-Carboxycyclohexanephosphonic acid (209) (200 mg, 0.96 mmol) was 
treated with ethanol (4 cm3) and dicyclohexylamine (174 mg, 0.96 mmol). The 
crude compound was recrystalised from methanol/ diethylether to yield the 
desired compound (212) as a white crystalline solid (336 mg, 90%). m.p. 250-
254°C (Found C, 58.69; H, 9.51; N, 3.69; C19H36NOSP (389.26) requires C, 
58.57; H, 9.32; N, 3.60%). 
6.3.13. General Procedure for Preparation of Tetraalkyll,l-cyc1oalkane-
bisphosphonates (214-216) 
A suspension of benzyltributylammonium chloride (1.78 g, 4.95 mmol) 
in 50 % aqueous NaOH (15 cm3) was treated with a solution of the 
tetraalklmethylenebisphosphonate (1.15 g, 4.95 mmol) in the appropriate 
1,ro-dibromoalkane (10 cm3). The reaction mixture was stirred at room 
temperature for 48 h, poured into dichloromethane (150 cm3), washed with 
water (7 x 100 cm3) and brine (2 x 100 cm3), dried over MgS04, filtered and the 
solvent removed under reduced pressure. TIc (petroleum ether:ethanol,93:7) 
indicated the presence of two products which were separated on silica gel by 
flash chromatography (petroleum ether:ethanol, 93:7) to yield the desired 
compound (214-216). 
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6.3.14. TetraethyI1,1-Cyclobutanebisphosphonate (214) 
o 
II 0< P(OEI) 2 
P(OEt)2 
II 
(214) o 
Tetraethyl 1,1-cyclobutanebisphosphonate (214) was prepared as 
described above (480 mg, 37 %). i}max/cm-1 (neat) 2984,2908,1647, 1369, 1249, 
1060; OH (250 MHz; CDCh) 1.23 (12H, t, J 7.3, OCH2CH3), 2.08 (2H, m, C(3)-H), 
2.50 (4H, m, C(2)-H & C(4)-H), 4.12 (8H, m, OCH2CH3); Oc (63 MHz; CDCh) 
16.13 (OCH2CH3), 17.46 (t, 3J CP 6.0, C-3), 24.95 (t, 2J CP 6.1, C(2) & C-4), 37.7 (t, 
JcP 140.7, C-1), 62.3 (OCH2CH3); op (162 MHz; CDCI3) 26.9; (EI) m/z 328 (M+, 
10%), 191 (100), 163 (20), 135 (30). 
6.3.15. Tetraethyl Diprop-2-enemethanebisphosphonate (219) 
(219) 
o 
II 
P(OEt)2 
P(OEt)2 
II 
o 
A by-product from the above reaction was identified as tetraethyl 
diprop-2-enemethanebisphosphonate (219) (125 mg, 10 %). i}max/ cm-1 (neat) 
4342, 3078, 2982, 2910, 1639, 1479, 1443, 1417, 1392, 1369, 1240; 0H (250 MHz; 
CDCI3) 1.23 (12H, m, OCH2CH3), 2.4-2.6 (4H, m, C(2)-H & C'(2)-H), 4.1 (8H, m 
OCH2CH3), 5.0 (4H, m, C(4)-H & C'(4)-H), 5.89 (2H, m, C(3)-H & C'(3)-H); oc 
(63 MHz; CDCI3) 16.11 (OCH2CH3), 34.85 (t, 2Jcp 4.7, C-2 & C'-2), 44.9 (t, JcP 
130.8, C-1), 62.2 (OCH2CH3), 117.81 (C-4 & C'-4), 133.14 (t, 3Jcp 6.1, C-3 & C'-
3); op (162 MHz; CDCI3) 26.3; (NH3 CI) m/z 369 ([M+H]+, 100 %), 232 (10), 215 
(10), 183 (12). 
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6.3.16. Tetra-iso-propyl1,1-Cyc1opentanebisphosphonate (215) 
o 
\I 
~p(OlPr)2 
U "P(O IPr)2 
II 
o 
(215) 
Tetra-iso-propyl1,1-cyclopentanebisphosphonate (215) was prepared 
as described above (650 mg, 50 0/0). i}max/cm-1 (neat) 2979, 1469, 1455, 1385, 
1374, 1245, 1108, 990; OH (250 MHz; CDC13) 1.3 (12H, d, J 6.4, OCH(CH3h), 
1.47-1.55 (4H, m, C(3)-H & C(4)-H), 2.1 (4H, tt, J 20.3, 7.9, C(2)-H & C(5)-H), 
4.61 (4H, m, OCH(CH3h); Oc (63 MHz; CDC13) 23.64 & 24.03 (OCH(CH3h), 
26.68 (t, 3JCp 4.2, C-3 & C-4), 31.35 (t, 2Jcp 4.3, C(2) & C-5), 44.93 (t, JcP 127.5, C-
1), 70.5 (OCH(CH3h); op (101 MHz; CDC13) 27.2; (EI) m/z 398 (M+, 16 %), 357 
(15),315 (11),273 (22),233 (88),213 (60), 191 (33), 149 (100),67 (61), 43 (81). 
6.3.17. Tetra-iso-propyl1,1-Cyc1ohexanebisphosphonate (216) 
o 
II 
O P(OIPr)2 P(OlPr)2 II o 
(216) 
Tetra-iso-propyl1,l-cyclohexanebisphosphonate (216) was prepared as 
described above (520 mg, 40 0/0) and some unreacted starting material. 
t}max/ cm-1 (neat) 2940, 1450, 1250, 1060; OH (250 MHz; CDC13) 1.26 (12H, d, J 
6.4, OCH(CH3)3), 1.46 (2H, quint, J 6.1, C(4)-H), 1.72 (4H, quint, J 7.4, C(3)-H2 
& C(5)-H2), 2.14-1.91 (4H, m, C(2)-H & C(6)-H), 4.61 (4H, m, OCH(CH3h); Oc 
(60 MHz; CDC13) 23.91 (OCH(CH3h), 24.22 (OCH( CH3h), 21.37 (t, 3Jcp 6.5, C-3 
& C-5), 24.84 (C-4), 26.93 (2JCp 4.7, C(2) & C-6), 46.25 (t, J CP C-1), 70.71 
201 
(OCH(CH3)2); op (162 MHz; CDCI3) 28.1; (NH3 CI) m/z 409 ([M+H]+, 20 0/0), 
371 (24),329 (18),287 (17), 247 (78), 207 (82), 163 (100),67 (57),43 (72). 
6.3.18. General Procedure for the Preparation of Cyc1oalkane-1,1-
bisphosphonic acids (220-222) 
The tetraethyl cycloalkane-1,1-bisphosphonate (300 mg, 0.92 mmol) 
was treated with bromotrimethylsilane (1.2 cm3, 9.2 mmol) in CH2CI (4 cm3) 
under nitrogen for 48 h. The product was lyophilised, shaken with water (10 
on3) and lyophillised again to yield the desired compound (220-222) as a 
colourless oil, which were converted into the bisdicyclohexylamine salts 
without any further purification. 
6.3.19. Cyc1obutane-1,1-bisphosphonic Acid (220) 
o 
II 
O<P(OH)2 P(OH)2 
II 
o 
(220) 
Cyclobutane-1,l-bisphosphonic acid (220) was prepared as described 
above (180 mg, 910/0). OH (250 MHz; D20) 2.15 (4H, m, C(2)-H & C(4)-H), 2.45 
(2H, m, C(3)-H); Be (63 MHz; D20) 21.53 (t, 3Jcp 4.0, C-3), 26.92 (t, 2Jcp 3.1, C-2 
& C-4, 40.1 (t, JcP 131, C-1); op (162 MHz; D20) 26.2; (NH3 CI) m/z 317 
([M+H]+, 45), 299 (23),281 (14) 253, 188 (100). 
6.3.20. Bisdicyclohexylammonium Cyc1obutane-1,1-bisphosphonic Acid 
(223) 
Treatment of cyclobutane-1,1-bisphosphonic acid (220) (150 mg, 0.69 
mmol) with ethanol (4 cm3) and dicyclohexylamine (126 mg, 0.49 mmol) 
yielded the crude title compound which was recrystallised from 
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methanol/ diethyl ether to give dicyclohexylammonium cyclobutane-1,1-
bisphosphonic acid (223) as a white crystalline solid (251 mg, 91 %). m.p. 
242-245°C (Found C, 57.83; H, 9.70; N, 4.81; C16H33N06P2 requires C, 58.09; 
H, 9.76; N, 4.84%). 
6.3.21. Cyclopentane-1,1-bisphosphonic Acid (221) 
o 
1\ 
~P(OH)2 
U"P(OH)2 
II 
o 
(221) 
Cyclopentane-1,1-bisphosphonic acid (221) was prepared as described 
above (257 mg, 90%). OH (250 MHz; D20) 1.71 (4H, m, C(3)-H & C(4)-H), 2.08 
(4H, m, 6.8, 4H, C(2)-H, C(5)-H); Oc (63 MHz; D20) 29.9 (t, 3Jcp 13.7, C-3 & C-
4),33.9 (t, 2Jcp 2.8, C-2 & C-5), 47.1 (t, JcP 126.9, C-1); op (162 MHz; D20) 26.2; 
(NH3 CI) m/z 231 ([M+H]+, 60 %), 213, (14), 195 (15), 188 (100). 
6.3.22. Bisdicyclohexylammonium Cyclopentane-1,1-bisphosphonic Acid 
(224) 
Cyclopentane-1,1-bisphosphonic acid (221) (200 mg, 0.87 mmol) was 
treated with ethanol (5 cm3) and dicyclohexylamine (160 mg, 0.87 mmol). The 
crude compound was recrystalised from methanol/ diethyl ether to yield the 
title compound (224) as a white crystalline solid (320 mg, 90 %). m.p. 240-243 
°c (Found C, 58.76; H, 9.92; N, 4.58; C17H3SN06P2 requires C, 58.71; H, 9.87; 
N, 4.73 %). 
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6.3.23. Cyc1ohexane-l,l-bisphosphonic Acid (222) 
o 
II 
a
p(OH)2 
P(OH)2 
II 
o 
(222) 
Cyclohexane-1,1-bisphosphonic acid (222) was prepared as described 
above (228 mg, 85 %). OH (250 MHz; D20) 1.38-1.53 (2H, m, C(4)-H), 1.65 (4H, 
quint, J 6.1, C(3)-H & C(5)-H), 1.86-2.13 (4H, m, C(2)-H & C(6)-H); Oc (250 
MHz; D20 ) 22.93 (t, 3JCp 6.1, C-3 & C-5), 27.82 (t, 2JCp 3.4, C2- & C-6), 27.75 (C-
4),41.55 (t, JcP 116, C-1); op (162 MHz; D20) 26.2; «NH3) CI) m/z 245 ([M+H]+, 
65). 
6.3.24. Biscyc1ohexylammonium Cyclohexane-l,l-bisphosphonic Acid 
(225) 
Cyclohexane-1,1-bisphosphonic acid (222) (200 mg, 0.82 mmol) was 
treated with ethanol (5 cm3 ) and dicyclohexylamine (151 mg, 0.82 mmol). The 
crude compound was recrystallised from methanol/ diethyl ether to yield the 
title compound (225) as a white crystalline solid (315 mg, 90 %). m.p. 
214-216°C (Found C, 59.21; H, 9.84; N, 4.55; C30H6()N206P2 requires C, 59.37; 
H, 9.97; N, 4.6%). 
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6.4 Synthesis of a-Phosphoryl Sulfoxides and Related 
Compounds 
6.4.1. (-)-(R)-Diethyl Phosphoryimethyl p-ToIyI Sulfoxide (256) 
o 0 
II II ~S"'-../P,OEt I OEt H3C ~ 
(256) 
To a solution of diethyl methanephosphonate (2.5 g, 20 mmol) in 
anhydrous THF (50 cm3) at -78°C, under an atmosphere of nitrogen, was 
added a solution of n- butyl lithium (8.8 cm3, 22 mmol). The mixture was 
stirred at -78°C for 30 min. A solution of (-)-(1R,2S,5R)-menthyl-p-toluene 
sulfinate (4.3 g, 15 mmol) in anhydrous THF (10 cm3) was added. After stirring 
at -78°C for 30 min, the reaction mixture was warmed to -20 °C and quenched 
with saturated ammonium chloride solution. The organic solvent was 
removed under reduced pressure and the aqueous layer was washed with 
petroleum ether (2 x 20 cm3) to remove the menthyl. The aqueous layer was 
then extracted with dichloromethane (3 x 30 cm3). The combined organic 
layers were washed with brine (2 x 20 cm3), dried over anhydrous magnesium 
sulfate, filtered and the solvent removed under reduced pressure. Excess 
diethyl methanephosphonate was removed by Kugelrohr distillation (50°C, 
0.1 mmHg) to leave the desired product which was further purified by silica 
gel chromatography (petroleum ether I ethyl acetate 1:3) to afford the title 
compound (256) (3.66 g, 84 0/0). [a]D20 147° (c 1.1 in acetone) (lit.,192 148° c 1 in 
acetone), (Found C, 49.56; H, 6.48; C12H1904PS requires C, 49.62; H, 6.60 %); 
t}maxl cm-1 (neat) 2981, 1597, 1495, 1445, 1395, 1256, 1087, 1025; OH (250 MHz; 
CDCI3) 1.20 (6H, m, OCH2CH3), 2.29 (3H, s, CH~r), 3.17 & 3.29 (2H, JAB 14.35, 
JAX 15.50, AB of ABX system, CH2P), 4.04 (4H, m, OCH2CH3), 7.38 (4H, A2B2 
system, ArH); oe (63 MHz; CDCh) 16.13 '(OCH2CH3), 21.32 (CH~r), 53.66 (d, 
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JcP 138, Sa-I2P), 62.58 (OCH2CH3), 124.19, 129.8, (4C, Ar), 141.22 (lC, d, 3Jcp 
7, Ar), 142.19 (lC, Ar); op (101 MHz; CDCl3) 16.44; (EI) m/z 290 (M+, 48 0/0),262 
(10),234 (24), 139 (100), 105 (12),91 (21),65 (10). 
6.4.2. (-)-(R)-Di-iso-propyl Phosphorylmethyl p-Tolyl Sulfoxide (257) 
o 0 
II II 
S p.- O-lPr ~, 
O-lPr 
(257) 
To a solution of di-iso-propyl methanephosphonate (2.5 g, 20 mmol) in 
anhydrous THF (50 cm3) at -78°C, under an atmosphere of nitrogen, was 
added a solution of n- butyllithium (8.8 cm 3, 22 mmol). The mixture was 
stirred at -78°C for 30 min. A solution of (-)-(lR,2S,5R)-menthyl-
p-toluenesulfinate (4.3 g, 15 mmol) in anhydrous THF (10 cm3) was added. 
After stirring at -78°C for 30 min, the reaction mixture was warmed to -20 °C 
and quenched with saturated ammonium chloride solution. The organic 
solvent was removed under reduced pressure and the aqueous layer was 
washed with petroleum ether (2 x 20 cm3) to remove the menthyl. The 
aqueous layer was then extracted with dichloromethane (3 x 30 cm3). The 
combined organic layers were washed with brine (2 x 20 cm3), dried over 
magnesium sulfate, filtered and the solvent removed under reduced pressure. 
Excess di-iso-propyl methanephosphonate was removed by Kugelrohr 
distillation (55°C, 0.1 mmHg) to leave the desired product which was purified 
by silica gel chromatography (petroleum ether / ethyl acetate 1:3) to afford the 
title compound (256) (2.85 g, 60 0/0). [a]D20 152° (c 1.2 in acetone), (Found C, 
52.64; H, 7.14; C 1.¥12304PS requires C, 52.80; H, 7.29 0/0); t}max/ cm-1 (neat) 
2983, 1583, 1478, 1445, 1395, 1255, 1085, 1025; OH (250 MHz; CDCb) 1.28 (12H, 
m, OCH(CH3)2), 2.26 (3H, s, CH3Ar), 3.15 & 3.27 (2H, JAB 14.60, J AX 15.91, AB 
of ABX system, SCH2P), 4.76 (2H, m, OCH(CRJ)2), 7.30 (4H, A2B2 system, Ar); 
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DC (63 MHz; CDCh) 21.32 (CH 3Ar), 23.72 (OCH(CH3}z), 54.95 (d, JcP 139, 
SCH2P), 71.62 (d, OCH(CH3)2), 124.25, 129.83, (4C, Ar), 144.74 (lC, d, 3Jcp 7.8, 
Ar), 142.01 (lC, Ar), ; Dp (101 MHz; CDCh) 16.8; (EI) m/z 318 (M+,48 %), 276 
(30),220 (52), 139 (100), 105 (60),91 (34), 77 (50), 65 (40). 
6.4.3. (lR)-Diethyll-phosphorylethyl p-Tolyl (R)-Sulfoxide (265) 
o 0 
II II ~s p'-OEt I Y'OEt H3C ~ fv1e 
(265) 
To a solution of diethyl phosphorylmethyl p-tolyl sulfoxide (256) 
(200 mg, 0.69 mmol) in dry THF (10 cm3) at -78 °C under a nitrogen 
atmosphere, was added a n-butyllithium (0.29 cm3, 0.73 mmol). The reaction 
mixture was stirred for 15 min and then a solution of iodomethane (200 mg, 
1.39 mmol) in THF (1 cm3) was added. The reaction mixture was warmed to 
room temperature and quenched with aqueous ammonium chloride solution 
(10 cm3). The THF was removed under reduced pressure and the aqueous 
solution extracted with dichloromethane (3 x 10 cm3). The organic extracts 
were washed with water (2 x 10 cm3) and brine (2 x 10 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent removed in vacuo to 
afford the crude product consisting of a mixture of the diastereoisomers in a 
ratio of 2.7:1 (as determined by 31P nmr spectroscopy). Purification by silica 
gel chromatography (dichloromethane/methanol 4:1) yielded the major 
diastereoisomer (265) (140 mg, 66 0/0) [a]D20 1540 (c 1.6 in acetone), OH (250 
MHz; CDCI3) 1.21 (6H, m, OCH2CH3), 1.30 (3H, dd, J=7.0 15.0, CH3CHP), 2.21 
(3H, s, CH3Ar), 3.17 (lH, m, CH3CHP), 4.04 (4H, m, OCH2CH3), 7.38 (4H, A2B2 
system, ArH); DC (63 MHz; CDCI3) 6.00 (d, 2Jcp=3.9, SCH(CH3)P), 16.14 (d, 
3Jcp=5.9, OCH2CH3), 21.31 (CH3Ar), 44.07 (d, JCp=138, SCH(CH3)P), 62.73 (d, 
2Jcp=6.9 OCH2CH3), 124.14 (129.85, 4C, Ar), 141.22 (lC, d, 3!Cp=7, Ar), 142.17 
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(lC, Ar), ); op (162 MHz; CDCI3) 20.18; (EI) m/z 304 (M+, 41 %), 276 (11), 248 
(30), 139 (100), 105 (15),91 (20),65 (13). 
6.4.4. (-)-(S)-1,1-Diphenyll,2-Dihydroxypropane (259) 
H Ph 
Me)---fPh 
HO a-t 
(259) 
Magnesium turnings (75.36 g, 3 mol) and four crystals of iodine in 
anhydrous THF (400 cm3) were placed in a dry 2 dm3, 3-necked round bottom 
flask equipped with an overhead stirrer, condensor and pressure equalising 
dropping funnel, under a positive pressure of nitrogen. Bromobenzene 
(16 cm3) was added to start the reaction, the remaining bromobenzene 
(300 cm3) in anhydrous THF (400 cm3)was added to the reaction mixture via 
the dropping funnel over a period of 90 min, allowing the reaction mixture to 
reflux gently. After the addition of the bromobenzene was complete the 
reaction mixture was heated to reflux for 3 h. After cooling to -5°C, (S)-ethyl 
lactate was added keeping the temperature below 0 °C. The reaction mixture 
was allowed to warm to room temperature and stirred overnight. The reaction 
was quenched by pouring the mixture in to a slush of ice and concentrated 
ammonium chloride solution (1 dm3) and neutralising with 6 M hydrochloric 
acid solution. The mixture was then extracted with diethyl ether (4 x 250 cm3), 
the combined etheral extracts were washed with water (4 x 200 cm3) and brine 
(2 x 100 cm3), dried over anhydrous magnesium sulfate and the solvent 
removed in vacuo. The crude product was recrystallised from cyclohexane to 
yield the title diol (259) (178 g, 78 0/0). m.p. 92-94 °C (lit.,194 94°C) [a]D20 -99.9° 
(c 1.8 in methanol) (lit.,194 [a]D20 -100°, c 1.8 in methanol), OH (250 MHz; 
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COC13) 1.12 (3H, d, J 6.4, CHCH3), 4.84 (lH, q, J 6.4, CHCH3), 7.1-7.8 (10H, m, 
Ar); (EI) m/z 228 (M+, 100 0/0),210 (32), 182 (65),91 (43),77 (56),65 (34). 
6.4.5. (-)-(2R,5S )-trans-4,4-Di p henyl-5-methyl-l,3 ,2-dioxathiolane 2 -Oxide 
(260) 
Ij Ph 
MeY-fPh 
0, /0 
jS.,;> 
ef 0 
(260) 
Triethylamine (30.5 cm3, 0.22 mol) in dichloromethane (300 cm3) was 
added dropwise to a solution of the (S)-diol (259) (25 g, 0.11 mol) and thionyl 
chloride (12 cm3, 0.16 mol) in dichloromethane (200 cm3) at -40°C. Once the 
addition was complete a white precipitate appeared and the flask was warmed 
to 0 °C. The reaction was quenched by the addition of water (300 cm3). The 
product was recovered by extraction with dichloromethane (2 x 100 cm3). The 
combined organic extracts were washed with water (2 x 100 cm3), 
concentrated sodium bicarbonate solution (4 x 75 cm3) and brine (2 x 100 cm3), 
dried over anhydrous magnesium sulfate and the solvent removed in vacuo. 
The crude product was recrystallised from cyclohexane/hexane (1:1) to afford 
the desired compound (17 g, 56 0/0). m.p. 110-111 °C (lit.,193 109-111 °C) [a]D20 
-245.1 ° (c 1.1 in CHCh) (lit.,193 [a]D20 -246° c 1.1 in CHCh), (Found C, 65.75; H, 
5.09; ClSH1403S requires C, 65.65; H, 5.15 0/0); OH (250 MHz; CDCh) 1.30 (3H, 
d, J 6.4, CHCH3), 5.71 (lH, q, J 6.4, CHCH3), 7.00 (, 2Hm, Ar), 7.31-7.52 (8H, m, 
Ar); oe (63 MHz; CDCI3) 16.51 (CH3), 80.37 (CHCH3), 95.83 (C(Phh), 126.7, 
127.4, 128.01, 128.3, 128.6, 138.2, 140.3 (12C, Ar); (NH3 CI) m/z 292 ([M+NH41+, 
60 0/0),274 (M+, 5 ), 228 (82),211 (100), 195 (45), 183 (73), 165 (48), 105 (87) 
209 
6.4.6. (-)-(lR,S S)-2,2-Diphenyl-l,2-dihydroxy-propyl 2-0-t-Butylsulfinate 
(262) 
H Ph 
Me~Ph 
o a; 
'8,- t-8u 
O~ "" " . • 
(262) 
A solution of t-butyl magnesium chloride (36.5 cm3, 1 Min THF) was 
added dropwise to a solution of the dioxathiolane (260) (10 g, 36.5 mmol) in 
anhydrous THF (100 cm3) at -78°C under an atmosphere of nitrogen. The 
reaction was followed by tIc (cyclohexane/ethyl acetate 5:1). When conversion 
was complete, the solution was quenched with saturated ammonium chloride 
solution, extracted with dichloromethane (2 x 50 cm3), washed with water (2 x 
40 cm3) and brine (2 x 40 cm3), dried over anhydrous magnesium sulfate and 
the solvent removed under reduced pressure. The crude product was 
recrystallised from cyclohexane to afford the title compound (262) (8.5 g, 70 
%). m.p. 137-138 °C (lit.,193 135-137 °C), [a]D20 -121.8° (c 0.7 in CHCh) (lit.,193 
[a]D20 -120° c 1.1 in CHCh), (Found C, 68.72; H, 7.31; C19H2403S requires C, 
68.64; H, 7.21 0/0); OH (250 MHz; CDCI3) 0.92 (9H, s, C( CH3h), 1.39 (3H, d, J 6.4, 
CHCH3), 3.00 (lH, s, OH), 5.36 (lH, q, J 6.4, CHCH3), 7.15-7.65 (10H, m, ArH); 
oe (63 MHz; CDCh) 16.24 (CHCH3), 21.47 (CH(CH3h), 57.71 (CH(CH3h), 79.63 
(CHCH3), 82.43 (C(Phh), 125.51, 126.02, 126.93, 127.00, 128.1, 128.2, 143.1, 145.1 
(12C, Ar); (NH3 CI) m/z 250 ([M+NR4]+, 48 0/0), 233 ([M+H]+, 32 0/0), 276 (24), 
228 (44), 165 (48), 105 (87). 
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6.4.7. (+)-(S)-Diethyl Phoshorylmethyl t-Butyl Sulfoxide (263) 
o 0 
II "_ OEt \\"'S~p, 
t-Bu OEt 
(263) 
n-Butyllithium (1.23 cm3, 3.08 mmol) was added to a solution of the 
sulfinate (262) (1.02 g, 3.08 mmol) in anhydrous THF (50 cm3) at -78°C under 
an atmosphere of nitrogen. To this solution, via a transfer needle, was added a 
solution of a-lithio diethyl methanephosphonate which had been prepared by 
the addition of n-butyllithium (3.1 cm3, 7.7 mmol) to diethyl 
methanephosphonate (1.17 g, 7.7 mmol) in anhydrous THF (20 cm3) at -78°C. 
The reaction mixture was stirred at -78 °C for 2 h, warmed to room 
temperature and quenched with saturated ammonium chloride solution (20 
an3). The THF was removed under reduced pressure and the aqueous 
solution extracted with petroleum ether (2 x 15 cm3) to remove the diol. The 
crude product was isolated by extraction of the aqueous layer with 
dichloromethane (4 x 20 cm3). The dichloromethane extracts were washed 
with water (2 x 15 cm3) and brine (2 x 15 cm3), dried over anhydrous 
magnesium sulfate and the solvent removed in vacuo. Excess diethyl 
methanephosphonate was removed by Kugelrohr distillation. Purification 
using silica gel chromatography (ethyl acetate) afforded the title compound 
(482 mg, 61 0/0). [a]D20 -73° (c 1.2 in acetone), (Found C, 42.25; H, 8.41; 
C9H2104PS requires C, 42.16; H, 8.26 0/0); -a-maxl cm-1 (neat) 2984,2973,2887, 
2858, 1495, 1445, 1392, 1255, 1027; OH (250 MHz; CDCI3) 0.98 (9H, s, 
CH(CHY3), 1.04 (6H, t, J 7.8, OCH2CH3), 2.36 & 2.73 (2H, JAB 14.81, J AX 18.00, 
AB of ABX system, SCH2P), 3.89 (4H, m, OCH2CH3); Oc (63 MHz; CDCI3) 
16.41 (d,3Jcp=4.8, OCH2CH3), 23.54 (C(CH3h), 43.22 (d, JcP 144, SCH2P),54.36 
(d, 3Jcp 7, C(CH3)3), 62.4 (d, 2Jcp=5.9, OCH2CH3); Op (101 MHz; CDCI3) 18.2; 
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(NH3 CI) m/z 257 ([M+H]+, 75 %),229 (40),201 (42), 183 (31), 144 (10), 108 (13), 
58 (60),41 (100). 
6.4.8. (+)-(S)-Di-iso-propyl Phoshorylmethyl t-Butyl Sulfoxide (264) 
o 0 
II 11_ Oi-Pr 
\\". S"-./ P, 
t-Bu Oi-Pr 
(264) 
n-Butyllithium (2.5 cm3, 5 mmol) was added to a solution of the 
sulfinate (262) (1.66 g, 5 mmol) in anhydrous THF (70 cm3) at -78°C under an 
atmosphere of nitrogen. To this solution, via a transfer needle, was added a 
solution of a-lithio di-iso-propyl methanephosphonate which had been 
prepared by the addition of n-butyllithium (5.0 cm3, 10 mmol) to di-iso-propyl 
methanephosphonate (1.8 g, 10 mmol) in anhydrous THF (20 cm3) at -78°C. 
The reaction mixture was stirred stirred at -78 °C for 2 h, warmed to room 
temperature and quenched with saturated ammonium chloride solution (20 
cm3). The THF was removed under reduced pressure and the aqueous 
solution extracted with petroleum ether (2 x 20 cm3) to remove the diol. The 
crude product was isolated by extraction of the aqueous layer with 
dichloromethane (4 x 25 cm3). The dichloromethane extracts were washed 
with water (2 x 20 cm3) and brine (2 x 20 cm3), dried over anhydrous 
magnesium sulfate and the solvent removed in vacuo. Excess di-iso-propyl 
methanephosphonate was removed by Kugelrohr distillation. Purification 
using silica gel chromatography (ethyl acetate) afforded the title compound 
(264) as a colourless oil (924 mg, 66 %). [a]D20 81.8° (c 1 in acetone), (Found C, 
46.52; H, 8.99; C UH2S04PS requires C, 46.44; H, 8.87 %); t}max/ cm-1 (neat) 
2982, 2972,2889,2855, 1495, 1443, 1392, 1256, 1028; OH (250 MHz; CDCh) 0.98 
(9H, s, C(CH3)3), 1.08 & 1.10 (12H, d, J 6.1 & 6.1, CH(CH3h), 2.39 & 2.71 (2H, 
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lAB 14.83, lAX 18.00, AB of ABX system, SCH2P), 3.89 (2H, m, OCH(CH3)); Be 
(63 MHz; CDCI3) 23.67 (C(CH 3h), 24.71 (OCH(CH3h), 43.44 (d, lcp 144, 
SCH2P), 54.42 (d, 3lcp 7, C(CH3h), 71.44 (OCH(CH3)2); op (101 MHz; CDCh) 
18.34; (NH3 CI) m/z 285 ([M+H]+, 80 0/0), 269 (40),229 (33), 181 (15), 163 (19), 
108 (11),58 (66),41 (100). 
6.4.9. General Procedure for the Synthesis of Diethyl 
l-Phosphory1cyc1oalkane Phenyl Sulfides 
A solution of freshly prepared LDA (3.84 mmol) in anhydrous THF (10 
an3) was added to a solution of diethyl phosphorylmethyl phenyl sulfide (1 g, 
3.84 mmol) in anhydrous THF (20 cm3) at -78°C under an atmosphere of 
nitrogen. The reaction mixture was stirred for 1 h and then the appropriate 
1,ro-dibromoalkane (3.84 mmol) in anhydrous THF (2 cm3) was added. The 
reaction mixture was allowed to warm to room temperature over a period of 1 
h, at which time the reaction mixture was re-cooled to -78°C and a second 
equivalent of LDA (3.84 mmol) in anhydrous THF (10 cm3) was added. The 
reaction mixture was stirred at -78°C for 1 h, then warmed to room 
temperature and quenched with a saturated solution of ammonium chloride 
(20 cm3). The THF was removed under reduced pressure and the aqueous 
solution extracted with dichloromethane (3 x 20 cm3), the organic extracts 
were washed with water (2 x 15 cm3) and brine (2 x 15 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent removed in vacuo. The 
crude product was purified by Kugelrohr distillation (160-170 °C, 0.1 mmHg) 
to afford the desired compounds. 
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6.4.10. Diethyl1-Phosphorylcyc1obutane Phenyl Sulfide (121) 
(121) 
Diethyl1-phosphorylcyclobutane phenyl sulfide (121) was prepared as 
described above (710 mg, 62 0/0). ()H (250 MHz; CDC13) 1.15 (6H, t, J 7, 
OCH2CH3), 1.91-2.15 (4H, br. m, C(2)-H & C(4)-H), 2.48-2.65 (2H, br. m, C(3)-
H), 3.90 (4H, m, OCH2CH3), 7.13 (3H, m, ArH), 7.51 (m, 2H, ArH); ()c (63 MHz; 
COC13) 16.15 (d, 3Jcp 5.8, OCH2CH3), 16.59 (d, 3Jcp 10.2, C-3), 30.10 (d, 2Jcp 
"-
loS, C(2) & C-4), 44.85 (d, JcP 151.4, C-1), 62.23, (d, J=5.4, OCH2CH3),127.92, 
128.22, 128.67, 134.62 (6C, Ar); ()P (162 MHz; CDCh) 19.5; (EI) m/z 300 (M+, 32 
%),272 (24),228 (35), 109 (100), 77 (67). 
6.4.11. Diethyl1-Phosphorylcyc1opentane Phenyl Sulfide (266) 
o 
II 
~P(OEt)2 
U"SPh 
(266) 
Diethyl 1-phosphorylcyclopentane phenyl sulfide (266) was prepared 
as described above (688 mg, 57 0/0). ()H (250 MHz; CDC13) 1.15 (6H, t, J 7, 
OCH2CH3), 1.64-2.13 (8H, br. m, C(2)-H, C(3)-H, C(4)-H & C(5)-H), 4.04 (4H, 
m, OCH 2CH3), 7.18 (3H, m, ArH), 7.62 (2H, m, ArH); ()c (63 MHz; CDC13) 
16.13 (d, 3JCp 5.8, OCH2CH3), 23.12 (d, 3JCp 9.9, C-3 & C-4), 35.61 (d, 2JCp 1.8, 
C-2 & C-5), 49.45 (d, JcP 151.4, C-1), 62.32 (d, 2Jcp=5.9, OCH2CH3), 127.94, 
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128.32, 128.64, 134.61 (6C, Ar); op (162 MHz; CDCh) 19.34; (EI) m/z 314 (M+, 
39),286 (35),242 (31), 109 (100), 77 (59). 
6.4.12. Diethyll-Phosphorylcyclohexane Phenyl Sulfide (267) 
o 
II 
rl<P(OEt)2 
V SPh 
(267) 
Diethyl 1-phosphorylcyclohexane phenyl sulfide (267) was prepared 
as described above (667 mg, 53 %). OH (250 MHz; CDCb) 1.09 (6H, t, J 7, 
OCH2CH3), 1.0-1.85 (10H, br. m, C(2)-H, C(3)-H, C(4)-H, C(5)-H & C(6)-H2), 
3.94 (4H, m, OCH2CH3), 7.12 (3H, m, Ar), 7.71 (2H, m, Ar); Bc (63 MHz; 
CDC13) 16.17 (d, 3JCp 5.8, OCH2CH3), 21.09 (d, 3Jcp 10.7, C-3 & C-5), 32.32 (d, 
2JCp 4.3, C-2 & C-6), 58.81 (d, JcP 148.4, C-1), 62.28 (d, 2Jcp=5.9, OCH2CH3), 
127.91, 128.35, 128.63, 134.65 (6C, Ar); Op (101 MHz; CDC13) 19.28; (EI) m/z 328 
(M+, 41 0/0),298 (31),256 (33), 109 (100), 77 (43). 
6.4.13. (+)-(S)-Methyl Tolyl Sulfoxide (268) 
(268) 
To a solution of (-)-(lR,2S ,5R)-menthyl-p-toluenesulfinate (4 g, 13.4 
rnmol) in anhydrous THF (60 cm3) at -78°C under an atmosphere of nitrogen, 
was added a solution of methylmagnesium bromide (6.71 cm3, 3M in Et20). 
The reaction mixture was stirred for 1 h, warmed to 0 °C and quenched with 
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saturated solution of ammonium chloride solution (15 cm3). The product was 
isolated by extraction into ether (2 x 30 cm3). The combined organic layers 
were washed with water (2 x 20 cm3) and brine (2 x 20 cm3), dried over 
anhydrous magnesium sulfate, filtered and the solvent removed in vacuo. The 
crude product was purified by silica gel chromatography (ethyl acetate) 
affording the title compound (268) (1.6 g, 77 %). [a]D20 +181° (c 1.2 in CHCh), 
OH (250 MHz; CDCI3) 2.40 (3H, s, ArCH3), 2.69 (3H, s, S(O)CH3), 7.30 (2H, d, J 
8.4, Ar), 7.51 (2H, d, J 8.4, Ar); (EI) m/z 154 (M+, 58 %), 139 (100), 91 (60), 77 
(20), 65 (28). 
6.4.14. (+)-(R)-2,2-dimethyl-2-hydroxymethyl p-Tolyl Sulfoxide (269) 
W OH fYs~:: HC~ 3 (269) 
To a solution of (-)-(S)-methyl tolyl sulfoxide (268) (750 mg, 4.9 mmol) 
in anhydrous THF (20 cm3) at -78°C under an atmosphere of nitrogen, was 
added n-butyllithium (2.1 cm3, 5.3 mmol). The reaction mixture was stirred for 
30 min and anhydrous acetone (2 cm3) was added. The reaction mixture was 
warmed to 0 °C and quenched with a saturated solution of ammonium 
chloride (10 cm3). The THF was removed in vacuo and the aqueous solution 
extracted with dichloromethane (3 x 20 cm3). The combined organic layers 
were washed with water (2 x 15 cm3) and brine (2 x 15 cm3), dried over 
anhydrous magnesium sulfate and the solvent removed under reduced 
pressure. Recrystallisation of the crude compound from diethyl ether 
containing a few drops of ethanol yielded the desired compound (269) (852 
mg, 82 0/0). m.p. 92-94° [a]D20 +201 ° (c 2 in acetone), (Found C, 62.40; H, 7.60; 
CUH 160 2S requires C, 62.21; H, 7.60 0/0); OH (250 MHz; CDCh) 1.33 (3H, s, 
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C(OH) CH3), 1.54 (3H, s, C(OH) CH3), 2.67 & 2.96 (2H, d, JAB 13.4, AB system, 
S(O) CH2), 7.27 (2H, d, J 7.85, Ar), 7.48 (2H, d, J 7.85, Ar); Be (63 MHz; CDCh) 
21.31 (ArCH3), 28.90 (C(OH)CH3), 30.34 (C(OH)CH3), 68.44 (S(O) CH2), 70.54 
(C(OH)(CH3)2), 123.84, 130.02, 140.55, 141.71 (6C, Ar); (EI) m/z 212 (M+, 8 %), 
196 (16), 140 (100), 123 (22),91 (74), 77 (19). 
6.4.15. (+)-(R)-2,2-Dipheny1-2-hydroxymethy1 p-To1y1 Sulfoxide (270) 
~ Cl-i ~~ S~Ph Ph H3C ~ (270) 
To a solution of (-)-(S)-methyl tolyl sulfoxide (268) (750 mg, 4.9 mmol) 
in anhydrous THF (20 cm3) at -78°C under an atmosphere of nitrogen, was 
added n-butyllithium (2.1 cm3, 5.3 mmol). The reaction mixture was stirred for 
30 min and benzophenone (885 mg, 4.86 mmol) was added. The reaction 
mixture was warmed to 0 °C and quenched with a saturated solution of 
ammonium chloride (10 cm3). The THF was removed in vacuo and the aqueous 
solution extracted with dichloromethane (3 x 20 cm3). The combined organic 
layers were washed with water (2 x 15 cm3) and brine (2 x 15 cm3), dried over 
anhydrous magnesium sulfate and the solvent removed under reduced 
pressure. The crude compound was purified using silica gel chromatography 
(petroleum ether/ethyl acetate 7:3) and recrystallised from diethyl ether to 
yield the desired compound (270) (1.23 g, 73 0/0). m.p. 141-143 °C [a]D20 184.3° 
(c 2 in acetone), (Found C, 74.75; H, 6.04; C21H2002S requires C, 74.95; H, 5.99 
%); BH (250 MHz; CDCI3) 2.42 (3H, ArGI3), 3.55 & 3.64 (2H, JAB 13.74, AB 
system, S(O)CH2), 5.91 (lH, OH), 7.23-7.71 (14H, br. m, ArH); Be (63 MHz; 
CDCb) 21.41 (ArCH3), 66.41 (S(O)CH2), 78.29 (C(OH)(Phh), 123.99, 125.53, 
126.57, 127.38, 127.55, 128.24, 128.48, 130.15, 140.31, 142.20, 144.08, 145.90 (18C, 
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Ar); (EI) m/z 336 (M+, 10 %), 2S8 (24), 140 (100), 123 (28), lOS (lS), 91 (80), 77 
(22), 6S (30). 
6.4.16. General Procedure for Diethylzinc Reactions 
A solution of the appropriate catalyst (10 mol %) in hexane (2 cm3) 
was added to a solution of benzaldehyde (1 g, 9.4 mmol) in hexane (8 cm3) and 
the solution was cooled to -S °C. Diethylzinc (18.9 mmol, 1 M solution in 
hexane) was added slowly to the reaction mixture. After completing this 
addition, the reaction mixture was allowed to slowly warm to room 
temperature. Samples of the reaction mixture were analysed by IH nmr 
spectroscopy until the signal due to the aldehydic proton was absent, 
indicating quantitative reaction, at which time ethanol (S cm3) was added to 
the reaction mixture and the organic solvent was removed under reduced 
pressure. The residue was dissolved in dilute hydrochloric acid (1 M, 20 cm3) 
and extracted with diethyl ether (3 x 40 cm3). The ethereal extracts were 
washed with dilute hydrochloric acid (2 x 20 cm3) and brine (2 x 20 cm3), dried 
over anhydrous magnesium sulfate and evaporated to dryness under reduced 
pressure. The crude product was purified by Kugelrohr distillation (100°C, 0.1 
mmHg) to afford pure 1-phenyl-1-propanol. The optical rotation of the alcohol 
was determined. bH (2S0 MHz; CDCb) LOS (3H, t, J 6.7, CH2CH3), 1.8S (2H, m, 
CHCH2CH3), 3.S2 (br. s, OH), 4.66 (lH, t, J 4.8, CH(OH)(CH2)), 7.52 (SH, s, 
ArH). 
6.4.17. General Procedure for Diethylzinc Reaction with Titanium Tetra-iso-
propoxide 
A solution of the appropriate catalyst (10 mol %) and titanium tetra-
iso-propoxide (3.96 g, 9 mmol) in hexane (S cm 3) was heated to reflux for 20 
min, cooled to -S °C and added to a solution of benzaldehyde (1 g, 9.4 mmol) 
in hexane (8 cm 3) at -S °C. Diethylzinc (18.9 mmol, 1 M solution in hexane) 
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was added slowly to the reaction mixture, after completing this addition the 
reaction mixture was slowly allowed to warm to room temperature. Samples 
of the reaction mixture were analysed by 1 H nmr spectroscopy until the signal 
due to the aldehydic proton was absent, indicating quantitative reaction. At 
which time ethanol (5 cm3) was added to the reaction mixture and the organic 
solvent removed under reduced pressure. The residue was dissolved in dilute 
hydrochloric acid (1 M, 20 cm 3) and extracted with diethyl ether (3 x 40 cm 3). 
The ethereal extracts were washed with dilute hydrochloric acid (2 x 20 cm 3) 
and brine (2 x 20 cm3), dried over anhydrous magnesium sulfate and 
evaporated to dryness under reduced pressure. The crude product was 
purified by Kugelrohr distillation (100 °e, 0.1 mmHg) to afford pure 1-phenyl-
1-propanol. The optical rotation of the alcohol was determined. 
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Appendix 1 
Table 1. Crystal Data and Structure Refinement for Z-Diethyl 
3-(Phenylacetoxy)-3-cyanocyc1obutanephosphonate 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
z 
Density ( calcula ted) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Absorption correction 
Refinement method 
Data/ restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
Largest diff. peak and hole 
230 
C17H22NOsP 
351.33 
220(2) K 
0.71073A 
Orthorhombic 
Pbca 
a = 9.991(5)A
o 
b = 12.885(8)A 
c = 28.39(2)A 
3655(4)A3 
8 
1.277 Mg/m3 
0.175 mm-1 
1488 
alpha = 90 deg. 
beta = 90 deg. 
gamma = 90 deg. 
0.49 x 0.34 x 0.29 mm 
2.49 to 22.54 deg. 
0<=h<=10, 0<=k<=13, -1<=1<=30 
3798 
2405 [R(int) = 0.0366] 
None 
Full-matrix least-squares on F2 
2400/8/217 
1.052 
Rl=0.0854, wR2=0.2242 
Rl=0.1471, wR2=0.2954 
0.481 and -0.750 e.A-3 
Table 2. Atomic coordinates (x 104) and equivalent isotropic 
displacement parameters (A2 x 103) for 1. U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
x y z U(eq) 
P(l) 1665(2) 2763(1) 3655(1) 47(1) 
0(1) 1073(5) 2402(4) 5609(2) 58(1) 
0(2) -309(4) 1795(3) 5050(2) 46(1) 
0(3) 3017(5) 3201(4) 3638(2) 63(2) 
0(4) 1599(5) 1556(3) 3740(2) 51(1) 
0(5) 914(5) 2974(4) 3181(2) 61(2) 
N(1) -1420(7) 4258(5) 5230(3) 74(2) 
C(1) 671(6) 3243(5) 4124(2) 43(2) 
C(2) 1249(6) 3056(6) 4625(2) 48(2) 
C(3) -163(7) 2775(5) 4799(3) 49(2) 
C(4) -630(6) 2666(5) 4284(2) 41(2) 
C(5) 2343(8) -252(5) 5946(3) 58(2) 
C(6) 3226(8) -512(6) 6302(4) 73(3) 
C(7) 3010(8) -174(7) 6754(3) 77(3) 
C(8) 1932(8) 457(7) 6849(3) 78(3) 
C(9) 1052(7) 734(6) 6497(3) 62(2) 
C(10) 1243(7) 375(5) 6040(2) 48(2) 
C(11) 242(8) 648(5) 5666(3) 55(2) 
C(12) 413(7) 1725(6) 5456(3) 45(2) 
C(13) -850(7) 3604(6) 5051(3) 50(2) 
C(14) 2669(10) 861(7) 3593(3) 72(2) 
C(15) 2457(13) 515(7) 3112(3) 100(4) 
C(16) -404(8) 2559(7) 3073(3) 73(3) 
C(17) -675(12) 2742(9) 2562(3) 111(4) 
231 
Table 3. Bond lengths [A] and angles [deg] for Diethyl 3-( 0-
Phenylacetoxy>-3-cyanocyclobutanephosphonate 
P(1)-O(3) 
P(1)-O(5) 
P(1)-O(4) 
P(l)-C(l) 
O(1)-C(12) 
O(2)-C(12) 
O(2)-C(3) 
O(4)-C(14) 
O(5)-C(16) 
N(1)-C(13) 
C(10)-C(5) 
C(10)-C(9) 
C(10)-C(11) 
C(5)-C(6) 
C(6)-C(7) 
C(7)-C(8) 
C(8)-C(9) 
C(11)-C(12) 
C(3)-C(13) 
C(3)-C(2) 
C(3)-C(4) 
C(4)-C(1) 
C(1)-C(2) 
C(14)-C(15) 
C(16)-C(17) 
O(3)-P(1)-O(5) 
O(3)-P(1)-O(4) 
O(5)-P(1)-O(4) 
O(3)-P(1)-C(1) 
O(5)-P(1)-C(1) 
O(4)-P(1)-C(1) 
C(12)-O(2)-C(3) 
C(14)-O(4)-P(1) 
C(16)-O(5)-P(1) 
C(5)-C(10)-C(9) 
C(5)-C(10)-C(11) 
C(9)-C(10)-C(11) 
C(6)-C(5)-C(10) 
C(7)-C(6)-C(5) 
C( 6)-C(7)-C(8) 
C(7)-C(8)-C(9) 
C(8)-C(9)-C(10) 
C(10)-C(11 )-C(12) 
O(1)-C(12)-O(2) 
O(1)-C(12)-C(11) 
232 
1.464(5) 
1.566(5) 
1.575(5) 
1.772(7) 
1.178(8) 
1.363(8) 
1.458(8) 
1.455(9) 
1.454(9) 
1.137(8) 
1.390(8) 
1.391(8) 
1.500(10) 
1.382(9) 
1.372(8) 
1.375(8) 
1.377(9) 
1.519(9) 
1.457(10) 
1.537(9) 
1.541(10) 
1.566(9) 
1.555(9) 
1.450(11) 
1.494(11) 
110.3(3) 
115.1(3) 
106.5(3) 
114.0(3) 
108.4(3) 
101.9(3) 
114.7(5) 
122.2(5) 
123.5(5) 
118.7(7) 
121.9(6) 
119.5(6) 
120.4(6) 
120.4(7) 
119.6(8) 
120.7(7) 
120.2(6) 
114.6(6) 
124.0(7) 
126.5(7) 
O(2)-C(12)-C(ll) 
C(13)-C(3)-O(2) 
C(13)-C(3)-C(2) 
O(2)-C(3)-C(2) 
C(13)-C(3)-C(4) 
O(2)-C(3)-C(4) 
C(2)-C(3)-C(4) 
N(l)-C(13)-C(3) 
C(3)-C(4)-C(l) 
C(2)-C(l)-C(4) 
C(2)-C(l)-P(l) 
C(4)-C(l)-P(l) 
C(3)-C(2)-C(l ) 
C(15)-C(14)-O( 4) 
O(5)-C(16)-C(17) 
233 
109.5(6) 
110.3(6) 
114.6(6) 
116.8(5) 
113.0(6) 
110.8(5) 
89.8(5) 
176.9(9) 
88.9(5) 
88.2(5) 
115.2(5) 
121.2(5) 
89.4(5) 
110.6(8) 
108.1(8) 
Symmetry transformations used to generate equivalent atoms: 
Table 4. Anisotropic displacement parameters (A 2 x 103) for 1. The 
anisotropic displacement factor exponent takes the form: 
-2 1t2[h2a*2Ull + ... + 2hka*b*UI2] 
U11 U22 U33 U23 U13 U12 
P(l) 36(1) 43(1) 63(1) 0(1) 6(1) -4(1) 
0(1) 49(3) 51(3) 73(3) 0(3) -17(3) -14(3) 
0(2) 31(3) 37(3) 70(3) 5(2) -3(3) -3(2) 
0(3) 44(3) 68(3) 77(4) -4(3) 13(3) -32(3) 
0(4) 46(3) 36(3) 73(3) -8(2) 10(3) 6(2) 
0(5) 59(3) 57(3) 69(3) 0(3) -3(3) -9(3) 
N(l) 66(5) 51(4) 106(6) -8(4) 33(5) 14(4) 
C(l) 31(4) 32(3) 65(5) 10(3) 0(4) -1(3) 
C(2) 27(4) 48(4) 68(5) -2(4) 10(4) 2(3) 
C(3) 30(4) 34(4) 84(6) 3(4) 10(4) -3(3) 
C(4) 25(4) 41(4) 57(4) -5(3) -5(3) 0(3) 
C(5) 55(5) 47(4) 72(5) -16(4) 15(5) -12(4) 
C(6) 45(5) 55(5) 119(8) -3(5) -12(6) 9(4) 
C(7) 59(6) 82(7) 90(7) 13(6) -32(6) 5(5) 
C(8) 65(6) 103(8) 65(6) 0(5) -2(5) 17(6) 
C(9) 44(5) 74(5) 68(5) 1(4) 2(5) 11(4) 
C(10) 41(4) 45(4) 57(5) -2(4) -2(4) -8(4) 
C(ll) 52(5) 53(5) 60(5) -3(4) -10(4) -20(4) 
C(12) 25(4) 45(4) 63(5) -14(4) 4(4) 1(4) 
C(13) 30(4) 45(4) 76(5) 8(4) 9(4) -5(4) 
C(14) 79(6) 69(5) 68(6) -2(5) 8(5) 21(5) 
C(15) 147(10) 75(7) 77(6) 14(5) 31(7) 2(7) 
C(16) 56(5) 81(6) 82(6) 7(5) -20(5) -12(5) 
C(17) 110(9) 136(10) 86(7) -6(7) -37(7) -11(8) 
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Table 5. 
H(l) 
H(2A) 
H(2B) 
H(4A) 
H(4B) 
H(5) 
H(6) 
H(7) 
H(8) 
H(9) 
H(llA) 
H(llB) 
H(14A) 
H(14B) 
H(15A) 
H(15B) 
H(15C) 
H(16A) 
H(16B) 
H(17A) 
H(l7B) 
H(17C) 
Hydrogen coordinates (x104) and isotropic displacement 
parameters (A 2 x 103) for 1. 
x y z U(eq) 
485(6) 3991(5) 4077(2) 51 
1882(6) 2476(6) 4641(2) 57 
1625(6) 3679(6) 4773(2) 57 
-1459(6) 3042(5) 4214(2) 49 
-685(6) 1945(5) 4176(2) 49 
2489(8) -500(5) 5639(3) 70 
3976(8) -927(6) 6236(4) 88 
3595(8) -369(7) 6998(3) 93 
1796(8) 700(7) 7157(3) 93 
318(7) 1161(6) 6569(3) 74 
-655(8) 598(5) 5804(3) 66 
301(8) 131(5) 5414(3) 66 
3527(10) 1226(7) 3615(3) 87 
2700(10) 258(7) 3803(3) 87 
3173(13) 50(7) 3019(3) 149 
2445(13) 1112(7) 2905(3) 149 
1607(13) 154(7) 3092(3) 149 
-1086(8) 2906(7) 3265(3) 87 
-433(8) 1814(7) 3142(3) 87 
-1579(12) 2521(9) 2489(3) 166 
-44(12) 2348(9) 2374(3) 166 
-580(12) 3475(9) 2492(3) 166 
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Appendix 2 
Table 1. Crystal Data and Structure Refinement for E-DiethyI3-(N-p-
Methoxybenzylamino)-3-cyanocyclobutanephosphonate 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Absorption correction 
Refinement method 
Data/ restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I> 2cr (I)] 
R indices (all data) 
Extinction coefficient 
Largest diff. peak and hole 
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C17H25N204P 
352.36 
220(2) K 
0.71073 A 
Triclinic 
P-1 
a=7.630(3) A 
b=9.882(5) A 
c=13.604(6) A 
975.4(8) A3 
2 
1.200 Mg/m3 
0.162 mm-1 
376 
ex =94.09(4) deg. 
~=104.07(3) deg. 
y=99.27(4) deg. 
0.78 x 0.22 x 0.12 mm 
1.55 to 25.05 0 
0<=h<=9, -ll<=k<=ll, -16<=1<=15 
3728 
443[R(int)=0.0548] 
Analytical 
Full-matrix least-squares on F2 
3441/8/225 
1.045 
R1=0.0538, wR2=0.1554 
R1=0.0675, wR2=0.1728 
0.033(6) 
0.523 and -0.312 e.A-3 
Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (A 2 x 103) for 1. U(eq) is defined as one third of the 
trace of the orthogonalized Uij tensor. 
x y z U(eq) 
P(l) 4010(1) 3127(1) 6540(1) 47(1) 
0(1) 2466(3) 2949(2) 7008(2) 67(1) 
0(2) 4663(3) 4664(2) 6360(2) 61(1) 
0(3) 3673(3) 2299(2) 5460(2) 65(1) 
0(4) 15423(2) 114(2) 11735(1) 54(1) 
N(l) 10145(3) 2902(2) 8481(2) 40(1) 
N(2) 10238(4) 6251(3) 7861(2) 71(1) 
C(l) 6014(3) 2586(3) 7234(2) 43(1) 
C(2) 7778(3) 2907(3) 6856(2) 47(1) 
C(3) 8837(3) 3664(2) 7922(2) 39(1) 
C(4) 7014(3) 3482(3) 8262(2) 46(1) 
C(5) 9628(3) 5128(3) 7887(2) 48(1) 
C(6) 4270(6) 5882(4) 6887(3) 82(1) 
C(7) 3151(7) 6600(5) 6163(3) 106(2) 
C(8) 2170(6) 2434(6) 4627(3) 111(2) 
C(9) 1827(10) 1205(8) 3883(5) 189(3) 
C(10) 11100(3) 3576(3) 9512(2) 46(1) 
C(ll) 12281(3) 2679(2) 10100(2) 40(1) 
C(12) 11539(3) 1627(3) 10581(2) 47(1) 
C(13) 12597(3) 783(3) 11109(2) 48(1) 
C(14) 14477(3) 984(2) 11179(2) 41(1) 
C(15) 15254(3) 2023(2) 10705(2) 43(1) 
C(16) 14154(3) 2865(2) 10173(2) 43(1) 
C(17) 17319(4) 199(3) 11751(2) 54(1) 
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Table3. Bond lengths [A] and angles [deg] for Diethyl 3-(N-p-
Methoxybenzylamino)-3-cyanocyclobutanephosphonate 
P(l)-O(l) 
P(1)-O(3) 
P(1)-O(2) 
P(l)-C(l) 
O(2)-C(6) 
O(3)-C(8) 
O(4)-C(14) 
O(4)-C(17) 
N(1)-C(3) 
N(1)-C(10) 
N(2)-C(5) 
C(1)-C(2) 
C(1)-C(4) 
C(2)-C(3) 
C(3)-C(5) 
C(3)-C(4) 
C(6)-C(7) 
C(8)-C(9) 
C(10)-C(11) 
C(11)-C(12) 
C(11)-C(16) 
C(12)-C(13) 
C(13)-C(14) 
C(14)-C(15) 
C(15)-C(16) 
O(1)-P(1)-O(3) 
O(1)-P(1)-O(2) 
O(3)-P(1)-O(2) 
O(l)-P(l)-C(l) 
O(3)-P(1)-C(1) 
O(2)-P(1)-C(1) 
C(6)-O(2)-P(1) 
C(8)-O(3)-P(1) 
C(14)-O( 4)-C(17) 
C(3)-N(1)-C(10) 
C(2)-C(1)-C(4) 
C(2)-C(1)-P(1) 
C(4)-C(1)-P(1) 
C(3)-C(2)-C(1) 
N(1)-C(3)-C(5) 
N(1)-C(3)-C(2) 
C(5)-C(3)-C(2) 
N(1)-C(3)-C(4) 
C(5)-C(3)-C(4) 
C(2)-C(3)-C(4) 
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1.462(2) 
1.571(2) 
1.575(2) 
1.775(3) 
1.466(4) 
1.434(4) 
1.363(3) 
1.430(3) 
1.448(3) 
1.469(3) 
1.138(4) 
1.549(3) 
1.551(4) 
1.548(3) 
1.484(4) 
1.557(3) 
1.446(5) 
1.471(7) 
1.499(3) 
1.384(4) 
1.389(3) 
1.372(4) 
1.395(3) 
1.380(3) 
1.391(3) 
116.15(13) 
113.69(13) 
103.45(12) 
114.95(12) 
101.59(12) 
105.50(12) 
124.8(2) 
121.3(2) 
117.7(2) 
113.2(2) 
90.1(2) 
117.8(2) 
114.9(2) 
89.9(2) 
113.7(2) 
112.5(2) 
112.8(2) 
112.5(2) 
113.3(2) 
89.9(2) 
C(l )-C( 4)-C(3) 
N(2)-C(5)-C(3) 
C(7)-C(6)-O(2) 
O(3)-C(8)-C(9) 
N(1)-C(10)-C(11) 
C(12)-C(11 )-C(16) 
C(12)-C(11)-C(10) 
C(16)-C(11 )-C(10) 
C(13)-C(12)-C(11) 
C(12)-C(13)-C(14) 
O( 4)-C(14)-C(15) 
O(4)-C(14)-C(13) 
C(15)-C(14)-C(13) 
C(14)-C(15)-C(16) 
C(ll )-C(16)-C(15) 
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89.5(2) 
179.8(2) 
110.2(3) 
107.2(4) 
111.2(2) 
117.7(2) 
121.1(2) 
121.2(2) 
121.8(2) 
119.9(2) 
124.6(2) 
115.8(2) 
119.6(2) 
119.5(2) 
121.5(2) 
Symmetry transformations used to generate equivalent atoms: 
Table 4. Anisotropic displacement parameters (A2 x 103) for 1. The 
anisotropic displacement factor exponent takes the form: 
-2 1t2[h2a*2U11 + ... + 2hka*b*U12] 
Ull U22 U33 U23 U13 U12 
P(I) 36(1) 65(1) 42(1) 11(1) 10(1) 10(1) 
0(1) 42(1) 102(2) 66(1) 23(1) 23(1) 16(1) 
0(2) 71(1) 63(1) 62(1) 19(1) 31(1) 24(1) 
0(3) 52(1) 88(2) 46(1) -6(1) -1(1) 15(1) 
0(4) 48(1) 55(1) 61(1) 25(1) 13(1) 13(1) 
N(I) 38(1) 44(1) 40(1) 2(1) 12(1) 12(1) 
N(2) 71(2) 52(2) 91(2) 15(1) 23(2) 12(1) 
C(I) 38(1) 51(1) 39(1) 9(1) 10(1) 6(1) 
C(2) 39(1) 64(2) 38(1) 1(1) 11(1) 9(1) 
C(3) 33(1) 49(1) 36(1) 6(1) 11(1) 9(1) 
C(4) 36(1) 68(2) 36(1) 7(1) 12(1) 11(1) 
C(5) 42(1) 56(2) 50(1) 9(1) 14(1) 14(1) 
C(6) 107(3) 76(2) 74(2) 12(2) 33(2) 34(2) 
C(7) 147(4) 112(3) 88(3) 37(2) 46(3) 73(3) 
C(8) 85(3) 158(4) 71(2) -11(3) -18(2) 38(3) 
C(9) 179(6) 184(6) 129(5) -72(4) -79(4) 40(5) 
C(10) 45(1) 46(1) 42(1) -2(1) 4(1) 13(1) 
C(II) 37(1) 44(1) 38(1) -2(1) 7(1) 8(1) 
C(12) 33(1) 53(2) 54(2) 3(1) 14(1) 4(1) 
C(13) 43(1) 49(1) 52(1) 12(1) 16(1) 1(1) 
C(14) 40(1) 41(1) 40(1) 6(1) 8(1) 6(1) 
C(15) 31(1) 47(1) 51(1) 9(1) 11(1) 4(1) 
C(16) 40(1) 40(1) 49(1) 11(1) 13(1) 5(1) 
C(17) 44(1) 49(2) 64(2) 10(1) 3(1) 14(1) 
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Table 5. Hydrogen coordinates (x 104) and isotropic displacement 
parameters (A 1\2 x 103) for Diethyl 3-( O-Phenylacetoxy)-3-
cyanocylobutanephosphonate 
x y z U(eq) 
H(l) 10881(37) 2741(26) 8160(20) 41(7) 
H(lA) 5744(3) 1599(3) 7335(2) 51 
H(2A) 8239(3) 2082(3) 6668(2) 56 
H(2B) 7674(3) 3511(3) 6312(2) 56 
H(4A) 7050(3) 2978(3) 8859(2) 55 
H(4B) 6566(3) 4346(3) 8353(2) 55 
H(6A) 3623(6) 5597(4) 7400(3) 98 
H(6B) 5426(6) 6501(4) 7238(3) 98 
H(7A) 2785(43) 7342(24) 6526(4) 159 
H(7B) 2064(25) 5961(10) 5769(19) 159 
H(7C) 3853(18) 6981(32 5708(18) 159 
H(8A) 2482(6) 3272(6) 4314(3) 133 
H(8B) 1072(6) 2493(6) 4869(3) 133 
H(9A) 944(79) 1325(33) 3264(22) 283 
H(9B) 1341(93) 399(14) 4167(23) 283 
H(9C) 2969(23) 1081(43) 3726(42) 283 
H(10A) 10192(3) 3778(3) 9876(2) 55 
H(10B) 11867(3) 4453(3) 9466(2) 55 
H(12) 10276(3) 1488(3) 10544(2) 56 
H(13) 12054(3) 71(3) 11422(2) 57 
H(15) 16517(3) 2160(2) 10742(2) 52 
H(16) 14691(3) 3575(2) 9856(2) 51 
H(17A) 17824(8) -475(14) 12167(13) 81 
H(l7B) 17989(6) 1118(7) 12037(14) 81 
H(17C) 17429(4) 10(20) 11062(3) 81 
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